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Abstract 
Rheumatoid arthritis (RA) is a chronic, inflammatory disorder, whereby synovial 
inflammation ultimately results in joint destruction.  Although the joints are the 
main target tissues affected, RA is also associated with a number of co-
morbidities - such as cardiovascular disease.  A key cell type involved in the 
perpetuation of disease pathogenesis is the macrophage, but the mechanisms 
underlying inflammatory gene expression in these cells are not fully understood.  
One fascinating and rather novel area of research that could provide insights 
into the activation of macrophages in RA comprises the biology of microRNA.  
These small, non-coding RNA molecules are implicated in the post-
transcriptional regulation of gene expression.  
Here, we show that the expression of one particular microRNA, miR-34a, is 
increased in synovial fluid CD14+ cells compared to matched peripheral blood 
cells from RA patients.  We have demonstrated that miR-34a expression is 
increased in synovial tissues from RA patients compared to osteoarthritis 
comparators, and that a proportion of these miR-34a positive cells are CD68+ 
macrophages.  Of particular interest, miR-34a was also up-regulated in 
peripheral blood CD14+ cells isolated from multiple drug-resistant RA patients 
compared to healthy controls.   
Using over and under-expression methodologies we were able to demonstrate 
that miR-34a over-expression reduces toll like receptor-induced cytokine 
production by macrophages, while miR-34a inhibition enhances cytokine 
production.  The altered cytokine activities included TNFα and IL-6 that are both 
critically linked to disease pathogenesis, therefore we propose that miR-34a 
over-expression in RA macrophages represents a failed attempt to attenuate on-
going inflammation.  
To further explore the mechanism of miR-34a action, a microarray was 
performed to investigate transcripts that were regulated in response to miR-34a 
over-expression in monocytes.  This study uncovered several pathways, including 
interferon, metallothionein and chemokine pathways, wherein many members 
were down-regulated upon miR-34a over-expression.  Future work will therefore 
  3 
 
aim to dissect the role of these pathways, and their relevance to miR-34a 
regulated macrophage and dendritic cell biology, and thus to the chronicity of 
synovitis.  
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PBS phosphate buffered saline 
PCR polymerase chain reaction 
pDC plasmacytoid DC 
PIP proximal interphalangeal 
piRNA piwi-interacting RNA  
PKR Protein kinase RNA-activated 
PNUTS phosphatase 1 nuclear targeting subunit 
RA rheumatoid arthritis 
RANKL receptor activator of nuclear factor kappa-B ligand 
RASF RA synovial fibroblast 
RF rheumatoid factor 
RIG-1 retinoic acid-inducible gene 1 
RIN RNA integrity number 
RISC RNA-induced silencing complex 
RMA robust multichip analysis  
RNA ribonucleic acid 
RPMI Roswell Park Memorial Institute medium 
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RT transfection reagents 
SCID severe combined immunodeficiency  
SF  synovial fluid 
SHIP SH2-containing inositol-5'-phosphatase 
SIRT Sitruin 
SJC swollen joint count 
SOCS suppressor of cytokine signalling 
SOX SRY-box 2 
SP serum plasma 
SRY sex determining region Y 
SSC saline-sodium citrate  
STAT signal transducers and activators of transcription 
TAE tris-acetate-EDTA 
TG Transgenic 
Tgif transforming growth factor-β-induced factor 
Th T helper 
TJC tender joint count 
TLR toll-like receptor 
TMB Tetramethylbenzidine 
TNC tenascin-C  
TNF tumor necrosis factor 
TRAF2 TNF receptor-associated factor 2  
TSLP thymic stromal lymphopoietin  
TSLPR thymic stromal lymphopoietin receptor 
WNT Wingless 
WT  wild type 
  
 
  
 
 
Chapter 1 – Introduction 
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Parts of this introduction are based on an online published review by the author  [8] 
 Rheumatoid Arthritis 1.1
Rheumatoid arthritis (RA) is a chronic, inflammatory disorder of unknown 
aetiology.  Principally attacking the diarthrodial joints of the body, RA is 
associated with inflammatory synovitis, where progression of the disease results 
in the destruction of articular cartilage and bone.  This often devastating 
condition affects around 0.8-1% of the general Caucasian population [1, 2], and 
in severe cases can cause permanent deformity and loss of function of the 
affected joints.  This in turn promotes substantial personal and societal 
socioeconomic impact.  In consequence, RA comprises one of the major 
autoimmune mediated causes of disability. 
Although the initial causes remain undefined, RA is thought to arise 
predominantly as a result of genetic susceptibility, upon which certain 
environmental and stochastic factors operate to drive disease.  It is also thought 
that a transition event may be required to focus the attack to the joints.  
Although not well understood, this could comprise an infection or local 
trauma/injury to the joint.  The result is a perpetuating cascade of 
inflammation, with many aspects of the immune system implicated in disease 
pathogenesis.  
Although the joints are the main areas affected by RA, it should be considered a 
systemic condition, reflected in the presence of a number of co-morbidities, and 
of decreased life expectancy.  These co-morbidities likely reflect systemic 
inflammatory activity, and can include pulmonary problems, increased cancer 
risk [3, 4], increased infection rates [5], psychological problems and vascular 
disease [6, 7] – particularly accelerated atherosclerosis.  Over the past decade 
the treatment of RA has improved remarkably, but disease remission is still rare 
and almost never achieved without on-going pharmaceutical intervention.  
 
  21 
 
 
 Diagnosis and Classification 1.1.1
There is no single test that can confirm or exclude the diagnosis of RA, and 
instead a number of different criteria are considered when making the diagnosis.  
These include assessing the number and location of affected joints, measuring 
acute phase reactants, and the presence or absence of rheumatoid factors (RF) 
or anti-citrullinated protein antibodies (ACPA) in the serum.  RA patients are 
now broadly divided in to two major serological subsets based on these tests – 
ACPA positive and ACPA negative.  Patients were initially separated by the 
presence or absence of RF in the blood, and although in established disease 
ACPA and RF positive patients represent largely overlapping populations, ACPA 
antibodies are more specific to RA, found in a higher percentage of patients, and 
shown to correlate with disease severity.  These therefore represent a better 
diagnostic tool. 
In order to achieve consistent identification of patients, primarily for clinical 
trial and cohort design purposes, the American Rheumatism Association 
developed the 1987 Criteria for Classification of Rheumatoid Arthritis [9].  Seven 
criteria were considered (listed in Table 1-1), of which the patient must show 
signs of 4 to be diagnosed with RA.  Although these criteria worked well in 
diagnosing patients with established disease, they didn’t help identify patients 
with early RA – who are the group most likely to benefit from aggressive 
interventions.  Therefore, in 2010, the American College of Rheumatology (ACR) 
and the European League against Rheumatism (EULAR) collaborated to update 
these criteria to better aid the diagnosis of early RA patients [10].  This updated 
criteria set for classification takes more factors into consideration (shown in 
Table 1-2).  Patients are given a point value between 0 and 10, with any patient 
showing synovitis of otherwise unexplained cause, and achieving a score of 6 or 
greater classified as having RA. 
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Criterion Definition 
Morning 
stiffness 
Morning stiffness in and around the joints, lasting at least 1 hour 
before maximal improvement 
Arthritis of 3 or 
more joint areas 
At least 3 joint areas simultaneously have had soft tissue swelling 
or fluid (not bony overgrowth alone) observed by a physician. The 
14 possible areas are right or left PIP, MCP, wrist, elbow, knee, 
ankle, and MTP joints 
Arthritis of hand 
joints 
At least 1 area swollen (as defined above) in a wrist, MCP, or PIP 
joint 
Symmetric 
arthritis 
Simultaneous involvement of the same joint areas on both sides of 
the body (bilateral involvement of PIPs, MCPs, or MTPs is 
acceptable without absolute symmetry) 
Rheumatoid 
nodules 
Subcutaneous nodules, over bony prominences, or extensor 
surfaces, or in juxtaarticular regions, observed by a physician 
Serum 
rheumatoid 
factor 
Demonstration of abnormal amounts of serum rheumatoid factor 
by any method for which the result has been positive in <5% of 
normal control subjects 
Radiographic 
changes 
Radiographic changes typical of rheumatoid arthritis on 
posteroanterior hand and wrist radiographs, which must include 
erosions or unequivocal bony decalcification localized in or most 
marked adjacent to the involved joints (osteoarthritis changes 
alone do not qualify) 
Table 1-1 The 1987 Criteria for Classification of Rheumatoid Arthritis 
Taken from [9]. PIP - proximal interphalangeal, MCP metacarpophalangeal - , MTP - 
metatarsophalangeal. 
 
Criteria Score 
Joint involvement 
   1 large joint 
   2-10 large joints 
   1-3 small joints (with or without involvement of large joints) 
   4-10 small joints (with or without involvement of large joints) 
   >10 joints (at least 1 one small joint) 
 
0 
1 
2 
3 
5 
Serology 
   Negative RF and negative ACPA 
   Low-positive RF or low-positive ACPA 
   High-positive RF or high-positive ACPA 
 
0 
2 
3 
Acute-phase Reactants 
   Normal CRP and normal ESR 
   Abnormal CRP or abnormal ESR 
 
0 
1 
Duration of Symptoms 
   < 6 weeks 
   ≥ 6 weeks 
 
0 
1 
Table 1-2 The 2010 ACR / EULAR classification criteria for rheumatoid arthritis 
Taken from [11]. RF – rheumatoid factor, ACPA – anti-citrullinated protein antibodies, CRP - C-
reactive protein, ESR – erythrocyte sedimentation rate. 
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 Risk Factors 1.1.2
Although the initial cause(s) of RA remain largely unknown, a number of genetic 
and environmental factors have been identified that are proposed to be 
associated with susceptibility to, and subsequent progression of disease. 
1.1.2.1 Genetic Susceptibility 
The link between genetics and RA has been known for many years.  A number of 
different genes have been linked to the development of disease, some affecting 
different patient subsets.  The use of twin studies has led to the proposal that 
genetic factors account for approximately 50%-60% of an individual’s 
susceptibility to RA [12], with the rest being down to environmental and chance 
factors.  Some of these genetic associations with disease have also led to 
insights into disease pathogenesis. 
HLA alleles were the first genetic factors associated with susceptibility to RA, 
with a number of different class II (DR/DQ) alleles now known to infer genetic 
susceptibility.  It was initially estimated that HLA alleles account for 50% of an 
individual’s genetic risk susceptibility to RA [13], although some more recent 
studies suggest it may be slightly lower.  Most of the RA-associated alleles 
contain a common amino acid motif in their β chain – referred to as the “shared 
epitope” [14].    This led to the suggestion that major histocompatibility 
complex (MHC) class II-dependant adaptive immune responses were important in 
RA. 
PTPN22 is another gene which has been linked to susceptibility of various 
autoimmune disorders, including RA.  The intracellular tyrosine phosphatase can 
associate with adapter proteins, and plays a role in setting the threshold for T 
cell activation, as well as having roles in B cell signalling.  A link between RA and 
PTPN22 was suggested in 2004 [15], with later studies confirming this as a 
susceptibility gene for RA [16, 17]. 
Although many studies have supported a link between certain HLA alleles and 
PTPN22 polymorphisms and RA, they appear to only infer susceptibility to 
seropositive disease, having little to no effect on the subset of patients which 
are negative for ACPA antibodies.  The link between these two genetic loci and 
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RA implicates T and B cells in the pathogenesis of RA, suggesting that adaptive 
immune responses play a role in the development, or the associated pathology 
of RA – at least in ACPA positive disease. 
It has also long been known that being of the female sex predisposes an 
individual to the development of RA, with more female than male sufferers at a 
ratio of approximately 3 : 1 [18].  It has recently been suggested that this is only 
true for individuals not encoding the shared epitope, with a study showing risk to 
be equal between the sexes where individuals are homozygous for the shared 
epitope [19].  The link between females and RA is thought, at least in part, to 
be due to sex hormones.  It has been shown that oestrogens can stimulate the 
production of inflammatory cytokines by RA macrophages.  This also partly 
explains the fluctuations of disease severity seen in females throughout the 
menstrual cycle, and the improvement of symptoms during pregnancy [20]. 
More recently, technological advances have seen the use of genome-wide 
association studies (GWAS) to assess genetic susceptibility to RA, and have 
implicated a variety of other immune system genes – including TRAF-1 [21, 22], 
OLIG3-AIP3 [23] and Signal Transducers and Activators of Transcription (STAT) -4 
[24] among many others.  Okada et al [25] recently performed a comprehensive 
GWAS meta-analysis using data from over 100,000 subjects of mixed ancestry.  
They discovered 42 novel RA risk loci, taking the current total to 101 risk loci.  
They found 377 genes in the associated region of linkage disequilibrium, and 
using BIOCARTA and Ingenuity pathway analysis softwares they found enrichment 
of pathways further implicating T cells, B cells and cytokine signalling (including 
interleukin (IL) 10, IFN and granulocyte macrophage colony-stimulating factor 
(GM-CSF)) pathways in RA pathogenesis.  They used a multi-factorial in silico 
bioinformatics pipeline to prioritise a list of 98 “candidate biological RA risk 
genes”.  The authors then proposed that if genetic methods like this were 
valuable for finding new drug targets, it would highlight therapies which are 
already used to treat RA.  Interestingly, when they looked at what drugs were 
known to target the protein products associated with their RA risk loci, they 
found significant enrichment for approved RA drugs.  These included the most 
common biologics used to treat RA, such as those targeting TNF, as well as 
Toculizimab and Abatacept.  Also highlighted by this method were CDK 
  25 
 
 
inhibitors, such as Flavopiridol.  Interestingly, this molecule has already been 
studied in the context of RA.  It was shown in the murine collagen-induced 
arthritis (CIA) model that it ameliorated disease symptoms and severity [26], and 
the compound is now in early clinical trials for the treatment of RA patients.  
This study has therefore highlighted the usefulness of such genetic approaches 
when looking for novel drug targets.  
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1.1.2.2 Environmental Factors 
The best established environmental link with RA is smoking.  Some studies have 
suggested that smoking is only a risk factor for the subset of RA patients which 
are ACPA positive [27], while having little to no influence on susceptibility in 
ACPA negative individuals [28].  Importantly, it is thought to have a cumulative 
dose effect, where the duration and quantity of cigarettes smoked are risk 
factors for more severe disease outcomes, particularly erosive progression [29, 
30].  Smoking is also thought to be a more important risk factor in patients 
carrying HLA-DR risk alleles [31, 32].  Interestingly smokers are less likely to 
respond to therapeutics.  As well as smoking, a number of other airway 
exposures have been associated with the development of RA, including silica 
dust [33], mineral oils [34] and charcoal – which is documented to cause severe 
RA symptoms in charcoal workers [35]. 
Another environmental link with the development of RA is infection.  Although 
the exact mechanisms remain unclear, infectious agents have long been 
implicated in the development and/or persistence of RA.  These include Epstein-
Barr virus (EBV), cytomegalovirus, Proteus species, Escherichia coli and 
Porphyromonas gingivalis (P. gingivalis).  
P. gingivalis is a pathogenic bacterium implicated in the development of many 
cases of periodontal disease.  Numerous studies have reported a link between 
incidence of periodontal disease and RA [36-38], but it is currently unclear 
whether there is a true causal link, or this is purely a consequence of the fact 
these diseases share a number of risk factors.  Interestingly though, P. gingivalis 
is the only bacterium known to produce peptidyl arginine deaminase enzymes 
capable of promoting the citrullination of mammalian proteins [39]. 
Although the relationship between EBV and RA remains unclear, there are 
several lines of evidence supporting a link between the two.  There is data 
suggesting that RA patients have elevated serum titres of anti-EBV antibodies 
[40, 41], and peripheral blood mononuclear cells (PBMCs) isolated from RA 
patients express far higher levels of EBV deoxyribonucleic acid (DNA) than 
control cells [42, 43].  The virus has also been detected in synovial fluid from RA 
patients [44]. 
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In more recent years, the focus has switched from studying a single infectious 
agent, to looking at the host microbiome in its totality.  Technological advances 
such as culture-independent 18S ribosomal ribonucleic acid (RNA) sequencing 
and the launch of the National Institute of Health (NIH) Human Microbiome 
Project in 2007 have led to increased interest in this field.  There are now a 
number of studies looking at faecal samples to study a link between possible gut 
dysbiosis and RA.  One study [45] looked at the different Lactobacillus species, 
and found higher diversity in early RA patients.  There were increased numbers 
of many species, with one – Lactobacillus mucosae – being unique to RA patients.  
In another, more comprehensive study [46], Scher et al performed 16S 
sequencing on 114 faecal samples derived from healthy controls, psoriatic 
arthritis, chronic treated rheumatoid arthritis (CRA) and new-onset untreated 
rheumatoid arthritis (NORA) patients.  This study found the presence of one 
particular species - Prevotella copri - correlated highly with NORA patients.  This 
bacterium has been associated with various other inflammatory events.  
Recently, high levels of Prevotella in the gut of healthy individuals was 
correlated with plasma levels of trimethylamine N-oxide (a substance thought to 
be predictive of cardiovascular events in humans) [47].  
Taken together these studies suggest a clear correlation between changes in the 
microbiome and development of RA, but evidence is still lacking to elucidate 
whether there is a true causative effect, or whether changes in the microbiome 
simply reflect a secondary response to on-going local and systemic inflammation. 
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 Current therapies 1.1.3
Over the past 10 to 20 years, the treatment of RA has improved remarkably. 
Previous treatment regimes involved giving patients non-steroidal anti-
inflammatory drugs (NSAIDs), corticosteroids and conventional disease modifying 
anti-rheumatic drugs (cDMARDS) – which were often used with little attention to 
pathogenic rationale.  However, advances towards understanding the 
mechanisms underlying disease activity have allowed the development of drugs 
targeting biological pathways known to play key roles in the disease. A list of the 
most commonly used conventional and biologic DMARDS is shown in Table 1-3. 
Therapy Target Mode of Action 
Conventional 
DMARDs 
  
Methotrexate 
Folate-dependent 
enzymes 
↓ folate-dependant enzymes results in 
impaired pyrimidine and purine synthesis 
and inhibition of lymphocyte proliferation 
Hydroxychloroquine 
Lysosomes, 
lysosomal enzymes 
TLR-9 
Lysomotropic properties hinder antigen 
presentation and also impairs activation of 
innate immune cells 
Sulfasalazine 
Folate-dependent 
enzymes 
Same as listed for methotrexate, also 
appears to block IκB and induce apoptosis 
of neutrophils and macrophages 
Leflunomide 
Dehydroorotate 
dehydrogenase 
(DHODH) 
↓ DHODH  results in impaired pyrimidine 
synthesis and inhibition of lymphocyte 
proliferation 
Biological 
DMARDs 
  
Etanercept   
Infliximab  Bind TNF-α thereby preventing 
Adalimumab TNF-α binding and signalling through 
Cetrolizumab  its receptor 
Golimumab   
Tocilizumab IL-6R 
Binds IL-6R preventing binding of IL-6 and 
subsequent signalling 
Anakinra IL-1R 
Binds IL-1 type I receptor  preventing 
binding of IL-1 and subsequent signalling 
Rituximab CD20 Binds to and depletes CD20+ B Cells 
Abatacept CTLA-4 Blocks T cell co-stimulation 
Table 1-3 List of the most commonly used drugs in the treatment of Rheumatoid Arthritis 
Adapted from [48]. DMARD - disease modifying anti-rheumatic drug, DHODH - dehydroorotate 
dehydrogenase, TNF – tumor necrosis factor, IL - interleukin.  
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Although methotrexate (MTX) is one of the older cDMARDS used to treat RA, it is 
often still used as the first line of therapy – either alone or in combination with 
other treatments [49].  MTX is a folate inhibitor, which functions by inhibiting 
folate dependant enzymes, thereby preventing purine and pyrimidine synthesis 
and resulting in impaired inflammatory lymphocyte proliferation [50].  Like MTX, 
sulfasalazine is known to inhibit folate-dependant enzymes leading to impaired 
lymphocyte function [51, 52].  The beneficial effects of sulfasalazine may also 
be due to its ability to induce apoptosis of neutrophils and macrophages [53, 
54].  The anti-malarial agents chloroquine and hydroxychloroquine (usually the 
latter) are also used to treat RA.  Although their exact anti-inflammatory 
mechanisms are not fully understood, it is thought they function in part through 
their ability to enter lysosomes and alter the pH, thereby influencing cell 
function [55].  They are also thought to negatively impact TLR signalling – 
particularly TLR-9 [56]. 
Although MTX and other cDMARDS are effective in treating the symptoms and 
clinical manifestations of disease for many patients, this does not always suffice 
to sufficiently control inflammatory disease activity or progressive joint 
destruction [57].  For this reason investigators turned to disease pathogenesis for 
clues to develop new biologic therapies. 
Tumor necrosis factor (TNF) is known to be present, and critically involved in the 
pathogenesis of RA.  The cytokine is highly expressed in both synovial fluid and 
tissues derived from RA patients, with expression of its receptors also shown to 
be up-regulated in the synovium – particularly in areas adjacent to erosions [58-
60].  Further evidence for the involvement of TNF in arthritis is seen in hTNFtg 
mice.  These mice are genetically altered to over-express human TNF, and in 
consequence develop spontaneous RA-like lesions in their joints [61].  Early in 
vitro studies showed that targeting TNF could reduce the expression of other 
inflammatory cytokines such as interleukin (IL) -1 and GM-CSF.  More 
importantly, targeting IL-1 or GM-CSF did not reduce TNF levels – suggesting TNF 
as a master regulator in inflammatory cytokine production [62-64].  In order to 
test the potential therapeutic benefit(s) of targeting TNF, it was blocked in the 
collagen induced arthritis (CIA) model, where it reduced inflammation in a dose 
dependant manner [65].  At the same time another group demonstrated that 
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administering TNF to mice with CIA led to more severe disease symptoms [66].  
The first studies of anti-TNF therapy in humans were performed with small 
numbers of patients, but data confirmed this treatment was capable of 
dramatically improving both clinical and acute phase reactant measures of 
disease activity in the majority of patients [67].  Since then five TNF inhibitors 
have been approved for clinical use (as described in Table 1-3), providing a 
major improvement in outcomes for many patients.  Owing to the success of 
anti-TNF, and the fact some patients still fail to respond to this treatment, a 
number of biologic therapies have been developed and licenced to treat RA. 
Cytokine inhibitors opposing the actions of IL-6 and IL-1 (Tocilizumab and 
Anakinra respectively), Rituximab that depletes CD20+ B cells and Abatacept 
that interrupts T cell / APC co-stimulation are now all routinely used in the 
management of disease. 
More recently there has been increased interest in deriving small molecule 
inhibitors that can recapitulate the effects of extra cellular biologic agents. 
Tofacitinib is a janus kinase (JAK) 1/3 inhibitor that has undergone several phase 
II [68-71] and phase III [72-75] trials in RA.  Many of these studies have 
demonstrated promising results in the treatment of patients who have currently 
failed to respond to methotrexate or anti-TNF therapies.  After three months a 
significant improvement in ACR20 and ACR50 responses were found, however, as 
with many immune-modulating therapies, this was accompanied with reduced 
neutrophil counts, increased infection rate and an increase in cholesterol. 
Longer term studies looking more closely at the potential risk benefit profile of 
the drug are therefore required, but this agent is now licenced and approved for 
use in several geographical areas.  Other biologic agents are also in 
development.  In particular an anti-GM-CSF receptor (mavrilimumab) is currently 
in phase IIb trials, having demonstrated efficacy in phase IIa studies thus far.  
Other trials are underway in which monoclonals targeting IL-20, IL-21 and IL-17 
are being tested – but it is currently too early to determine the likely success of 
these approaches.  The blockade of IL-17 in particular has been generally 
disappointing in RA, despite showing remarkable benefits in the treatment of 
psoriasis patients.  
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These new medications have provided a step change in disease management, 
and have led to an improvement in disease outcomes for many patients. 
However, partial or non-response to these treatments remains common, and 
drug free remission is rarely achieved.  This means that there is still significant 
unmet clinic need, and new therapies are still required for the treatment of RA.   
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 The Synovial Lesion 1.1.4
In a healthy joint, a thin synovial membrane comprising primarily of two main 
cells types (synovial fibroblasts and resident macrophages), lines the joint and 
acts as a lubricating tissue to ensure free movement of the joint without friction 
or discomfort.  In RA however, the synovial membrane becomes hyperplastic.  
There is an increasedleukocytes.  Technological advances have allowed detailed 
analysis of the synovial lesion, which as such, is increasingly well characterised.  
Among the immune cells found in the joint are innate immune cells such as 
macrophages, dendritic cells (DCs), neutrophils and mast cells, but there are 
also components of the adaptive immune system found.  These include activated 
T helper (Th) 1 and Th17 cells and B cells exhibiting somatic hyper-mutation.  
The resident host tissue cells include fibroblast-like synoviocytes (FLS), 
chondrocytes and osteoclasts, which do not act as passive bystanders but rather 
assume a ‘pro-inflammatory’ phenotype that actively contributes to articular 
inflammation and damage.  The result of this recruitment and proliferation of 
cells is “pannus” formation, where the proliferating synovial cells penetrate 
cartilage and bone and ultimately cause joint destruction [76].  A representation 
of a healthy and RA joint is shown in Figure 1-1. 
The immune cells that influx to the RA synovium represent both arms of the 
immune response, innate and adaptive immunity, both of which are crucial in 
protecting the host from infection.  The innate immune system mounts the first 
line of defence.  It has evolved to detect common molecular patterns expressed 
by pathogenic organisms, allowing it to respond quickly to infection.  The 
adaptive immune response, on the other hand, provides a slower, but more 
specific response to a given threat.  The adaptive immune response critically 
offers memory of the given insult, so that a faster response can be mounted if 
the same insult is encountered again.  Under normal circumstances these two 
arms of the immune system work together to provide the best protection from 
infections, but when this goes awry and the immune system is triggered 
unnecessarily or fails to switch off appropriately, this protective immune 
response can cause damage to self.  This is known as autoimmunity, and is 
considered to lie at the base of the pathogenesis of RA.  The potential role of 
innate, adaptive and resident cells in RA will now be discussed individually. 
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Figure 1-1 Comparative illustration of a healthy and RA joint 
The above diagram shows a representative healthy (a) and RA (b) joint. Taken from [77]. 
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1.1.4.1 Innate Immunity in RA 
Innate immune cells found in the synovial lesion in RA include monocytes and 
macrophages – which are the focus of my PhD and will be discussed in section 
1.2 – as well as dendritic cells, neutrophils, mast cells and NK cells.  Many of 
these cells influx to the RA synovium and become activated at the sites of 
inflammation, resulting in the production of molecules which further perpetuate 
inflammation, and ultimately result in joint damage.  One of the ways these 
cells become activated is by innate immune sensing pathways.  These pathways 
include those initiated by toll-like receptors (TLRs), NOD-like receptors and 
inflammasome components [78, 79].  These receptors are involved in recognising 
DAMP (damage associated molecular pattern) and PAMP (pathogen-AMP) 
products and likely serve to amplify and perpetuate disease. 
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1.1.4.1.1 Toll-like Receptors 
TLRs are the best studied of these pathways.  These receptors are crucial for the 
innate immune response to invading microbial and viral pathogens, and function 
by sensing PAMPs such as the bacterial cell wall components lipopolysaccharide 
(LPS) and peptidoglycan.  This TLR ligation results in a signalling cascade which 
ultimately causes the release of pro-inflammatory cytokines and other 
inflammatory mediators from the cell.  Important in the context of RA, however, 
TLRs can also be activated by a number of endogenous DAMPs, many of which 
have been found in the inflamed RA synovium.  These include heat shock 
proteins, fibronectin and hyaluronan [80, 81], as well as more recently described 
TLR ligands such as Tenascin-C (TNC).  TNC is an extracellular matrix 
glycoprotein of which the expression is increased at sites of tissue damage or 
injury.  TNC levels return to normal after the resolution of inflammation, but in 
conditions like RA, where there is on-going inflammation and tissue remodelling, 
the expression of TNC is shown to remain elevated [82, 83].  This could result in 
the persistent stimulation of synovial cells via TLRs.  A list of TLRs and their 
potential ligands in infection and inflammation is given in Table 1-4.  
TLR Location 
Pathogen 
associated 
molecular patterns 
Potential 
endogenous TLR 
ligands in RA 
(DAMPS) 
Experimental 
Ligands 
used 
TLR2 
(dimerises 
with TLR1 
or TLR6) 
Extracellular 
Lipoglycans 
(Mycobacterium) 
Lipoteichoic Acids 
(Gram-positive 
bacteria) 
Peptidoglycan 
(Gram-positive 
bacteria) 
Zymosan (Yeast) 
HSP 60 / 70, gp96, 
HMGB-1, Biglycan, 
Serum amyloid A 
Pam3 
TLR4 Extracellular 
LPS (Gram-negative 
bacteria) 
Mannan (Candida) 
Envelope protein 
(Virus) 
HSP 22 / 60 / 70, 
EDA fibronectin, 
Fibrinogen, HMGB-
1, Biglycan, 
Tenascin C 
LPS 
TLR3 Intracellular dsRNA Necrotic cells PolyI:C 
TLR5 Extracellular Flagellin   
TLR7 Intracellular 
ssRNA 
 
Cl097 
TLR8 Intracellular Necrotic cells 
TLR9 Intracellular CpG motifs   
Table 1-4 Summary of toll-like receptors and their ligands 
Adapted from [79]. TLR – toll-like receptor, HSP – heat shock protein, LPS – lipopolysaccharide, 
HMGB-1 - high-mobility group box 1. 
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TLRs are present on many cell types, and numerous studies have examined the 
expression of TLRs on synovial cells in RA.  The levels of TLRs 3, 7 and 9 have 
been shown to be increased in RA cells compared to those derived from OA 
patients or healthy controls [84-86].  Expression of TLRs on innate immune cells 
like macrophages and dendritic cells was initially thought to be most functionally 
relevant, but increased expression of TLRs on RA synovial fibroblasts (RASFs) is 
now known to be important.  One study demonstrated increased TLR-2 and TLR-
4 expression on RASFs compared to OASFs [87], and while another study found no 
significant differences in the TLR expression of these cells, they found that 
RASFs produced more IL-6, matrix metalloproteinase (MMP) -3 and MMP-13 [84] 
in response to TLR stimulation.  In abstract form, Chamberlain et al reported 
data confirming that TLR-7 is up-regulated in monocytes and macrophages from 
RA patients, and suggested that TLR-7 ligands are chemotactic for monocytes.  
They therefore hypothesised that TLR-7 ligation could actually promote 
monocyte migration to the joint [88]. 
A role for these TLRs in arthritis is also suggested in rodent models, with mice 
deficient in TLR2 or TLR4 showing reduced CIA and streptococcal-cell-wall-
induced arthritis [89].  In vitro cytokine production by cultures of human 
synovial cells is also dependant on TLR adapter proteins [90]. 
  
  37 
 
 
1.1.4.1.2 Dendritic Cells in RA 
DCs are often referred to as the classical antigen presenting cells, and are 
thought to be the principal cell-type involved in the activation of naive T cells.  
During T cell priming they play a role in determining the developmental fate of 
these cells, and influence whether they become a particular Th subset or develop 
regulatory function [91].  DCs are also involved in the initiation and maintenance 
of both central and peripheral tolerance, and are capable of deleting auto-
reactive T cells in the periphery [92], as well as expanding regulatory T cell 
populations.  Using models of autoimmune disease, DCs have been shown to be 
important in the generation of MHC-restricted immune responses [93, 94].  The 
resulting T cell activation is involved in autoantibody production, and the 
development/perpetuation of chronic inflammation.  The many and varied roles 
of DCs suggest they could be involved in several aspects of RA disease pathology.  
There are two major DC subsets, myeloid (mDCs) and plasmacytoid (pDCs) DCs, 
both of which are found in the SF of RA patients [95].  Many DCs found in the 
synovium of RA patients are positive for nuclear RelB, and therefore have a high 
capacity to stimulate T cells [96, 97].  It has also been shown that DCs and T 
cells are found in close association in the RA synovium, where it is thought the 
DCs may be involved in priming and activating the T cells [98].  Synovium-
infiltrating DCs also process and present antigen locally, which could sustain 
local inflammation and perpetuate disease pathogenesis [96, 98, 99]. 
DCs also have a role in the production of pro-inflammatory cytokines, working in 
concert with macrophages and other cells within the synovial compartment they 
produce inflammatory mediators, such as TNF, which can drive the inflammatory 
pathology seen in RA [94, 100].  In fact, inflammatory DCs have been shown to 
act as effectors in cartilage destruction via an indirect mechanism involving the 
production of TNF [101].  It has also been demonstrated that synovial DCs from 
RA patients produce higher levels of CCL18 – which is a T cell chemo-attractant 
and can also induce fibroblasts to produce collagen [102].  A recent paper by 
Segura et al studied cells derived from inflammatory fluids, including RA synovial 
fluid, and found a discrete population of cells which shared many features 
similar to in vitro monocyte-derived DCs, and clearly distinct from inflammatory 
macrophages.  They went on to show that these “inflammatory DCs”, but not 
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inflammatory macrophages, could promote Th17 cell differentiation, in part 
through their secretion of IL-17.  This study highlights a potential role for DCs in 
promoting pathogenic Th17 cell differentiation in inflammatory conditions like 
RA [103]. 
Recent data suggest an important role for thymic stromal lymphopoietin (TSLP) 
in DC : T cell interactions in RA.  This cytokine plays important roles in DC-
induced maturation of T cells, and its levels are significantly higher in SF from 
RA patients compared to OA-derived samples.  mDCs from the SF of RA patients 
also express significantly higher levels of its receptor (TSLPR).  Exposure of mDCs 
to TSLP resulted in their increased production of CCL17 and macrophage 
inflammatory protein (MIP) 1α, and also increased their capacity to induce CD4+ 
T cell proliferation [104].  Administration of TSLP during the CIA model in mice 
was also found to significantly exacerbate disease severity, while TSLPR-/- mice 
developed less severe arthritis than their wild-type counterparts.  The knockout 
mice had lower levels of inflammatory cytokines including IL-17, IL-1β and IL-6 
[105].  Due to the results of these and other studies, TSLP has been suggested as 
a potential therapeutic target in RA. 
Despite the many possible pro-inflammatory roles of DCs in RA, it has been 
shown that selective depletion of pDCs in vivo in a murine arthritis model 
actually increased the severity of articular pathology and both T and B cell 
autoimmune responses against type II collagen.  This suggests that pDCs may in 
fact offer a net anti-inflammatory effect in this situation [106].  This could, in 
part, be due to the involvement of DCs in maintaining peripheral tolerance.  This 
occurs where an antigen is encountered in the absence of co-stimulatory signals 
from APCs [107].  Immature DCs express low levels of the co-stimulatory 
molecules CD80 and CD86, and produce high levels of IL-10.  These cells are 
often termed “tolerogenic” as it is thought presentation of antigens by these 
cells induces T cell anergy, thereby promoting peripheral tolerance.  
It is possible in inflammatory diseases, like RA, that the balance between DCs as 
tolerance inducing vs pro-inflammatory cells is swayed towards the latter, 
inflammation promoting phenotype.  For this reason many groups are looking to 
harness the potential of tolerogenic DCs as an immunotherapeutic tool to induce 
or restore tolerance.  Many different methods are currently being studied, with 
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the aim to generate autologous, tolerogenic DC populations in vitro which can 
be re-introduced to patients, with the hope that this could reinstate immune 
tolerance [108]. 
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1.1.4.1.3 Neutrophils in RA 
Neutrophils are the most abundant circulating leukocytes found in mammals, 
and are primarily involved in host defence against bacterial and fungal 
pathogens.  In order to protect us from such infections, neutrophils are armed 
with a number of antimicrobial proteins, which among other things, are capable 
of degrading microbial proteins and cell wall components.  Unnecessary 
activation of these cells however, can be detrimental and result in immune 
mediated damage to host cells.  In RA, neutrophils are the most abundant cells 
found in synovial fluid, and when isolated they show clear signs of activation.  
This suggests these cells have been primed, and could be partly responsible for 
the increased expression of cytokines such as IL-1β, IL-18 and IL-8 seen in the RA 
synovial environment [109, 110].  The location of these neutrophils also suggests 
they could be involved in disease pathogenesis.  They are often found at the 
pannus: cartilage junction, which is the location where most tissue damage 
occurs [111].  Evidence to suggest a role for neutrophils in arthritis pathogenesis 
is also seen in animal models.  Using an anti-Gr1 antibody to deplete these cells 
protects mice from several experimental models of arthritis, including the CIA 
and K/BxN serum transfer models [112, 113]. 
More recently neutrophils have been implicated in the pathogenesis of RA 
through their formation of neutrophil extracellular traps (NETs).  These were 
first described in 2004 as a new method by which neutrophils could kill bacteria 
[114].  NETs consist of networks of extracellular fibres, mainly chromatin that 
are covered with antimicrobial peptides normally present in the granules of 
neutrophils [114].  Stimulation of neutrophils in vitro with IL-8 or LPS has been 
shown to result in their release of these NETs, which cause the externalisation of 
pro-inflammatory, immune-stimulatory molecules [115, 116].  This is particularly 
relevant in conditions like RA where there is an abundance of neutrophils 
together with many stimulatory factors that could cause their release of these 
NETs.  Indeed, NET formation is enhanced in both circulating and synovial fluid 
neutrophils from patients with RA, compared to neutrophils from healthy 
controls [117]. 
Another indicator that neutrophil NET formation may be important in RA 
pathogenesis is the link between citrullination and NET formation.  It is reported 
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that citrullination of histones is an essential step during NET formation, and that 
citrullinated proteins are detected in NETs.  Indeed, RA sera containing ACPA 
can react with citrullinated histone derived from NETs [118].  These findings 
suggest that neutrophil NET formation is enhanced in RA, and has the potential 
to expose other cells in the synovium to citrullinated autoantigens that could 
lead to ACPA formation. 
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1.1.4.1.4 Other innate cells implicated in RA pathogenesis 
Although monocytes, macrophages, dendritic cells and neutrophils are the most 
studied innate immune cells in RA, other innate cells and present in the 
heterogeneous cell milieu and have functions that could be important in RA 
pathogenesis.  These include mast cells and natural killer (NK) cells. 
Mast cells are granulocytic cells that are best known for their roles in allergy and 
anaphylaxis, though they also play important roles in host defence against 
pathogens and wound healing [119].  In RA, both the numbers of mast cells, and 
the concentration of many of their mediators are increased in the synovium 
[120-122].  Mast cells express TLRs 1 through 9 [123-127], and stimulation of 
blood-derived mast cells with TLR ligands causes their production of cytokines - 
including GM-CSF, IL-8, MIP-1α and TNF-α.  This study went on to show that mast 
cells also express FcγRII, and stimulation with immune complexes can lead to 
their production and release of IL-8.  IL-8 production by these blood-derived 
mast cells was further increased by TLR stimulation in the presence of plate-
bound IgG, suggesting synergy between FcγR and TLR stimulation, which could 
be of particular interest in the RA synovium where stimulation of both pathways 
together is likely [123].  This study highlights the potential roles of mast cells in 
RA, though further studies looking specifically at primary mast cells rather than 
those differentiated from blood precursors would be useful to reinforce these 
findings. 
NK cells are another group of innate immune cells that are crucial for host 
defence, but could play a significant role in the perpetuation of inflammatory 
diseases when activated unnecessarily.  It is reported that a subset of NK cells, 
CD56 bright cells, are greatly expanded within the synovium of RA patients 
[128].  As the name suggests, these cells were initially defined by their ability to 
spontaneously kill tumour and virally infected cells [129, 130].  It is now known 
these cells express FcγRIIIA and are capable of performing antibody-dependant 
cellular cytotoxicity (ADCC) [131].  As well as FcγRIIIA, NK cells express many 
other surface receptors, including NKG2D and CD244, which allow them to 
recognise and kill stressed or antibody coated cells.  Some reports suggest that 
the expression of these receptors is actually reduced in RA, which could 
contribute to an impaired NK cell activity in these patients [132].  Another 
  43 
 
 
function of NK cells is cytokine production.  One of the key cytokines they 
produce is IFN-γ.  This cytokine is capable of enhancing immune responses by 
promoting Th1 development and also increasing the expression of MHC class I 
molecules on other cells, such as APCs.  It has also been reported that sub-
populations of NK cells can produce many other cytokines, including TNF-α, IL-15 
and GM-CSF [131, 133, 134], all of which have previously been implicated in RA 
pathogenesis.  NK cells could therefore contribute to RA disease progression 
through cell : cell interactions and their production of inflammatory mediators 
in the joint. 
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1.1.4.2 Adaptive Immunity in RA 
Several strands of evidence support a role for adaptive immunity in RA.  GWAS 
clearly identify a variety of loci that are vital for T cell activation and co-
stimulation – notably the strong association with Class II suggests a core role for 
peptide presentation in pathology at some point.  The presence of ACPA and IgG 
(rheumatoid factors) antibodies, arising often from class switched B cells which  
rely on T cell help, and also strong evidence from a large number of animal 
model systems implicate adaptive immune responses in RA.  Nevertheless, it is 
unclear what causes breach of immune tolerance in the offset. 
1.1.4.2.1 T cells 
As mentioned above, a role for T cells in the pathogenesis of RA is suggested by 
the genetic association of RA with certain class II MHC alleles and PTPN22.  The 
presence of high numbers of T cells in synovium of RA patients, and the 
requirement for T cells in many animal models of arthritis also implicates these 
cells in disease pathogenesis [135].  A number of approaches have been used to 
target T cells in RA, most with disappointing results [136], but some benefit has 
been seen with the use of CTLA-4-Ig fusion protein Abatacept [137].  Abatacept 
can inhibit T cell co-stimulation and subsequent activation, and may also 
promote T-cell tolerance and regulatory function [138].  In vitro studies have 
also suggested that treatment of cytokine activated T cells with Abatacept can 
suppress their ability to induce the production of TNF-α and other pro-
inflammatory cytokines by macrophages in a co-culture system [139].  The 
clinical efficacy of this therapy implicates T cells directly in the pathogenesis on 
RA. 
In RA auto-reactive T cells have been found; these include populations specific 
for ACPA antigens, type II collagen and also cartilage glycoprotein 39, but the 
significance of these cells in vivo is debated.  In a recent study Klarenbeek et al 
[140] set out to determine whether the T cell receptors of RA patients displayed 
an abnormal repertoire.  They looked at synovial T cells from early and 
established RA patients, as well as peripheral blood T cells.  The study found 
that the T cell repertoire of synovial cells from early RA patients in particular, 
was dominated by highly expanded clones (determined by a frequency of over 
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0.5%).  The group went on to speculate that these clones could be auto-reactive, 
and that their expansion could be due to the presence of specific auto-antigens 
in the synovium.  Although this is an interesting hypothesis, further studies will 
be required to find these possible auto-antigens and determine their role in RA 
pathogenesis. 
T cells are also likely to be one of the cell types involved in inflammatory 
cytokine production in the joint.  Naive CD4+ T cells can differentiate into 
diverse effector phenotypes depending on the cytokine milieu to which they are 
exposed, such as T helper 1 (Th1), Th2, Th17 and T regulatory (Treg) cells.  This in 
turn determines their pattern of cytokine release. 
RA was initially thought to be a Th1-mediated disorder, with more recent data 
suggesting Th17 cells could be the dominant T cell players.  Matters are even less 
clear in early disease in which the first T cell subset to emerge appear to have 
more of a Th2 phenotype [141].  One of the key cytokines Th17 cells produce is 
IL-17.  In recent years, what was originally termed IL-17 is now known as IL-17A, 
with 5 other members of this family being discovered (IL-17 B through F).  Of 
these, IL-17A and IL-17F are most closely related, sharing around 50% homology 
[142].  Because of this, it is thought that they exhibit many of the same 
functions, though IL-17A often appears more potent than IL-17F.  Both of these 
cytokines and their receptors are expressed in the synovium of RA patients, 
where they likely contribute to disease pathogenesis [143-147].  IL-17A has been 
implicated in many autoimmune diseases, with a role in RA pathogenesis 
suggested in many animal models.  Here it has been shown that its up-regulation 
or down-regulation of can worsen or suppress joint inflammation, respectively 
[148].  It is known that IL-17A can act on synovial cells, including monocytes and 
neutrophils, driving their activation and subsequent cytokine release.  It can also 
act on synovial fibroblasts, and is involved in their production of prostaglandins 
and matrix metalloproteinases [149].  As well as IL-17, Th17 cells are capable of 
secreting many other inflammatory cytokines, including IL-21, IL-22 and TNF 
[150].  More recent data, in fact, suggests that the production of GM-CSF by Th17 
cells could be responsible for many of their pathogenic functions [151].  The GM-
CSF released by these cells can act on macrophages and dendritic cells 
increasing their activation state, and also causing their release of cytokines such 
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as IL-23, which can further enhance Th17 cell development and maturation – 
thereby creating a positive feedback loop.  As well as RA, GM-CSF produced by 
Th17 cells has now been implicated in a number of other autoimmune diseases, 
including multiple sclerosis and myocarditis [152, 153]. 
In addition to these “pathogenic” T cells, there is also evidence of regulatory T 
cell populations expressing FoxP3, CD4 and CD25 in the RA synovium.  These 
regulatory cells are normally involved in the maintenance of tolerance and 
regulation of immune responses.  They can do this in a cell contact dependant 
manner using molecules such as CTLA-4, but also through their secretion of 
soluble mediators such as IL-10 and TGF-β.  In RA, there is some evidence to 
suggest that although these cells are present in the synovium of patients; their 
function may be impaired due to high levels of TNF.  While they are able to 
supress the proliferation of effector cells, their ability to supress pro-
inflammatory cytokine production appears defective [154, 155]. 
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1.1.4.2.2 B Cells 
The successful use of Rituximab in treating RA has generated a lot of interest in 
the role of B cells in disease pathogenesis.  Rituximab is a CD20+ B cell / 
plasmablast depleting monoclonal antibody, which provides significant (and in 
some cases prolonged) clinical benefit in RA patients [156].  This, together with 
the fact that B cells have been shown crucial in several murine models of 
arthritis [157-159], has generated a lot of interest in the role of these cells in 
RA.  B cells have many diverse functions though, so could play multiple roles in 
the pathogenesis of RA.  They are the cells that produce antibodies, and could 
therefore be responsible for the generation of autoantibodies, but they can also 
contribute to pathogenesis by acting as antigen presenting cells and cytokine 
producers.  
The role of B cells as antibody producers is seen in patients positive for RF and 
ACPA antibodies.  The presence of ACPA antibodies is often seen many years 
before the onset of disease symptoms, and patients are often subdivided based 
on the presence of absence of these antibodies.  ACPA+ RA patients generally 
develop a more aggressive condition with a worse prognosis [160], and disease 
severity has even been correlated to antibody titres.  Although not fully 
understood, it is possible these antibodies contribute to disease pathogenesis.  
ACPA antibodies are generated against citrullinated self-proteins. 
Peptidylarginine deiminase (PAD) enzymes are a family of enzymes that can 
cause the post-translation modification known as citrullination; where arginine 
residues are converted to citrulline.  In RA ACPA have been found that target 
many self-proteins, including fibrinogen, vimentin, α-enolase and collagen type 
II.  Increasing evidence suggests that these antibodies are not simply a diagnostic 
tool in RA, but they also play a role in disease pathogenesis.  One study 
demonstrated that immune complexes carrying ACPA could stimulate 
macrophages via TLR and FC gamma receptor-mediated pathways [161, 162], 
and they have also been shown to activate complement [163] and promote 
osteoclastogenesis [164].  One particular study looking at the effect of ACPAs on 
macrophage activation demonstrated that ACPA-containing immune complexes 
stimulated the macrophages to produce TNF-α – providing a clear link between 
the ACPAs found in RA and disease mechanisms [162]. 
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The genetic susceptibility of certain HLA-DR positive individuals to developing RA 
supports a role for MHC-dependant antigen presentation in the development and 
/ or pathogenesis of RA.  Although not likely to be involved in the initial priming 
of naïve T cells, B cells can act as antigen-presenting cells, and are thought to 
be important in later T cell responses [165].  They can also express some of the 
co-stimulatory molecules crucial for T cell activation, including CD80, CD86 and 
CD40, so it is possible that they could support the generation of autoreactive T 
cells [166]. 
B cells are also capable of producing chemokines (including CXCL13 [167]) and 
pro-inflammatory cytokines such as IFNγ, IL-4 and IL-6.  These cytokines can act 
on other cells and provide nonspecific help to bystander T cells, further 
perpetuating the on-going inflammation.  
Due to the partial success of Rituximab treatment and the many possible roles of 
B cells in RA, a number of other B cell targeting therapies have been considered 
for the treatment of RA patients.  These include Belimumab and Atacicept.  
Belimumab is an anti-BAFF/BLyS (B-cell activating factor/B-lymphocyte 
stimulator) antibody, while Atacicept blocks both BLyS and APRIL (A 
PRoliferation Inducing Ligand).  These are two factors known to be crucial in 
promoting B cell function and survival.  Both drugs went onto the clinical trial 
stage for rheumatoid arthritis, but failed to meet expectations.  Belimumab 
showed only modest efficacy, with ACR20 responses being marginally improved 
compared to the placebo group [168], while Atacicept produced no significant 
clinical improvement in phase II trials [169, 170].  These therapeutic failures 
very clearly demonstrate the incomplete understanding that we currently have 
as to the role of B cells in RA disease pathogenesis. 
As well as their possible pathogenic roles, B cells are also demonstrated to have 
a protective function in autoimmune and inflammatory disorders [171], 
highlighting a need to determine which populations of B cells may be 
pathogenic, and which may actually be protective and beneficial in RA.  
Regulatory B cells exist which produce IL-10, and experiments have shown that 
the transfer of these IL-10 producing cells into a CIA model reduces disease 
severity [172].  
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1.1.4.3 Host tissue cells and joint destruction in RA  
Host tissue cells, including fibroblast-like synoviocytes (FLS), chondrocytes and 
osteoclasts, do not act as passive bystanders in RA, but rather assume a pro-
inflammatory phenotype that actively contributes to articular inflammation and 
damage.   
Bone and cartilage destruction are the hallmarks of structural damage in RA – 
and are both at least partly caused by the inflammatory microenvironment found 
in RA joints.  Evidence from both animal and human studies suggests that several 
key pro-inflammatory cytokines – e.g. IL-1, IL-17, IL-6 and TNF-α – can drive 
elements of both cartilage and bone destruction [173, 174].  The key cells 
involved in the turnover of bone and cartilage, and their possible roles in the 
destruction observed in RA joints are discussed below. 
1.1.4.3.1 Osteoclasts and osteoblasts in RA 
Osteoclasts are specialised multi-nucleated cells that are the primary cells 
responsible for bone resorption [175].  They play a critical role in normal bone 
remodelling, but they are also involved in the destructive bone erosion seen in 
RA, which occurs as a result of bone resorption at the joint surface.   
Various growth factors and cytokines secreted by both inflammatory and 
resident cells can promote the development and differentiation of osteoclasts.  
Mononuclear precursor cells are recruited to the joint, and their differentiation 
to osteoclasts driven by locally produced macrophage colony-stimulating factor 
(M-CSF) and receptor activator of nuclear factor kappa-B ligand (RANKL).  
Synovial fibroblasts and activated T cells are thought to be a primary source of 
these cytokines [176].  Several pro-inflammatory cytokines present in the RA 
synovium (predominantly TNF, IL-1 and IL-6, although roles are also emerging for 
other cytokines such as IL-15 and IL-17) can induce RANKL expression, and also 
up-regulate RANK expression by osteoclast precursor cells, thereby promoting 
osteoclast formation [177-180].  The inflammatory environment in the synovium 
of RA patients therefore drives osteoclast formation and differentiation, which 
in turn causes increased bone resorption, resulting in local bone erosions. 
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While osteoclasts are the key cells involved in bone resorption, osteoblasts are 
the cells involved in bone formation.  Under normal circumstances when bone 
erosions occur, osteoblast activity increases, but in RA these repair mechanisms 
are not seen.  This suggests that osteoclast activity ‘overpowers’ osteoblast 
activity, or that osteoblast activity is somehow impaired.   
One family of molecules involved in regulating bone formation are the wingless 
(WNT) proteins.  These bind to the low density lipoprotein (LRP) 5/6 receptor, 
initiating a signalling pathway that ultimately drives osteoblastogenesis [181].  
Dickkopf (DKK) proteins, particularly DKK-1, are highly expressed in both 
experimental arthritis models and human RA inflammatory lesions.  This family 
of proteins can be induced by TNF, and regulate WNT-induced osteoblast activity 
by competing with the WNT proteins to bind LRP5/6.  They also bind the 
negative co-receptor Kremen-1, and therefore prevent WNT induced LRP5/6 
signalling [182, 183].  DKK-1 inhibition completely prevents bone erosions 
occurring in various rodent arthritis models, and results in bone formation.  In 
humans, treatment of RA patients showing increased DKK-1 levels with anti-TNF 
reduces its expression, suggesting that inflammatory cytokines like TNF can 
induce the production of molecules which block bone formation. 
It was thought that regulating the balance between bone resorbing osteoclasts 
and bone forming osteoblasts could provide therapeutic potential in the 
treatment of RA.  Treatment with the anti-RANKL monoclonal antibody 
Denosumab has been shown effective in treating osteoporosis, and it can also 
reduce inflammation in a rat RA model, but in humans its effects are less clear.  
Phase II trials of Denosumab have shown a significant improvement in joint 
destruction and erosions compared to placebo groups, but the treatment doesn’t 
appear to have quite as remarkable an effect on joint space narrowing or the 
measures of disease activity observed [184].  Thus targeting osteoclasts has not 
found a place in the current therapeutic armamentarium in the treatment of RA.  
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1.1.4.3.2 Chondrocytes in RA 
Chondrocytes are the only cell type present in cartilage, and along with the 
matrix components collagen and proteoglycan, they form the joint protecting 
cartilage structure.  In the absence of disease, chondrocyte proliferation is very 
limited, and the penetration of cartilage by other cell types is restricted.  In RA, 
however, FLS invasion into this normally privileged site occurs. 
Some data suggest that chondrocytes themselves may play a role degrading the 
cartilage matrix in RA.  Experiments in early RA have shown proteoglycan loss in 
zones deep in the cartilage [185, 186], and chondrocytes are capable of 
producing some proteinases which can degrade cartilage collagens and 
proteoglycans, such as MMP-1 [187], MMP-3 and MMP-10 [188].  Chondrocytes 
may also produce inflammatory cytokines which can effect local responses and 
inhibit normal anabolic repair mechanisms.  The destruction of cartilage in RA, 
however, predominantly occurs near the synovial pannus [189], areas where high 
numbers of fibroblast-like synoviocytes and macrophages are found.  These cells 
can produce large quantities of MMPs and other proteinases, which play an 
important role in the degradation of structural proteins in the cartilage.  It is 
now believed, however, that the primary cell type involved in cartilage 
destruction are the fibroblast-like synoviocytes (FLS). 
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1.1.4.3.3 Fibroblast-like synoviocytes in RA 
In a healthy joint, the intimal lining layer of the synovium is composed a thin 
layer of cells consisting primarily of two main cell types - macrophages and 
fibroblasts.  In RA, however, these cells are known to greatly expand in number.  
It is thought that the FLS found in RA develop an unusual, aggressive and 
invasive phenotype – at least partly as a result of their exposure to the 
inflammatory environment in the inflamed synovium.  These cells can produce a 
number of pro-inflammatory cytokines and proteolytic enzymes, as well as small 
molecule mediators of inflammation.  Because of this, they can play a role in 
perpetuating inflammation, and also mediate local damage by degrading the 
extracellular matrix. 
When FLS are cultured from human samples, they spontaneously produce a 
number of inflammatory mediators, as well as destructive proteinases.  This 
production gradually decreases, but upon exposure to cytokines like TNF or IL-1 
(cytokines abundantly present in the RA synovium) this is restored [190, 191].  
Further evidence of the destructive behaviour of these cells has been 
demonstrated in severe combined immunodeficiency (SCID) mice, where human 
cartilage is co-transplanted with FLS.  In these experiments, RA FLS, but not OA 
or normal FLS, enter and destroy the cartilage [192].  The production of 
cathepsins and MMPs are thought to be primarily responsible for this cartilage 
degradation.  These molecules are expressed by RA FLS, and their production 
can be increased in vitro by IL-1 and TNF.  FLS are also the primary producers of 
IL-6 in RA joints, and its production is also increased by exposure to IL-1 or TNF 
[193].  These data suggest that inflammatory cytokines, which are known to be 
abundantly expressed in the RA synovium, could promote destructive behaviour 
by FLS. 
FLS may also play a role in both recruiting and then promoting the survival of 
other cell types important in RA pathogenesis, either by secreting soluble 
molecules or via cell-cell interactions.  Upon stimulation with IL-1 and TNF, they 
are capable of producing a number of macrophage/monocyte recruiting 
molecules – including IL-1, RANTES, MCP-1, MIP-1α and MIP-1β.  Both T and B cell 
survival has also been shown to increase when they are incubated with FLS, 
which can produce SDF-1α – thereby inhibiting T cell apoptosis – and BAFF – 
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which promotes B cell survival [194, 195].  In expanding joints neovascularisation 
is a requirement to support the increased cell numbers.  Chemokines produced 
by the FLS such as VEGF, IL-8 and SDF-1 can promote angiogenesis [196]. 
A body of evidence now suggests that some of these changes observed in RA FLS 
could be the result of epigenetic alterations.  A recent definition of epigenetics 
states it is “the structural adaptation of chromosomal regions so as to register, 
signal or perpetuate altered activity states” [197]. Several methods of 
epigenetic changes in FLS have been studied in the context of RA, including DNA 
methylation and histone modifications.  A global hypomethylation signature is 
found in RASF compared to those from OA or healthy controls [198, 199].  
Hypomethylation was found in specific loci associated with genes that have 
significant relevance to RA.  These include the cartilage glycoprotein GP39, the 
transcription factor STAT3 and TNF receptor-associated factor 2 (TRAF2) - which 
is involved in TNF receptor signal transduction [199].  Hypomethylation is 
generally associated with increased gene expression, so hypomethylation of 
these targets could be involved in the pathogenetic phenotype witnessed in 
RASF.  Many therapeutics in RA currently target the immune system directly, but 
due to the common adverse effects of immunosuppression, many studies are now 
looking at the potential therapeutic benefit of targeting fibroblasts. 
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 Monocytes and macrophages 1.2
Monocytes and macrophages are mononuclear phagocytes that play crucial roles 
in tissue homeostasis and immunity.  Since the hypothesis proposed by van 
Furths of the mononuclear phagocyte system in 1968 [200], it was generally 
accepted that monocytes circulate in the blood, and can then move into 
peripheral tissues for further maturation and differentiation towards 
macrophages (process summarised in Figure 1-2). 
 
Figure 1-2 Original theory of monocyte, macrophage and dendritic cell differentiation 
It is known that hematopoietic stem cells (HSC) give rise to myeloid progenitors (MP) and then 
macrophage / DC progenitors (MDP). It was originally thought that these MDPs in turn gave rise to 
monocytes and common DC progenitors (CDP) in the blood, which moved into tissues to 
differentiate into macrophages, monocyte-derived DCs, plasmacytoid (pDC) or conventional (cDC) 
DCs. 
Technological advances, and the discovery of diverse and unique mononuclear 
cell populations have questioned this idea, and our understanding of monocyte 
and macrophage differentiation and function has changed dramatically in recent 
years.  Many of these new ideas are based on experiments carried out in mice.  
Although monocyte subsets in mice are phenotypically different and carry 
different surface markers, many experiments suggest at least some similarities 
between the functions of these cells and their human counterparts, so parallel 
experimentation in rodents and humans appears warranted on this basis.  
Broadly speaking there are two main monocyte populations found in mice that 
have great similarities to human populations (summarised in Table 1-5).  Murine 
HSC MP MDP
pDC cDC
Tissue
Macrophage
CDPmonocyte
Monocyte 
derived DC
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cells are subdivided based on their expression of Ly6C (Ly6Chi and Ly6Clo/-), 
whereas human monocytes are generally subdivided based on their expression of 
CD14 and CD16 (CD14hi CD16- and CD14dim CD16+).  Gene expression profiling of 
these subsets has suggested that the CD14hi human monocytes are very similar to 
Ly6Chi murine cells, while CD16+ human monocytes may be the counterparts of 
Ly6Clo/- murine cells [201].  While this approach has shown that the murine and 
human monocyte subsets are quite broadly conserved, it also highlighted a 
number of differences, which could have important consequences when 
considering how to apply findings from murine experimental models directly to a 
human setting. 
Monocyte 
population 
Species Markers Primary Functions Refs 
Classical 
monocytes 
Human CD14hi CD16- Highly phagocytic cells that are 
recruited to sites of inflammation 
[202] 
Mouse Ly6Chi [203] 
Alternative 
monocytes 
Human 
CD14dim 
CD16+ 
Crawl along the inside of the lumen, 
possible roles in surveying endothelial 
integrity and responding to local 
stresses and viral infection 
[204] 
Mouse Ly6Clo/- [205] 
Table 1-5 Table of the main monocyte populations in humans and mice 
 
Although many of the first studies comparing monocyte subsets in mice and 
humans focussed on these two populations, for both mice and humans a third 
population has been suggested.  This is often referred to as the intermediate 
monocyte population as it may represent an intermediate phase during 
differentiation - although these cells appear to have their own unique set of 
marker expression profiles.  In humans, the third monocyte population are CD14+ 
CD16+ cells [206], while in mice they are Ly6C intermediate cells (Ly6Cint).  Flow 
cytometry plots of these three populations in both humans and mice are shown 
in Figure 1-3.  
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Figure 1-3 FACS representations of monocyte populations in humans and mice 
New studies suggest the division of human and murine monocytes into three subsets – classical 
(red box), intermediate (purple box) and non-classical (blue box) cells. Shown are flow cytometry 
plots from my own work, which are representative of others in the literature, showing the markers 
that are suggested to differentiate between the subsets. In humans the monocyte populations can 
be separated based on their expression of CD14 and CD16 – CD14
hi
 CD16
-
, CD14
hi
 CD16
+
 and 
CD14
dim
 CD16
+
. In mice however, a single marker (Ly6C) is used to differentiate between the 
subsets – Ly6C
hi
, Ly6C
int
 and Ly6C
lo/-
. 
The phenotype of these intermediate cells is somewhere between the classical 
and non-classical monocytes, and in time courses of inflammatory disease in 
mice an increase in intermediate monocytes is followed by an increase in non-
classical monocytes.  This could suggest that the intermediate cells develop into 
non-classical monocytes [207]. 
One of the main changes to our thinking in recent years is that tissue 
macrophages may not be primarily derived from monocytes.  Macrophages were 
originally thought of as fully differentiated cells with little proliferative 
capacity.  Instead of self-renewal, it was thought that macrophages were 
replenished by monocyte recruitment into the tissues.  For many sites though, 
macrophage replenishment by self-renewal has now been demonstrated in mice.  
This includes the highly specialised Langerhans cells in the skin [208, 209] and 
brain microglia [210], but also classical tissue-resident peritoneal macrophages 
[211, 212].  However, it has also been demonstrated that bone marrow derived 
cells are able to replace resident cells after their experimental ablation [212, 
213], although it was not determined whether these cells recapitulate all 
functions of the cells they replace. 
CD11b
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Although more recent experiments dispute whether monocytes differentiate into 
macrophages in the steady state, it is well established that during infection or 
when tissues are damaged following injury, monocytes are recruited into the 
tissues where they can differentiate into monocyte-derived macrophages 
(reviewed in [214, 215]).  
The signals these cells receive once in the tissues are thought to determine their 
mature phenotype.  Although there is still controversy over whether these 
represent distinct populations, or are simply cells responding to their micro-
environment, macrophages are generally split into two major subsets – M1 and 
M2 cells.  The M1 macrophages (often referred to as classical or inflammatory 
macrophages) differentiate in response to inflammatory cytokines such as IFN-y, 
GM-CSF and TNF-α or TLR stimulation (such as LPS), while M2 macrophages 
(often referred to as alternative or anti-inflammatory macrophages) are induced 
upon exposure to IL-4, IL-13 and M-CSF.  
Cells recruited to an inflammatory environment therefore differentiate into 
inflammatory M1 macrophages.  These cells are crucial for host defence as they 
facilitate the clearance of invading micro-organisms, but they can also cause 
substantial damage, especially where the response is uncontrolled or triggered 
unnecessarily.  When this happens damage can be caused by the macrophages 
production of inflammatory cytokines, toxic reactive oxygen and nitrogen 
species, and their promotion of pathogenic Th1 and / or Th17 cells [216, 217]. 
Because of this, macrophages have been implicated in the pathogenesis of a 
number of autoimmune diseases, including multiple sclerosis, inflammatory 
bowel diseases and rheumatoid arthritis, where they are thought to be an 
important source of many of the inflammatory cytokines that drive the on-going 
inflammation. 
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 Monocytes and macrophages in rheumatoid arthritis 1.2.1
Monocytes and macrophages are known to be crucial players in RA disease 
pathogenesis.  Herein they display clear signs of activation, both in the synovium 
and also in extra-articular locations such as the peripheral blood, which could be 
important in the systemic complications associated with RA [218].  In healthy 
individuals, CD16+ monocytes account for just under 10% of the total blood 
monocyte population, but in RA this is increased to between 11 and 15% [219, 
220].  Monocytes from RA patients were also found to have increased expression 
of TLR2 [221], and CD16+ monocytes produce higher TNF-α levels in response to 
TLR2-specific ligands [222].  CD16 expression on blood monocytes has also been 
shown to correlate with disease activity [223].  Together these data suggest that 
monocytes in the periphery of RA patients have a “pro-inflammatory” phenotype 
and display clear signs of activation.  Moreover, CD16+ monocytes in the 
periphery and lining layer of synovial tissue display increased CX3CR1 expression.  
This is the ligand for fractalkine, a receptor found at high levels in the synovial 
fluid of RA patients and thought to be involved in the recruitment of monocytes 
into the inflamed synovium [224]. 
When monocytes arrive in the inflammatory environment of the inflamed 
synovium, they will mature and differentiate into various effector cell lineages – 
including macrophages [225, 226].  These cells will become activated by the 
various inflammatory signals, including cytokines and TLR ligands, and in turn 
will be stimulated to produce a variety of cytokines that further perpetuate the 
on-going inflammation.  The key cytokines macrophages produce include IL-1, IL-
6 and TNF-α.  Biologic therapies opposing the actions of these cytokines are all 
successful to some degree in treating RA patients, further establishing a role for 
the cytokines and macrophages in RA pathogenesis.  Another indication that 
macrophages are involved in disease pathogenesis is the correlation between the 
degree of macrophage infiltration in the synovium, therapeutic response and 
radiological progression of disease in RA patients [227].  The two main ways 
macrophages are thought to influence other cells and processes in the synovium 
are via cell-cell interactions or by their release of soluble mediators. 
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1.2.1.1 Cell-cell interactions 
Cell-cell interactions between macrophages and other inflammatory cells, as 
well as mesenchymal cells, are known to be important in immune function. 
Interactions between macrophages and synovial fibroblasts are thought to be 
important in RA, and in vitro co-cultures of these cells have shown that they 
induce much higher cartilage degradation together than either cell type can 
induce alone [228].  Direct cell contact between macrophages and fibroblasts 
has also been shown to promote the production of IL-6, GM-CSF and IL-8 [229]. 
In synovial tissue, macrophages are also found in very close contact with T cells 
[230].  It is known that T cell contact can stimulate human monocytes and 
macrophages to produce inflammatory mediators such as IL-1, IL-6 and TNF-α in 
a cell-contact dependant manner [231, 232]. 
A recent study by Evans et al has shown that CD14+ monocytes isolated from the 
SF of RA patients, but not from the PB, spontaneously and specifically induce a 
Th17 phenotype in blood-derived CD4+ T cells.  Co-culture of PB CD4+ cells with 
RA SF CD14+ cells resulted in a higher percentage of IL-17 expressing cells, but 
similar numbers of IFN-γ and IL-4 expressing cells compared to co-culture with 
PB CD14+ cells, suggesting specific enhancement of the capacity to expand Th17 
responses, but not Th1 or Th2 cells.  These data suggest that CD4+ T cells that 
migrate into the inflamed RA synovium could be driven towards a Th17 cell 
phenotype by interactions with activated monocytes or macrophages – indicating 
a crucial role for monocytes and macrophages in the synovium in shaping the 
phenotype of other cell populations [233]. 
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1.2.1.2 Soluble mediators 
Fully differentiated and activated macrophages produce a number of soluble 
mediators that act in an autocrine fashion, and also on neighbouring cells to 
contribute to the continual inflammation and joint destruction.  These soluble 
mediators include the numerous inflammatory cytokines as well as a range of CC 
and CXC chemokines. 
Among the chemokines of interest is CXCL16.  This is the ligand for CCR6 that is 
present on RA peripheral blood monocytes, and involved in their recruitment 
into synovial tissue [234].  Synovial macrophages also produce chemotactic 
factors for other cells – including CXCL8, CXCL1, CXCL7 and CCL18 - which could 
be involved in recruiting neutrophils and T cells to the joints [102, 235].  
Of the cytokines synovial macrophages produce, TNF-α, IL-1 and IL-6 are among 
the most important.  TNF and IL-1 are thought to be primarily produced by 
macrophages, while IL-6 is produced by macrophages and FLS.  The key roles of 
these cytokines relevant to RA are outlined in Table 1-6. 
Cytokine Key functions relevant to RA 
TNF-α 
 activates leukocytes and endothelial cells, causing their production of 
cytokines, chemokines, adhesion molecules and matrix degrading enzymes 
 blocks the activity of regulatory T cells 
 activates osteoclasts 
 promotes resorption or cartilage and bone 
IL-6 
 promotes activation of leukocytes and osteoclasts 
 important role in driving B cell proliferation, differentiation and antibody 
production 
 regulates lipid metabolism 
 important regulator of the acute-phase response 
IL-1 α/β 
 promotes activation of leukocytes and endothelial cells 
 induces matrix enzyme production by chondrocytes 
 activates osteoclasts 
Table 1-6 Key functions of TNF-α, IL-6 and IL-1 relevant to RA 
Adapted from [236]. 
 
Therapies targeting these molecules are validated therapies in the treatment of 
RA.  Treatment of patients with anti-TNF and IL-6 provide marked improvement 
in disease, but the clinical benefits of anti-IL-1 therapy appear to be modest.  
TNF is present in most RA synovial biopsies, and its inhibition has been shown to 
suppress several arthritis models in mice. Anti-TNF therapy is effective in 
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treating around 70% of patients with established disease, resulting in reduced 
levels of IL-6 and acute-phase proteins [237], with treatment also thought to 
help impaired T cells regain their regulatory function [155].  The levels of IL-1 
found in the synovial fluid of RA patients has been shown to correlate with 
inflammation [238].  This cytokine could have numerous roles in disease 
pathogenesis.  It is involved in proteoglycan synthesis and degradation, and was 
shown to play a role in the breakdown of articular cartilage in an antigen 
induced arthritis model [239].  The IL-1 type 1 receptor mediates IL-1-induced 
cell activation and is found on many cells in the RA synovium [240], so IL-1 
produced by synovial macrophages could have effects of various other cells 
within the synovium. 
Taken together these data show the many and varied potential ways monocytes 
and macrophages could contribute to RA pathogenesis, but the mechanisms 
underlying inflammatory gene expression in these cells are not fully understood.  
We therefore chose to investigate this area of research in our study. 
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 Non-coding RNA 1.3
One fascinating and rather novel area of research that could provide new 
treatment targets in RA comprises the RNA interactome – especially the 
potential role of microRNA.  Protein coding genes make up less than 2% of the 
human genome, with the remainder made up of non-protein coding 
deoxyribonucleic acid (DNA) [241].  Originally thought of as ‘junk’ DNA, it is now 
estimated that approximately 75% of the human genome is transcribed [242], so 
non-coding ribonucleic acid (RNA) accounts for a large proportion of our 
transcriptional output.  Non-coding RNA includes transfer RNA and ribosomal RNA 
which are important for protein synthesis, as well as the more recently 
discovered long non-coding RNAs, piwi-interacting RNA (piRNA) and microRNAs 
(miRNAs/miRs) [243, 244]. 
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 microRNA 1.4
MicroRNA are a family of small, non-coding RNA species around 22 nucleotides 
long, which have emerged as key regulators of mammalian gene expression.  
They were first discovered in Caenorhabditis elegans (C. elegans) as a small non-
protein coding RNA that could negatively regulate the protein level of LIN-14 
through binding of an antisense sequence in its 3’ un-translated region (3’-UTR) 
[245].  Since this finding in 1993, hundreds of miRNAs have been discovered 
which are believed to regulate a large proportion of the human genome [246].  
At present there are 1881 suggested mature microRNA sequences in the miRbase 
database, although some of these are predicted from small RNA deep sequencing 
experiments, so it is unclear how many of these are bona fide true microRNA 
with regulatory function.  They are involved in the post-transcriptional 
regulation of target messenger RNA (mRNA) expression; a single miRNA is 
capable of regulating a number of mRNA – often from the same biological 
pathway.  This renders them appealing therapeutic targets, as it could offer the 
potential benefit of ‘combination therapies’ since a single drug (notionally 
targeting a single miR) could modulate multiple effector pathways (by 
manipulating multiple mRNAs of a given biological pathway).  microRNA are now 
known to be involved in the regulation of many cellular processes – including cell 
cycle, apoptosis and inflammatory cytokine production.  
 miR biogenesis 1.4.1
The main steps involved in the muti-step process of miR biogenesis are shown in 
Figure 1-4.  microRNA are primarily transcribed from intergenic sequences, but 
are also found within the introns of coding genes [247, 248].  In the latter case, 
microRNA often share a common transcriptional unit with the host gene and 
therefore show similar expression patterns [249].  miRNA biogenesis begins in 
the nucleus, where transcription results in the generation of the primary miRNA 
(pri-miR) [250].  The structure of these pri-miRs allows them to be recognised by 
the miRNA “microprocessor complex”, Drosha and DiGeorge critical region 8 
(DGCR8) [251, 252].  Drosha contains two RNase III domains which allow it to 
cleave the pri-miRNA [253], resulting in a double-stranded stem-loop precursor 
miRNA (pre-miR) around 60 - 100 nucleotides long.  These pre-miRs are then 
transported to the cell cytoplasm by Exportin 5, where they are processed by 
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Dicer.  This enzyme facilitates removal of the hairpin loop, leaving a small, 
double stranded miRNA consisting of a “functional” and a “passenger” strand 
(often referred to as miR*).  It was initially thought that the functional strand 
provided the main biological functionality, but increasing data now support a 
role of both strands in gene regulation, with many passenger strands now proven 
to target and suppress their own target genes [254-256].  It is possible that both 
strands have unique roles, or that depending on the cell type and conditions, the 
strand that is preferentially loaded to the RNA-induced silencing complex (RISC) 
may vary.  When the selected miRNA strand is loaded to RISC with argonaute 
proteins it creates a miRISC complex, which can then induce target silencing. 
A microRNA recognises its target through complementary base pairing, and the 
degree of complementarity is thought to be important in determining whether 
mRNA degradation or repression occurs [244].  Full complementary of a miRNA 
with its target mRNA can result in direct Argonaute2-catalysed endonucleolytic 
cleavage of the target [257, 258].  This process is common in plants, but rare in 
mammals [259].  In mammals complementarity between the microRNAs “seed 
sequence” and its target mRNA appears to be the primary method for target 
recognition.  The seed sequence is nucleotides 2 to 7/8 in the 5’ region of the 
miRNA [260].  It was initially thought that this reduced complementarity would 
primarily result in translation inhibition, but several studies looking into the 
abundance of miRNAs and their respective mRNA targets have shown that they 
largely inversely correlate with each other [261, 262], suggesting that mRNA 
degradation is a major mechanism of microRNA-mediated target inhibition in 
mammals. 
Another important finding concerning microRNA is that they can be released 
from cells in exosomes.  These are cell-derived vesicles that can be found in 
biological fluids such as blood and urine, and also in the medium of cultured 
cells.  Many groups are looking at the potential use of microRNA as biomarkers of 
disease or response to therapy, so the relative accessibility of blood and urine 
make microRNA measurement in their vesicles a promising biomedical approach 
[263, 264].  It has in fact been shown that microRNA derived from exosomes in 
metastatic prostate cancer differ significantly compared to those derived from 
non-recurrent cancer patients [265].  This, and many other studies suggest that 
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microRNA in exosomes could be useful as biomarkers.  Possibly a more 
interesting role of these exosomes though, is the transfer of microRNA between 
cells.  It has been shown in vitro that exosomes derived from cells can be taken 
up by other cells, and microRNA within these exosomes are then functional in a 
miRNA reporter assay in the host cell [266]. 
 
 
Figure 1-4 Typical microRNA biogenesis pathways  
MiRNA are mainly transcribed from specific, miR-encoding, intergenic regions of the host genome, 
though some can be found in intronic sequences.  Intergenic miRs are transcribed by RNA 
polymerase enzymes to form a primary miRNA (pri-miR) transcript, which is then bound to anchor 
protein DGCR8 and cleaved by the enzyme Drosha to create the pre-miR.  Intronic miRs are co-
transcribed with protein-coding genes, then spliced by the lariat debranching enzyme (Ldbr) to form 
the pre-miR.  These pre-miRs are then transported to the cell cytoplasm by Exportin 5, where they 
are cleaved by Dicer to form a short, double-stranded miRNA molecule.  It was initially thought that 
the passenger strand was degraded, while the functional strand was loaded with argonaute 
proteins into the RISC complex.  The miRISC complex can then induce target mRNA silencing. 
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 The role of microRNA in development 1.4.2
The first suggestion that microRNA could play a role in development came with 
their discovery.  The microRNA lin-4 was shown to negatively regulate the 
expression of lin-14 [245, 267] – a key protein involved in controlling larval 
development in C. elegans [268].  A key role for microRNA in development is also 
suggested in studies of knockout (KO) mice lacking some of the key microRNA-
processing factors.  Lack of Dicer, Drosha or Ago2 individually in mice was 
embryonically lethal [269-271].  So, in order to study the role of microRNA 
conditional knockouts were made.  
Embryonic stem cells (ESCs) are stem cells derived from the undifferentiated 
inner mass cells of a human embryo, and are the pluripotent cells that have the 
potential to develop into each of the more than 200 cell types of the adult body 
under the correct signals.  A conditional knockout of dicer-1 in embryonic stem 
cells alone, results in viable mice, but the cells display severe defects in 
differentiation [272].  ESCs have been shown to express a unique set of 
microRNA, including the miR-302 family.  This cluster of 5 miRs are not detected 
in cells at later stages of development or in adult tissues.  It is thought that 
these miRNAs may play an essential role in maintaining pluripotency and aiding 
the differentiation of ESCs [273, 274]. 
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 miRNA in immune cell regulation 1.4.3
Several studies have now highlighted the role of microRNA in both the 
development and function of immune cells.  The differentiation of 
haematopoietic stem cells to committed progenitor cells and then mature 
effector cells has to be tightly regulated at both the transcriptional and post-
transcriptional level.  One of the first studies to highlight the importance of 
microRNA in this process focussed on miR-181.  This microRNA is expressed in 
murine bone marrow cells, and up-regulated specifically during the 
differentiation of B cells.  It was also shown in vitro that ectopic expression of 
miR-181 in haematopoietic progenitor cells promotes B cell differentiation – 
suggesting that this microRNA is a positive regulator of B cell differentiation 
[275]. 
Since then several studies have followed microRNA expression during mammalian 
haematopoiesis and have shown that many microRNA are differentially expressed 
throughout differentiation of haematopoietic stem cells to mature, 
differentiated effector cells [275-277].  This said, few studies have actually 
identified the targets of these microRNA – so future studies should focus on 
potential targets that could influence lineage commitment to determine 
whether microRNA really are important regulators of this process.  A regulatory 
role for microRNA in cell differentiation is, however, implicated in a study of 
mice deficient in Dicer specifically in myeloid progenitor cells.  In this system 
there was impaired differentiation of myeloid cells, and progenitor cells even 
regained self-renewal potential [278]. 
As well as being important for immune cell differentiation, many microRNA are 
now known to be involved in the activation of immune cells.  For example, one 
study showed that miR-146a, miR-155 and miR-132 were up-regulated after 
exposure of a human monocytic cell line - THP-1 cells - to LPS [279].  This group 
then went on to show that microRNA up-regulation was not solely a response to 
cell activation – but they showed a more specific pattern of expression.  miR-
146a up-regulation was only induced upon stimulation of TLRs recognising 
bacterial components (TLR2, 4 and 5) but not intracellular TLRs recognising viral 
components (TLR3, 7 and 9).  Other groups went on to define possible targets of 
miR-146a and miR-155 that could be involved in cell activation.  Current 
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evidence suggests that while miR-146a up-regulation could be an attempt to 
attenuate inflammation, increased miR-155 actually promotes inflammation. 
miR-146a has been shown to target interleukin-1 receptor-associated kinase 1 
(IRAK1) and TNF receptor associated factor 6 (TRAF6) – key signalling molecules 
that can promote inflammation [280].  miR-155, on the other hand, has been 
shown to target SH2-containing inositol-5'-phosphatase 1 (SHIP-1) [281] and 
suppressor of cytokine signalling 1 (SOCS-1) [282] – two important negative 
regulators of the TLR pathway.  Increased miR-155 expression could therefore 
down-regulate SHIP-1 and SOCS-1 expression, in turn increasing inflammatory 
cytokine production.  Indeed, mice deficient in miR-155 show increased 
expression of both SHIP-1 and SOCS-1, and their macrophages show impaired 
inflammatory response to LPS stimulation [283].  
miR-187 is a further anti-inflammatory miR.  Increasing its expression in 
monocytes reduces their LPS-induced release of TNFα, IL-6, and IL-12p40, while 
inhibiting miR-187 increases their production.  The effects of miR-187 on TNF 
are direct, but it is thought to down-regulate IL-6 and IL-12p40 indirectly via 
IκBζ, a master regulator of the transcription of these latter two cytokines [284] 
With regards to autoimmune, inflammatory conditions, microRNA-21 is 
demonstrated to be up-regulated in many diseases, including SLE [285, 286], 
ulcerative colitis [287, 288] and psoriasis [289].  In psoriasis miR-21 was shown 
increased in lesional, but not non-lesional skin, where it is thought to play a role 
in promoting T cell survival by inhibiting apoptosis.  Indeed, in vitro inhibition of 
miR-21 resulted in an increase in apoptosis, while the overexpression of miR-21 
reduced the apoptosis rate in T cells [289].  Inhibition of miR-21 was also found 
to ameliorate disease pathology in patient-derived psoriatic skin xenotransplants 
in mice and in a psoriasis-like mouse model [290].  
These studies, along with many others, highlight the role of microRNA in both 
the positive and negative regulation of inflammation. 
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 MicroRNA in RA 1.4.4
It is known that miRNA regulate a wide range of cellular processes, including cell 
growth, proliferation and death, so it is unsurprising that they have now been 
implicated in a number of disease states.  A large literature base has described 
their potential roles in a variety of cancers [291, 292], and more recently 
interest has grown in their potential activities in autoimmunity [293, 294].  In 
RA, there is an increasing literature describing miRNA dysregulation, and the 
potential consequence this could have on disease activity.  
In 2008, Stanczyk et al provided the first report that microRNAs were 
dysregulated in RA patients [295].  They found that two particular microRNA – 
miR-155 and miR-146a – were markedly up-regulated in RA synovial fibroblasts 
(SF) compared to osteoarthritis (OA) SFs.  They further found that miR-155 was 
up-regulated in response to stimulation of these cells with inflammatory 
cytokines (TNF-α and IL-1β) and TLR ligands (LPS and polyI:C), but its forced up-
regulation resulted in reduced MMP production in response to stimulation.  They 
therefore concluded that the inflammatory microenvironment of the RA 
synovium could alter the microRNA expression of resident cells, and that the 
increased miR-155 expression was an attempt to modulate the destructive 
nature of RASFs.  Since this report in 2008, a number of studies have looked at 
microRNA expression in RA, and many miRs are now known to be up or down-
regulated in various cell subsets in the synovium and peripheral blood of RA 
patients (summarised in Table 1-7), which have been contributed to a variety of 
pathological consequences. MiRs have been implicated in the regulation of 
leukocyte activation and subsequent cytokine production, and also in the 
generation of the activated and invasive phenotype of RA-fibroblast like 
synoviocytes [295-297].  
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miRNA Where 
Known targets in 
RA cells 
Known effects of 
Dysregulation 
Refs 
miR-155 
↑ SF   [298] 
↑ SP   [298] 
↑ PBMC   [299] 
↑ FLS MMP-1 and 3 Decrease MMP production [295] 
↑ CD14+ cells SHIP-1 
↑ pro-inflammatory cytokine 
production 
[300] 
miR-
146a 
↑ SF   [298] 
↑ SP   [298] 
↑ PBMC TRAF-6, IRAK-1 Inhibits osteoclastogenesis [299] 
↑ FLS   [295] 
↑ CD4+ T 
cells 
  
[301, 
302] 
miR-223 
↑ CD4+ T 
cells 
  [303] 
↑ synovial 
monocytes & 
macrophages 
Osteoclastogenesis 
markers 
Inhibits osteoclastogensesis [304] 
miR-
124a 
↓ FLS CDK-2, MCP-1 
Contributes to apoptosis 
resistance and promotes 
proliferation and chemokine 
production 
[297, 
305] 
miR-203 ↑ FLS  ↑ MMP-1 and IL-6 [306] 
miR-
34a* 
↓ FLS XIAP 
Contributes to apoptosis 
resistance 
[254] 
miR-
19a/b 
↓ FLS TLR2 
Impaired regulation of MMP-3 
and IL-6 
[307] 
miR-
23b 
↓ FLS TAB2, TAB3, Ikk-α 
Impaired regulation of NFkβ 
activation and pro-
inflammatory cytokine 
production 
[308] 
miR-221 ↑ FLS   [309] 
miR-222 ↑ FLS   [309] 
miR-
323-3p 
↑ FLS Β-transducin 
Enhanced WNT/Cadherin 
signalling 
[309] 
Table 1-7 List of microRNA dysregulated in RA and suspected consequences 
↑ - up-regulated, ↓ - down-regulated, SF - synovial fluid, SP - serum plasma, FLS - fibroblast-like 
synoviocytes, PBMC - peripheral blood mononuclear cells. 
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MiRNA regulate some of the pro-inflammatory cytokines that play key roles in RA 
disease pathogenesis – including TNF, although relatively few studies have as yet 
focussed especially on RA derived tissues.  Several miRNA have been shown to 
promote TNF-α down-regulation, with others increasing its expression.  MiR-16 
and miR-369-3 both bind to the TNF AU-rich element (ARE), which regulates 
mRNA stability.  miR-16 is required for ARE-mediated degradation of TNF [310], 
whilst miR-369-3 promotes TNF mRNA translation [311].  miR-125b has also been 
shown to inhibit TNF while miR-155 enhances its production [300], showing that 
even for a single cytokine, miRNA regulation is complicated, but an incredibly 
important mechanism of regulation. 
Growing evidence suggests that miRNA networks govern the unique biology of 
FLS in RA.  An over-production of IL-6 by these cells appears to correlate with 
elevated miR-203 expression [306], whilst reduced levels of miR-124a and miR-
34a*, which target a cell cycle progression protein (cyclin-dependent kinase 2) 
[297] and an inhibitor of apoptosis (X-linked inhibitor of apoptosis) [254] 
respectively, could explain the increased expansion of FLS in RA joints, and 
consequent cartilage invasion.  On the other hand, high levels of miR-155, which 
inhibits MMP production, and miR-146a, which targets TLR signalling molecules, 
may reflect the initiation of inflammation counterbalance mechanisms in these 
cells [295]. 
1.4.4.1 MiRs in in vivo Animal Models of RA 
Much of the research examining a potential role of miRNA in inflammatory 
arthritis has been undertaken in vitro.  Although useful for understanding their 
basic functions and targets, this can in no way elicit the role these complicated 
RNA species play in a whole organism during disease processes.  Our 
understanding of how miRNA function is further complicated with the idea of 
competing endogenous RNA (ceRNA) and miRNA networks.  The relationship 
between a miRNA and its target is not linear, but instead is likely to depend 
upon the levels of other targets of the given miR (other mRNA and pseudogenes), 
and also the expression level of other miRs that may positively or negatively 
regulate the given mRNA [312].  Together this means that in order to get a true 
picture of a miRNAs effects, we must study the consequence of miRNA 
  72 
 
 
dysregulation in an organism as a whole.  A number of groups have now looked 
at the effects of miRNAs in vivo in established animal models of arthritis. 
Possibly the most extensively studied miRNA in arthritis is miR-155.  This miRNA 
is up-regulated in cells of both the synovium and peripheral blood of RA 
patients, and is thought to be involved in regulating the production of pro-
inflammatory cytokines by macrophages and metalloproteinases by FLS [295, 
299, 300].  In vitro experiments suggest that over-expression of miR-155 in 
monocytes/macrophages results in the up-regulation of a number of pro-
inflammatory cytokines, including TNF-α and IL-6 [300] – cytokines proven to be 
involved in RA disease pathogenesis and validated therapeutic targets of the 
disease.  Consistent with a pro-inflammatory role, one of the candidate 
molecular regulatory targets of miR-155 – at least in myeloid cells – is the 
inflammatory inhibitor SHIP-1 [281, 300]. 
To test a possible role of miR-155 in vivo, two groups - Kurowska-Stolarska et al 
and Bluml et al, used the murine model of collagen-induced arthritis (CIA).  
Kurowska-Stolarska et al showed that, similar to the RA synovium, miR-155 
expression was up-regulated in the joints of WT CIA mice compared to control-
immunised mice, and in both studies, miR-155 deficiency offered protection 
from the development of arthritis.  After induction of CIA, wild type (WT) mice 
develop the expected levels of disease, but miR-155-/- mice fail to develop any 
clinical signs of arthritis [300, 313].  Both groups noted a decrease in joint and 
systemic inflammation, Th17 cell expansion, and a reduced capacity of cells to 
produce collagen-specific IgG antibodies in the miR-155-/- mice.  Together these 
studies suggest that miR-155 regulation has an important role in the 
development of both innate and adaptive arms of immune responses.  Although 
the primary trigger of miR-155 in CIA and RA has not yet been defined, it has 
been shown that miR-155 is up-regulated upon TLR stimulation [281, 300].  
Therefore it is likely that endogenous TLR ligands, generated by tissue damage, 
may up-regulate miR-155 in monocytes/macrophages, resulting in the production 
of pro-inflammatory cytokines by myeloid cells, which goes on to drive 
inflammation and support Th17 cell development.  Consistent with this data it 
has been reported that miR-155 is involved in the development of Th17 cells in 
other experimental murine diseases [314].  In addition, miR-155 is intrinsically 
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involved in plasma cell differentiation and B cell class switching by targeting 
lymphotoxin-alpha and activation induced cytidine deaminase [315-317]. 
Bluml et al also used the K/BxN serum-transfer murine arthritis model to 
determine whether miR-155 deficiency affects the FcR-mediated innate effector 
response during arthritis, and found under these circumstances WT and miR-155-
/- mice develop comparable arthritis in terms of paw swelling and histological 
examination.  This suggests that miR-155 regulated pathways are not non-
redundantly involved in the effector antibody-mediated responses [313].  This 
supposition is supported by in vitro data showing that there was no difference in 
TNF-α production by WT or miR-155 deficient macrophages upon stimulation 
with immune-complexes [300].  The miR-155/- mice did, however, develop fewer 
bone erosions, thought to be due to a reduced number of osteoclasts. The group 
went on to show impaired RANK-L-induced osteoclast formation in vitro from 
miR-155-/- murine bone marrow.  Thus, unbalanced miR-155 expression in 
myeloid cells leads to the profound perturbation in their activation and 
development into osteoclasts.  Given that miR-155 appears to be involved in the 
regulation of many pathways involved in development and progression of 
arthritis, it may represent a novel and promising therapeutic target in the 
treatment of autoimmune disease.  Its wider biologic activities, however, 
indicate that such approaches should be made in a cautious manner at this 
stage, as on target adverse events in other tissues might be predicted. 
A critical pathogenic aspect of RA is the expansion and proliferation of FLS.  
These cells develop an aggressive and invasive phenotype, which allows them to 
invade and degrade the articular cartilage.  miR-15a has been shown to induce 
cell apoptosis by down-regulating the anti-apoptotic Bcl-2, which has previously 
been shown up-regulated in RA FLS [318-320].  To investigate whether miR-15a 
could exert its effects in vivo, Nagata et al injected the double-stranded 
microRNA into mice with autoantibody mediated arthritis [321].  In this study, 
intra-articular injection resulted in the down-regulation of Bcl-2 and an increase 
in caspase 3 expression compared to the control group.  This led to the induction 
of apoptosis in synovial fibroblasts, thus limiting their invasion into adjacent 
cartilage.  This study provides a promising indication that local administration of 
miRNA mimics targeting proliferation and survival pathways in synovial 
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fibroblasts, could be a useful approach to tackle the inflammatory synovitis 
associated with RA. 
Another miRNA of which the function has been studied in vivo is miR-146a.  This 
miRNA is highly expressed in RA FLS, and in RA synovial tissue as a whole [295, 
296].  It is also overexpressed in PBMCs from RA patients, compared to healthy 
controls or OA patients [299].  miR-146a is induced in macrophages [279] and 
synovial fibroblasts [295] upon stimulation with TLR ligands or IL-1β.  Numerous 
functional in vitro studies suggest that miR-146a acts as a negative feedback 
regulator of innate immune responses by targeting the TLR signalling molecules 
IRAK1 and TRAF6, as well as cytokine signalling molecules, such as STAT1 [279].  
Consistent with these data miR-146a deficient mice spontaneously develop 
autoimmunity [280].  Interestingly, systemic administration of miR-146a mimics 
into mice with full-blown CIA prevented cartilage and bone destruction, but not 
inflammation and synovitis.  This group also showed that transfection of PBMCs 
with miR-146a inhibits osteoclastogenesis in vitro [322].  This study suggests that 
miR-146 may be involved in targeting pathways regulating bone turnover, but its 
potential contribution to dampening on-going inflammation is still controversial. 
It is likely that injection of miR-146a mimics into mice with late phase CIA was 
not able to affect inflammation, as other pathways – such as immune-complexes 
and cell-cell interactions – are known to be involved in driving inflammation at 
this stage.  Thus, administration of miR-146a mimics before the onset of 
arthritis, and studies of miR-146-/- mice in different arthritis models would help 
to understand and validate its potential role in preventing and limiting chronic 
inflammation. 
Most microRNA that are studied in the context of inflammation are found due to 
their increased expression in disease, but microRNA-23b was found to be down-
regulated in inflammatory lesions of lupus and rheumatoid arthritis, as well as in 
the mouse models of lupus, rheumatoid arthritis and multiple sclerosis.  In 
transgenic mice over-expressing miR-23b, the onset of CIA as well as EAE was 
delayed and found to be less severe compared to wild-type mice.  Also 
consistent with a protective, anti-inflammatory role, administration of a miR-
23b sponge that inhibits the microRNAs function caused more severe disease 
symptoms and bone erosion during a CIA model.  The study went on to identify 
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TGF-Beta Activated Kinase 1/MAP3K7 Binding Protein (TAB) 2, TAB3 and IkappaB 
kinase complex (IKK) α as novel miR-23b targets.  These molecules act in 
signalling cascades downstream of inflammatory cytokines.  Suggesting that miR-
23b regulates inflammatory cytokine-mediated signalling. [308] 
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 miRNA in Other Joint Diseases 1.4.5
A role for miRNA in osteoarthritis (OA) has also been established.  miR-140 is 
expressed in normal human articular cartilage, but is significantly reduced in 
patients suffering from OA.  Treatment of chondrocytes in vitro with IL-1β – a 
cytokine known to be associated with OA – also results in reduced miR-140 
expression [323].  The same group went on to do a serious of in vivo 
experiments, using three different animal models to further elucidate the role of 
miR-140 in cartilage homeostasis - an aging model, a surgical model, and an 
antigen-induced arthritis (AIA) model.  In the aging model, miR-140-/- mice 
develop age-related OA symptoms much earlier than WT mice and OA scores are 
much higher in KO mice than age-matched WT mice.  The KO mice also develop 
more severe proteoglycan loss and demonstrate higher OA scores than WT mice 
in the surgical model.  The AIA model was studied in WT, miR-140-/- and 
transgenic (TG) mice overexpressing miR-140 in cartilage.  While synovial 
hyperplasia was not affected in any of the mice genotypes, proteoglycan loss 
was shown to be significantly higher in the miR-140-/-, and lower in the TG mice 
compared to WT [324].  Together, these findings suggest that miR-140 is 
indispensable for cartilage homeostasis and is protective in OA, possibly by its 
repression of the critical cartilage-degrading enzyme – Adamts-5.  
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  microRNA-34a 1.4.6
In mammals, miR-34a is one of a family of three microRNA.  While miR-34a is 
transcribed from chromosome 1, miRs-34b and 34c are co-transcribed from a 
location on chromosome 11.  The mature sequence of these three microRNA is 
shown in Figure 1-5. 
 
 
Figure 1-5 The mature microRNA sequence for human miR-34a, miR-34b and miR-34c 
Shown is the nucleotide sequence for the mature microRNA-34a, 34b and 34c. Highlighted in red is 
the seed sequence which is identical for all three microRNA. In blue are the nucleotides shared by 
at least two of the microRNA. 
 
  
1.4.6.1 miR-34a in cancer 
microRNA-34a is most highly studied in the cancer field, as it is dysregulated in a 
variety of cancers and known to target many genes involved in cell cycle and 
apoptosis.  miR-34a is completely absent or significantly down-regulated in 
numerous pancreatic carcinoma cell lines [325], neuroblastoma [326], as well as 
colon, pancreatic, lung and prostate cancer [327].  Moreover, it has been shown 
that over-expression of miR-34a in both cancer cell lines and primary cells can 
lead to cell cycle arrest [328, 329] and even cellular senescence [330]. 
A mimic of miR-34a – MRX34 – is in fact the first microRNA mimic to enter clinical 
trials [331].  In 2013 a phase one trial started in patients suffering primary liver 
cancer or metastatic cancer with liver involvement, where it is hoped restoring 
miR-34a expression to a more physiological level will restore tumour suppressive 
function to the liver cells. 
The first study published on miR-34a-/- mice highlighted a potential role for miR-
34a in regulating somatic cell reprogramming [332].  This is a process whereby 
differentiated somatic cells are induced to generate pluripotent stem cells 
(iPSCs) by forced expression of a set of specific transcription factors - octamer-
Mature hsa-miR-34a UGGCAGUGUCUUAGCUGGUUGU  
Mature hsa-miR-34b AGGCAGUGUAAUUAGCUGAUUGU
Mature hsa-miR-34c AGGCAGUGUAGUUAGCUGAUUGC
seed sequence same nucleotides
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binding transcription factor 4 (OCT4), SRY (sex determining region Y)-box 2 
(SOX2), Krüppel-like factor 4 (KLF4) and MYC [333].  Although this is an 
inefficient process with slow kinetics, it had previously been shown to be 
enhanced in p53-/- mice [334, 335].  Given the known relationship between p53 
and miR-34a, this group set out to determine whether miR-34a had a role in 
regulating somatic cell reprogramming.  When reprogramming was induced in 
mouse embryonic fibroblasts (MEFs), miR-34a, b and c were all induced in a p53 
dependant manner, with miR-34a being most highly up-regulated.  Similarly to 
p53-/- cells, when this process was induced in MEFs from miR-34a-/- mice, a 
higher number of iPSCs were generated.  The group also showed that miR-34a 
directly targeted Nanog, Sox2 and N-Myc – 3 transcription factors involved in 
maintaining self-renewal and pluripotency of ESCs.  As suggested by its role in 
cancer, this study further declares a role for miR-34a in restraining somatic 
reprogramming.  
1.4.6.2 Other roles of miR-34a 
miR-34a has more recently been implicated in cardiac ageing.  Expression of 
miR-34a, and to a lesser extent miRs 34b and c, is increased in heart tissue 
during ageing in both humans and mice.  miR-34a’s expression is also further 
enhanced in a murine model of acute myocardial infarction.  This study by Boon 
et al went on to show that treatment with a miR-34a inhibitor could reduce age-
associated cardiac cell death and functional decline – at least in part due to its 
targeting of Phosphatase 1 Nuclear Targeting Subunit (PNUTS) [336], which is 
known to be involved in DNA repair [337] and apoptosis [338]. 
A role for microRNA-34a in the regulation of bone turnover has recently been 
highlighted.  Krzeszinski et al reported that miR-34a was down-regulated during 
osteoclast differentiation, and that over and under-expression of this microRNA 
in vitro resulted in decreased and increased osteoclast formation, respectively.  
They also demonstrated that miR-34a knockout mice exhibit elevated bone 
resorption, while transgenic mice overexpressing miR-34a are less susceptible to 
ovariectomy-induced osteoporosis.  Transforming growth factor-β-induced factor 
2 (Tgif2) was identified as a pro-osteoclastogenic target of miR-34a that could 
be responsible for these phenotypes [339]. 
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miR-34a has also been implicated in metabolic disorders.  Its expression is 
elevated in obese mice, and it has been shown to directly target SIRT1, which is 
implicated in the prevention of metabolic disorders [340].  A more recent study 
also suggested that miR-34a could target Nicotinamide phosphoribosyltransferase 
(NAMPT).  This enzyme is proposed to have insulin-mimetic effects, and be 
capable of lowering blood glucose and improving insulin sensitivity. Its serum 
levels also correlate with obesity.  miR-34a inhibition in obese mice restored 
NAMPT levels and improved steatosis, inflammation, and glucose intolerance.  
Therefore miR-34a inhibition could be a potential new target in the treatment of 
obesity and age-related diseases like steatosis and type 2 diabetes [341].  Thus 
far there are no data concerning the role of miR-34a in the pathogenesis of RA. 
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 Research aims 1.5
Although the treatment of rheumatoid arthritis has improved markedly over the 
past 10 – 20 years, there remain a considerable number of patients that fail to 
respond to current therapies – therefore there is still significant unmet clinical 
need.  
microRNA are emerging as an important class of post-transcriptional regulators, 
with a profound and broad effect on many cellular processes.  Accumulating ex 
vivo and in vitro studies suggest that miRNA dysregulation could contribute to 
the development and progression of clinical arthritis, but the complicated 
interactions that take place between miRNA and their targets make it difficult to 
define whether a given miR is simply a fine-tuner, or a master switch regulator 
of the pathways driving arthritis.  Recent progress in the field, including the 
generation of miR deficient mice and development of in vivo quality miRNA 
mimic and inhibitors, will provide an opportunity to understand the hierarchy of 
miRNA networks, and reveal that interfering with miRNA networks could be a 
promising approach to target RA pathogenesis.  In particular, dissecting the role 
of microRNA in regulating the inflammatory gene expression of synovial 
macrophages could provide new insights into disease pathogenesis.  Preliminary 
data from our laboratory have suggested miR-34a may be dysregulated in RA.  I 
wished to follow this observation up and dissect its functional importance in 
detail.  Accordingly, this project has three main aims; 
1. To confirm dysregulated expression in the periphery and / or synovium of 
RA patients 
2. To study the functional consequences of miR-34a dysregulation in 
macrophages – particularly on inflammatory cytokine production 
and 
3. To investigate potential pathways miR-34a may regulate in monocytes and 
macrophages, with an aim to dissect the mechanism of action of any 
functional changes induced by miR-34a 
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 Hypothesis 1.6
Given the previous work carried out in the laboratory looking at microRNA which 
are differentially expressed in RA, my starting hypothesis is that miR-34a is a 
microRNA which is up-regulated in monocytes and macrophages in RA, that 
promotes the pro-inflammatory nature of these cells – therefore contributing to 
RA disease pathogenesis. 
 
  
 
 
Chapter 2 – Materials and Methods 
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 General reagents and buffers 2.1
 Materials and reagents 2.1.1
Basic Chemicals: All chemicals were purchased from Sigma unless otherwise 
stated. 
Plastics: All plastics used for tissue culture were purchased from Corning or 
Greiner unless otherwise stated. 
 Buffers and culture media 2.1.2
Complete RPMI: Roswell Park Memorial Institute (RPMI) 1640  medium 
supplemented with 10% heat inactivated foetal bovine serum (FBS), Penicillin 
(100 units/ml), Streptomycin (100 μg/ml) and L-Glutamine (2 nM) (all 
Invitrogen). 
Complete DMEM: Dulbecco's Modiﬁed Eagle's Medium (DMEM) supplemented with 
10% heat inactivated foetal bovine serum (FBS), Penicillin (100 units/ml), 
Streptomycin (100 μg/ml) and L-Glutamine (2 nM). 
Wash media: RPMI 1640 supplemented with Penicillin (100 units/ml) and 
Streptomycin (100 μg/ml). 
FACS / MACS buffer: Phosphate buffered saline (PBS) (Invitrogen) supplemented 
with 2% FBS, Penicillin (100 units/ml) and Streptomycin (100 μg/ml). The only 
difference between fluorescence-activated cell sorting (FACS) and magnetic 
activated cell sorting (MACS) buffer is that MACS buffer is kept sterile, as cells 
are frequently cultured after its use. 
ELISA wash buffer: 1x PBS (VWR, diluted from 10x with dH2O) with 0.05% Tween 
20 (Sigma). 
Tris-acetate-EDTA (TAE) buffer: A 50x stock solution was made by dissolving 
242g of Tris base in 750 ml dH2O. This was mixed with 57.1 ml glacial acetic acid 
and 100ml 0.5 M Ethylenediaminetetraacetic acid (EDTA) (pH 8).  The final 
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volume was made up to 1000 ml by the addition of dH2O. Before use the 50x 
stock was diluted 1:50 with dH2O. 
Diethyl Pyrocarbonate (DEPC) H2O: DEPC was used to inhibit nucleases and clean 
H2O so it could be used for in situ hybridisation buffers.  1 ml DEPC was used per 
1 L dH2O.  DEPC was dissolved and mixed in water by magnetic stirring.  DEPC-
treated dH2O was then autoclaved to destroy remaining DEPC. 
Saline-Sodium Citrate (SSC) buffer: A 20x stock solution was purchased (Sigma), 
and diluted to the required concentrations in DEPC-treated H2O. 
Tail tip lysis buffer: The alkaline lysis buffer is made up in dH2O containing NaOH 
at a final concentration of 25 nM and 0.2 mM EDTA, pH12. 
Tail tip neutralising buffer: The neutralising buffer is 40 mM Tris in dH2O, pH5. 
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 Collection and culture of human cells and tissues 2.2
 Clinical samples and controls 2.2.1
All samples were obtained from buffy coats, healthy volunteers or patients who 
fulfilled the 2010 American College of Rheumatology/European College Against 
Rheumatism criteria for RA after obtaining written consent. 
Ethical approval for the studies was obtained from the West of Scotland 
Research Ethics committee.  They covered the use of human buffy coat samples, 
and also the use of clinical material from patients with rheumatoid arthritis, 
psoriatic arthritis, osteoarthritis and matched healthy volunteers as required. 
 Purification of mononuclear cells from buffy coats and 2.2.2
peripheral blood 
Peripheral blood mononuclear cells (PBMCs) were purified from blood samples by 
density gradient centrifugation.  Buffy coats were diluted 1 : 1 in wash media, 
while fresh peripheral blood samples were used neat.  10 mls of the blood 
preparation was layered carefully on top of 4 mls Histopaque 1077 (Sigma) in 15 
ml centrifuge tubes.  These were then centrifuged at 2100 RPM for 20 minutes at 
room temperature.  The mononuclear cell layer was carefully removed using a 
Pasteur pipette into a clean 50 ml tube, and an equal volume of wash medium 
added.  Samples were then spun at 1800 RPM for 10 minutes at room 
temperature.  Cell pellets were re-suspended in 20 mls of cold MACS buffer, and 
the number of viable cells determined using Trypan Blue and a haemocytometer. 
Finally, cells were centrifuged at 1800 RPM for 5 minutes at 4ºC before being re-
suspended at the required concentration. 
 Purification of mononuclear cells from synovial fluid 2.2.3
Synovial fluid samples were centrifuged at 2000 RPM for 20 minutes to pellet 
cells.  The cell-free fluid was stored in aliquots at -80ºC, and the cell pellet was 
re-suspended in wash medium.  This cell preparation was layered on top of 4 mls 
Histopaque 1077 in a 15 ml tube and centrifuged at 2100 RPM for 20 minutes at 
room temperature.  The mononuclear cell layer was carefully removed using a 
Pasteur pipette into a clean 50 ml tube, and an equal volume of wash medium 
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added.  Samples were then spun at 1800 RPM for 10 minutes at room 
temperature.  Cell pellets were re-suspended in 20 mls of cold MACS buffer, and 
the number of viable cells determined using Trypan Blue and a haemocytometer. 
Finally, cells were centrifuged at 1800 RPM for 5 minutes at 4ºC before being re-
suspended at the required concentration 
 Isolation of CD14+ monocytes and from mixed PBMCs 2.2.4
CD14+ monocytes were isolated using magnetic-activated cell sorting (MACS) 
positive bead selection (Miltenyi) on an AutoMACS Pro Separator according to the 
manufacturer’s instructions.  We used the Posseld programme, meaning that 
cells are run through two columns to ensure a higher purity was achieved.  After 
isolation, the purity of cells was determined using flow cytometry (described in 
section 2.5.1), and was routinely > 95%. 
 Culture of CD14+ monocytes 2.2.5
Unless otherwise stated, CD14+ cells were either classed as immature monocytes 
and used for stimulation / transfection experiments straight away, or were 
matured using macrophage colony-stimulating factor (M-CSF) (Peprotech) for 7 
days and classed as M-CSF-matured macrophages.  In this case, cells were 
cultured with 50 ng/ml recombinant M-CSF for 3 days before spent media and 
non-adherent cells were removed and fresh media supplemented with 50 ng/ml 
M-CSF was added.  The cells were then cultured for a further 4 days, and classed 
as M-CSF-matured macrophages by day 7. 
 Monocyte / macrophage stimulation 2.2.6
Both human immature monocytes and M-CSF matured macrophages were 
routinely stimulated using the TLR ligands; LPS, poly I:C (both Sigma), Cl097 and 
Pam3CSK4 (Pam3 - Invivogen) at varying concentrations and durations of stimuli 
(noted in the results for each experiment). 
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 Cell transfection 2.3
In order to determine the consequence of microRNA-34a dysregulation, we used 
under and over expression experiments.  Control and microRNA-34a mimics 
(Dharmacon) were used to investigate the effects of its increased expression, 
while control and microRNA-34a inhibitors (Qiagen) were used to look at the 
effects of decreased expression.  Controls routinely run to check effective 
transfection included measuring the microRNAs expression by PCR and using 
miRIDIAN microRNA Mimic Transfection Control with Dy547 to check cellular 
uptake of a labelled mimic. 
 Transfection of human monocytes 2.3.1
For the transfection of CD14+ monocytes freshly isolated from peripheral blood, 
the N-TER nanoparticle siRNA transfection reagent (Sigma) was used at a final 
concentration of 20 nM miRNA mimic or inhibitor.  It important to mention that, 
previous studies carried out in our laboratory had concluded that 20 nM is the 
optimal concentration for the transfection of monocytes using this reagent.  
Transfection reagents were routinely left in cell cultures for 16-24 hours before 
being removed and fresh media added for the remainder of the experiment. 
 Transfection of M-CSF matured macrophages 2.3.2
For the transfection of CD14+ cells which were M-CSF matured, and had 
therefore become adherent, TransIT-TKO® transfection reagent was used 
(mirus) at a final concentration of 25 nM mimic or inhibitor (as advised in 
standard reagent protocol).  Transfection reagents were routinely left in cell 
cultures for 16-24 hours before the cells were taken off for further analysis (flow 
cytometry / ELISA) or stimulated. 
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 Isolation of murine cells 2.4
 Mice 2.4.1
Wild type and miR-34a knockout (miR-34a-/-) C57BL/6 background breeding pairs 
were purchased from Jackson Laboratory, and animals were then bred in house.  
To avoid substrain divergence, miR-34a-/- mice were periodically backcrossed to 
the parental C57BL/6J strain.  All animals were housed in pathogen-free 
conditions within the central research facility (CRF) at the University of 
Glasgow.  All procedures were carried out in accordance with project licences 
approved by the United Kingdom Home Office and in accordance with the 
Animals (Scientific Procedures) Act 1986. 
All mice were culled using recommended schedule 1 methods. 
 PCR genotyping of mice 2.4.2
2.4.2.1 Preparation of tail tips for genotyping 
Mice were genotyped from tail tips cut prior to animals being used for 
experiments.  Mice were first anaesthetised with isofluorane before a 5 mm tail-
tip was cut and the tail cauterised.  The tail tip was then placed in 75 μl tail-tip 
lysis buffer and incubated at 90ºC for 1 hour.  75 μl of neutralising buffer was 
then added to the tubes.  This was either used straight away or stored at -20ºC 
until a polymerase chain reaction (PCR) was performed. 
2.4.2.2 Primers and cycling conditions 
The following primers (as suggested by Jackson) were used for genotyping: 
Common primer 5’- ACTGCTGTACCCTGCTGCTT 
Wild Type  5’- GTACCCCGACATGCAAACTT 
miR-34a KO  5’- GCAGGACCACTGGATCATTT 
Primers were ordered from IDT and made to stock concentrations of 100 μm.  
Working stock solutions were made with all 3 primers together at 2.5 μM and 
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stored at -20ºC.  The 15 μl PCR reaction was made by mixing 7.5 μl Taq (go) 
Colourless Master Mix (Promega), 1 μl of the genomic tail tip DNA and primers at 
a final concentration of 250 nM.  The PCR product was then amplified using a 
thermal cycler with the settings shown in Table 2-1. 
Temperature Time Cycles 
94ºC 2 min - 
94ºC 
65ºC (-0.5ºC/cycle) 
68ºC 
20 sec 
15 sec 
10 sec 
10 cycles 
94ºC 
60 ºC 
72 ºC 
15 sec 
15 sec 
10 sec 
28 cycles 
72ºC 1 min - 
4ºC hold - 
Table 2-1 Thermal cycler settings for tail tip DNA amplification 
 
2.4.2.3 Agarose gel electrophoresis 
All gels used for genotyping were 2% agarose gels made up in Tris-acetate-EDTA 
(TAE) buffer.  This was heated in a microwave to dissolve the agarose before 
ethidium bromide (Sigma) was added and mixed in by gentle shaking.  The 
mixture was then poured into a gel cast and left to set for approximately 20 
minutes.  Once set, the gel was placed in an electrophoresis tank containing TAE 
buffer.  1.5 μl Blue Juice (Invitrogen) was then added to the 15 μl PCR reaction 
before it was added to gel wells.  10 μl of 1 kb plus DNA ladder (Invitrogen) was 
added to one or two wells per gel to estimate the size of PCR products visible.  
The gel was left to run for approximately 40 minutes at 100v before being 
visualised under a UV light. 
Expected results are; 
 WT mouse   - 1 band at ~471 bp 
 KO mouse   - 1 band at ~180 bp 
 Heterozygous mouse - 2 bands at ~471 and ~180 bp 
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 Isolation and preparation of murine cells 2.4.3
2.4.3.1 Isolation of bone marrow cells 
All mice were culled using suggested schedule 1 methods, before the rear legs 
were cut away and removed.  All skin and muscle was cut off and clean tibia and 
femurs were placed in a bijoux containing cold PBS on ice.  The rest of the 
procedure was carried out in a tissue culture flow hood.  Sterile scissors were 
used to cut the ends of the bones, and bone marrow was flushed out with 
complete media using a 25 gauge, 5/8th inch needle and a 2 ml syringe.  The 
syringe was then used to create a single cell suspension and cells pelleted by 
centrifugation at 500 g for 5 minutes.  The number of viable cells was counted 
using Trypan Blue and a haemocytometer before cells were re-suspended at the 
required concentration. 
2.4.3.2 Isolation of splenocytes 
Spleens were removed after culling and placed in a bijoux containing complete 
media on ice.  A single cell suspension was then made by using the plunger of a 
syringe to push the spleen through a 70 μm filter into a 50 ml tube containing ice 
cold FACS buffer.  Cells were pelleted by centrifugation at 500g, 4ºC for 5 
minutes.  The pellet was then re-suspended in 5 mls red blood cell (RBC) lysis 
buffer (Stem Cell Technologies) and placed on ice for 10 minutes.  Immediately 
after the incubation, 30 mls of ice cold FACS buffer was added and the cells 
washed a further 2 times to remove any residual RBC lysis buffer.  The number 
of viable cells was then counted using Trypan Blue and a haemocytometer and 
cells were re-suspended at the required concentration. 
2.4.3.3 Isolation of cells from the blood 
Blood was collected by cardiac puncture into lithium heparin tubes immediately 
after animals were culled.  The blood was later transferred to a 15 ml centrifuge 
tube and mixed with 3 mls of RBC lysis buffer.  This was placed on ice for 10 
minutes before cells were washed with ice cold FACS buffer.  If necessary this 
process was repeated.  The number of viable cells was then counted using 
Trypan Blue and a haemocytometer and cells were re-suspended at the required 
concentration. 
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 Preparation of bone marrow macrophages 2.4.4
Bone marrow cells were isolated and counted as described in section 2.4.3.1 
above.   Generally cells from four age and genotype matched mice were grouped 
together.  Cells were then re-suspended in complete media supplemented with 
10 ng/ml recombinant murine M-CSF (Peprotech) at a concentration 1 x 106 
cells/ml.  10 mls in total was cultured per petri dish, and cells were incubated 
at 37ºC, 5% CO2.  After 3 days, spent medium and non-adherent cells were 
removed and fresh medium supplemented with 10 ng/ml M-CSF was added.  
Cells were then incubated for a further 4 days.  On day 7 the media and non-
adherent cells were removed, and ice cold PBS was added to the petri dishes to 
aid cell scraping.  The number of viable M-CSF matured cells was then counted 
and cells were plated out at the required concentration for further experiments.   
 Induction of peritoneal inflammation by LPS 2.4.5
Each mouse was injected intraperitoneally with either PBS as a control, or 100 
μg of LPS (Sigma).  After 4 hours mice were culled using accepted schedule 1 
methods.  Immediately after death had been established a peritoneal wash was 
performed and blood taken by cardiac puncture. 
The peritoneal cavity was flushed using 2 mls PBS, which was then placed in an 
eppendorf on ice.  This was later centrifuged at 500g for 5 min at 4ºC to pellet 
cells.  The supernatant was aliquoted and stored at -80ºC for future luminex, 
and the cells were counted and used for flow cytometry. 
The blood collected from these mice was centrifuged at 8000g for 30 min at 4ºC, 
after which the pellet was discarded and the serum was stored at -80ºC for 
future luminex. 
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 Flow Cytometry 2.5
 Assessment of cell purity after MACS 2.5.1
All samples isolated by positive selection were checked for purity using flow 
cytometry.  Approximately 1 x 105 cells from the positive fraction were added to 
2 clean FACS tubes per sample in 100 μl total FACS buffer.  1 μl human Fc block 
(Human TruStain FcX™, Biolegend) was added per tube, and samples incubated 
at 4ºC for 15 minutes.  After this, the anti-human CD14 antibody was added to 
one tube and an isotype control added to the other. 
Antibody Isotype Dilution (μl/100 μl)  Source / Cat No. 
PE anti-human 
CD14 
IgG2a 10 μl 
 
Miltenyi / 130-091-242 
PE Mouse 
IgG2a 
IgG2a 10 μl 
 
Miltenyi / 130-091-835 
Table 2-2 List of antibodies used to determine cell purities 
 
Cells were then incubated at 4oC for 30 minutes before being washed 3 times 
with FACS buffer and re-suspended in 200 μl FACS buffer to be analysed on the 
FACS Calibur (BD Biosciences).  When calculating the cell purity, gates were set 
to ensure < 2% of cells were positive for CD14 in the isotype.  Greater than 95% 
purity was routinely observed. 
 Assessment of transfection efficiency 2.5.2
During the transfection process some cells were routinely put aside for 
transfection using the miRIDIAN microRNA Mimic Transfection Control with 
Dy547.  After the 24 hour transfection, cells were taken off and measured for 
uptake of the fluorescent mimic on a FACS Calibur (BD Biosciences).  When 
calculating the cell purity, gates were set to ensure < 2% of cells were positive 
for Dy547 in the unlabelled control mimic cells. 
 Separation of human monocyte subsets using the ARIA cell 2.5.3
sorter 
In order to separate monocyte subsets from human blood, blood from healthy 
donors was taken into lithium heparin tubes, and PBMCs isolated as described in 
section 2.2.2.  Cells were then counted and re-suspended at 1 x 107 cells / 
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100μl, and incubated with human Fc block for 15 minutes at 4°C to reduce non-
specific binding via Fc receptors.   
In order to determine the best concentration for each antibody, titrations were 
performed, and the concentration which gave the biggest separation between 
the positive and negative fractions was chosen.  This was calculated by taking 
the mean fluorescence intensity (MFI) of the positive fraction and dividing it by 
the MFI of the negative fraction.  An example is shown in Table 2-3 for one 
antibody.  1 μl in 100 μl gave the biggest separation so this was the chosen 
concentration. 
 
Antibody Dilution (μl/100 μl) 
0.5 1 2.5 5 
MFI +ve 2302 3154 3365 3412 
MFI –ve 35.4 36.2 41.9 47.4 
MFI +ve ÷ MFI –VE 65.0282 87.1271 80.3103 71.9831 
Table 2-3 Calculation used to determine optimal antibody concentration 
 
For sorting of monocyte populations, cells were stained with specific antibodies; 
CD14, CD16 and HLA-DR, as well as on one channel having several “dump” stains 
to be removed from analysis before sorting; NKp46, CD56, CD19, CD15 and CD2 
(all antibodies and concentrations shown in Table 2-4).  These stains were all 
added together and incubated for 30 minutes at 4°C.  Cells were then washed 
twice in FACS buffer before being re-suspended for sorting.  All experiments 
were routinely controlled with unstained cells, appropriate isotype antibodies 
and FMO (fluorescence minus one) controls. 
Antibody Clone 
Dilution 
(μl/100 μl) 
Source / Cat No. 
APC anti-human 
CD14 
HCD14 5 μl Biolegend / 325608 
FITC anti-human 
CD16 
3G8 5 μl Biolegend / 302006 
Pacific Blue anti-
human HLA-DR 
L243 2.5 μl Biolegend / 307633 
PE anti-human NKp46 9E2 5 μl Biolegend / 331908 
PE anti-human CD56 AF12-7H3 1 μl Miltenyi / 130-090-755 
PE anti-human CD19 HIB19 10 μl Biolegend / 302208 
PE anti-human CD15 W6D3 10 μl Biolegend / 323006 
PE anti-human CD2 TS1/8 10 μl Biolegend / 309208 
Table 2-4 List of antibodies used for cell sorting 
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10 minutes prior to sorting, 7-aminoactinomycin D (7-AAD; BD Biosciences) was 
added to each sample for the exclusion of dead cells.  Cells were then run on an 
Aria cell sorter.  During the sort cells were initially gated on the basis of FSC : 
SSC, then single, live cells were gated for on the basis of being positive for HLA-
DR and negative for all antibodies in the dump channel.  These cells were then 
sorted for collection into three tubes based on their expression of CD14 and 
CD16 - CD14hi CD16-, CD14hi CD16+ and CD14dim CD16+.  Sorted populations were 
centrifuged at 500 g for 5 minutes, and then re-suspended in Qiazol (Qiagen) for 
subsequent RNA extraction. 
 Staining of human cells for flow cytometry 2.5.4
After miR-34a manipulation by transfection, human M-CSF-matured macrophages 
were stained to assess the expression of HLA-DR, CD16 and CD64 by flow 
cytometry.   After the 24 hour transfection cells were washed with PBS before a 
cell dissociation solution (Sigma) was added directly to the wells.  Tissue culture 
plates were then placed back in the 37ºC incubator for 15 minutes before gentle 
pipetting was used to detach adherent cells.  The liquid was transferred to FACS 
tubes and centrifuged at 500g for 5 minutes to pellet cells, which were then re-
suspended in 100 μl FACS buffer containing 1 μl human Fc block and incubated at 
4ºC for 15 minutes.  Antibodies were then added to tubes at the concentrations 
indicated in Table 2-5, and cells incubated for a further 30 minutes at 4ºC in the 
dark. After the incubation, cells were washed three times in FACS buffer before 
being re-suspended in 200 μl and filtered through a cell strainer prior to running 
on the machine (LSR II, BD Biosciences). 
Antibody Clone 
Dilution 
(μl/100 μl) 
Source / Cat No. 
Pacific Blue 
anti-human HLA-DR 
L243 2.5 μl Biolegend / 307633 
PerCP/Cy5.5 
anti-human CD64 
10.1 2 μl Biolegend / 305024 
FITC 
anti-human CD16 
3G8 5 μl Biolegend / 302006 
Table 2-5 List of antibodies used for flow cytometry analysis of human cells 
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 Staining of murine cells for flow cytometry 2.5.5
Throughout this project, cells isolated from the blood, spleen, bone marrow and 
peritoneal cavity of mice were stained to allow assessment of cell populations.  
Cells were isolated using the aforementioned conditions, and then re-suspended 
at 1 x 106 cells per 100 μl in FACS buffer.  100 μl of each sample was then 
transferred to a FACS tube, and 1 μl murine Fc block (TruStain fcX™, Biolegend) 
was added per tube.  Cells were then incubated at 4ºC for 15 minutes before the 
antibodies were added at the concentrations indicated in Table 2-6.  Cells were 
incubated for a further 30 minutes at 4ºC in the dark, after which they were 
washed three times in FACS buffer before being re-suspended in 200 μl and 
filtered through a cell strainer prior to running on the machine (LSR II, BD 
Biosciences). 
Antibody Clone 
Dilution 
(μl/100 μl) 
Source / Cat No. 
APC anti-mouse 
CD115 
AFS98 1 μl Biolegend / 135509 
Af700 anti-mouse 
CD11b 
M1/70 1 μl Biolegend / 101222 
PE Cy7 anti-mouse 
Ly6C 
HK1.4 1 μl Biolegend / 128017 
APC Cy7 anti-mouse 
Ly6G 
1A8 1 μl Biolegend / 127623 
PerCP anti-mouse 
F4/80 
BM8 1 μl Biolegend / 123126 
Table 2-6 List of antibodies used for flow cytometry analysis of murine cells 
 
  Analysis of flow cytometry data 2.5.6
All flow cytometry data was analysed using FlowJo, software version V10.  
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 Cytokine and chemokine analysis of cell 2.6
supernatants 
Cytokine and chemokine concentrations in cell supernatants, and murine serum 
and peritoneal washes, were measured in singleplex format by Enzyme Linked 
Immunosorbent assay (ELISA), and / or multiplex format using luminex kits. 
 Basic ELISA protocol 2.6.1
Enzyme Linked Immunosorbent assay (ELISA) was frequently used to measure the 
concentration of human and murine TNF-α (Life Technologies cat. no. CHC1753 
and R&D Systems cat. no. DY410 respectively). 
2.6.1.1 ELISA measurement of human TNFα 
All protocols were performed using the manufacturer’s instructions, but in brief: 
high binding microplates (Corning) were coated with the detection antibody 
diluted in PBS and incubated overnight at 4ºC.  Plates were then washed in wash 
buffer (0.5% Tween / PBS), then blocked for 1 hour in the appropriate assay 
buffer (0.5% bovine serum albumin in PBS) at room temperature.  Plates were 
then inverted to remove liquid, and blotted on absorbent paper before samples 
and standards (2000 pg/ml top standard) were added to the appropriate wells.  
Dilutions for samples were determined depending on the specific experiment.  
The detection antibody was then diluted in assay buffer and 50 μl added 
alongside samples and standards for a joint 2 hour incubation.  After the 
detection step, plates were again washed 3 times in wash buffer before 
streptavidin HRP was added.  Plates were then washed again before the addition 
of 100 μl of 3,3’,5,5’-tetramethylbenzidine (TMB) peroxidase (Biosource).  Once 
appropriate colour change in the standards had developed the reaction was 
stopped with the addition of 100 μl Stop Solution (Biosource) and the intensity 
read on a microplate reader at the appropriate wavelength 
2.6.1.2 ELISA measurement of murine TNFα 
The murine TNFα ELISA kit is almost identical to the human kit with a few minor 
changes.  For this kit the assay buffer is 1% BSA in PBS, and rather than using a 
joint sample, standard and detection antibody step, the samples and standards 
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are added to the plate for a two hour incubation, then the plates are washed 
before the detection antibody is added alone for a subsequent two hour 
incubation. 
 Luminex assay  2.6.2
Multiplex cytokine and chemokine analysis was performed using luminex assays. 
For the measurement of cytokines in human cell culture supernatants the 
Cytokine Human 25-Plex Panel from Life technologies (cat. no. LHC0009) was 
used, capable of measuring IL-1RA, IFN-γ, IL-7, IFN-α, IP-10, Eotaxin, MIG, IL-5, 
IL-6, IL-10, MIP-1α, IL-17, IL-8, IL-12 (p40⁄p70), RANTES, MIP-1β, GM-CSF, TNF-α, 
IL-1β, IL-2, IL-4, IL-2R, IL-15, MCP-1 and IL-13.  For the measurement of 
cytokines in murine peritoneal wash and serum samples the Life Technologies 
Cytokine Mouse 20-Plex Panel (cat. no. LMC0006) was used, capable of 
measuring FGF-Basic, IL-1α, MCP-1, MIG, VEGF, KC, MIP-1α, GM-CSF, TNF-α, IL-
1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-17, IP-10, IL-13 and IFN-γ.  All protocols 
were run according to manufacturer’s instructions on a Bio-Plex system (Bio-
Rad).  
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 Analysis of gene expression 2.7
 Purification of RNA from cell culture 2.7.1
In order to extract RNA from cells, cell pellets were re-suspended in 700 μl of 
Qiazol (Qiagen) to disrupt cell membranes and release RNA.  These samples were 
then stored at -20ºC until required for RNA extraction.   
RNA was extracted from Qiazol samples using the miRNeasy kit (Qiagen), using 
the manufacturer’s recommended protocol.  This kit was chosen as it allows the 
quantification of both microRNA and standard mRNA using the same sample.  In 
brief, Qiazol samples were vortexed to ensure adequate homogenisation of cells.  
140 μl chloroform was then added to samples, which were shaken vigorously 
before being centrifuged for 15 minutes at 12,000 g, 4oC.  This separated the 
samples into three different layers.  The upper (colourless) aqueous phase 
containing the RNA was transferred to a fresh eppendorf and mixed with 1.5 
volumes of 100% ethanol.  This was mixed thoroughly before applying to the 
RNeasy spin column.  Columns were centrifuged for 15 seconds at 8000g and the 
flow through discarded.  700 μl of RWT wash buffer was then applied to the 
column, centrifuged for 15 seconds at 8000g and the flow through discarded.  
Next, 500 μl of buffer RPE was applied to the column, which was then 
centrifuged for 15 seconds at 8000g.  This step was repeated with a subsequent 
2 minute spin to ensure all contaminants were removed, and the column spun 
for a further minute at full speed.  Finally the RNA was eluted in RNase-free 
water (30-50 μl depending on the expected RNA yield).  The quantity and quality 
of RNA was determined using a NanoDrop spectrophotometer. 
Initially, a DNase step was included in the RNA extraction, but as all primers 
were designed or known to cross intron / exon boundaries, and therefore should 
not detect genomic DNA, this step was later removed. 
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 cDNA Synthesis 2.7.2
All cDNA was made using commercially available kits.  At the beginning of this 
project one kit was used for microRNA (Life Technologies microRNA RT kit) and 
another for mRNA (Life Technologies High Capacity cDNA RT Kit).  This method 
was initially used as we found it more sensitive for microRNA detection, and it 
allowed reliable detection from a very low starting RNA concentration.  
However, once expression levels were established, Qiagen’s miScript II RT kit 
was used as it allowed for quantification of both miRNA and mRNA from the 
same cDNA sample, and this method is much more time and cost effective. 
2.7.2.1 Life Technologies microRNA RT kit 
Originally, when measuring microRNA expression by PCR, we used the TaqMan 
MicroRNA Reverse Transcription Kit along with the miR specific RT primers from 
Life Technologies TaqMan microRNA Assays (assays used listed in Table 2-7).  
Assay Name Cat. no Assay ID 
hsa-miR-34a 4427975 000426 
hsa-miR-34b 4427975 002102 
hsa-miR-34c 4427975 000428 
hsa-miR-22 4427975 000398 
U6 snRNA 4427975 001973 
Let-7a 4427975 000377 
Table 2-7 Life technologies TaqMan microRNA Assays used 
 
This allowed the reliable and highly sensitive detection of microRNA from only 
10 ng of starting RNA.  The components of the 15 μl cDNA reaction are shown in 
Table 2-8.  This reaction was then put in a thermal cycler (Veriti®, Applied 
Biosystems) using the profile outlined in Table 2-9. 
Component Volume / reaction 
100mM dNTPs 0.15 μl 
MultiScribe Reverse 
Transcriptase 
1 μl 
10x RT Buffer 1.5 μl 
RNase Inhibitor 0.19 μl 
RNase-free H2O 4.16 μl 
5x RT primers 3 μl 
Template RNA (at 2 ng/μl) 5 μl 
Total Volume = 15 μl 
Table 2-8 Life technologies microRNA RT kit reaction components 
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Temperature Time 
16ºC 30 mins 
42ºC 30 mins 
85ºC 5 mins 
4ºC Hold 
Table 2-9 Life technologies microRNA RT kit thermal cycler profile 
 
2.7.2.2 High Capacity cDNA RT kit 
As the microRNA RT kit used specific RT primers in the cDNA reaction, a separate 
cDNA was required for quantification of mRNA in the samples, for this we 
frequently used the high capacity cDNA kit (Life Technologies).  The components 
of the 20 μl cDNA reaction are shown in Table 2-10.  This reaction was then put 
in a thermal cycler (Veriti®, Applied Biosystems) using the profile outlined in 
Table 2-11. 
Component Volume / reaction 
100mM dNTPs 0.8 μl 
MultiScribe Reverse 
Transcriptase 
1 μl 
10x RT Buffer 2 μl 
RNase Inhibitor 1 μl 
RNase-free H2O 3.2 μl 
10x RT Random Primers 2 μl 
Template RNA 10 μl 
Total Volume = 20 μl 
Table 2-10 Life technologies high capacity cDNA RT kit reaction components 
 
Temperature Time 
25ºC 10 mins 
37ºC 120 mins 
85ºC 5 mins 
4ºC Hold 
Table 2-11 Life technologies high capacity cDNA RT kit thermal cycler profile 
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2.7.2.3 miScript II RT kit 
Once we were confident in the expression level of our microRNA, and were 
simply using PCR to determine up or down-regulation of miR-34a following 
transfection of cells with mimics and inhibitors, we switched back to the 
miScript II RT kit (Qiagen).  Here we used the miScript II RT kit with HiFlex 
buffer as it allows parallel quantification of mature microRNA and mRNA from a 
single cDNA sample.  Depending on the experiment and RNA concentration 
achieved, between 200 and 600 ng of starting RNA was used per 20 μl PCR 
reaction.  The components of the 20 μl cDNA reaction are shown in Table 2-12.  
This reaction was then put in a thermal cycler (Veriti®, Applied Biosystems) 
using the profile outlined in Table 2-13.  Prior to using these samples, cDNA was 
diluted by the addition of 180 μl RNase-free H2O. 
Component Volume / reaction 
miScript HiFlex Buffer 4 μl 
10x Nucleics mix 2 μl 
RNase-free H2O 2 μl 
miScript Reverse 
Transcriptase 
2 μl 
Template RNA 10 μl 
Total Volume = 20 μl 
Table 2-12 miScript II RT kit reaction components 
 
Temperature Time 
37ºC 60 mins 
95ºC 5 mins 
4ºC hold 
Table 2-13 miScript II RT kit thermal cycler profile 
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 qPCR 2.7.3
2.7.3.1 Taqman qPCR 
To measure microRNA expression the taqman PCR primers from the TaqMan 
microRNA assays were used.  For the measurement of mRNA, Taqman primers 
were ordered from IDT or Life technologies (all taqman primers used in this 
project are listed in Table 2-14).  For both mRNA and microRNA detection, 
Taqman Universal Master Mix no UNG (Life Technologies) was used.  The primers 
and RNase/DNase-free H2O were added to the master mix, which was then 
pipetted into 96 or 384 well PCR plates before the cDNA was added.  The qRT-
PCR reaction was performed on Applied Biosystems 7900HT or 7500 machines for 
40 cycles according to the assay instructions. 
Gene 
Name 
Cat no. / 
Assay Name 
Probe Company 
IRF1 4331182 FAM Life Technologies 
MTF1 4331182 FAM Life Technologies 
TLR7 4331182 FAM Life Technologies 
SIRT6 4331182 FAM Life Technologies 
MT1E Hs.PT.53.19749017 FAM IDT 
MT1F Hs.PT.53.19974633 FAM IDT 
MT1G Hs.PT.53.25205882 FAM IDT 
GAPDH Hs.PT.53.26895230.g Cy5 IDT 
IRF3 Hs.PT.53.19791480.g Cy5 IDT 
STAT1 Hs.PT.53.26308725 Cy5 IDT 
IRF7 Hs.PT.53.23026870 Hex IDT 
DDX58 Hs.PT.53.27193757 Hex IDT 
IFIH1 Hs.PT.53.18912568 Hex IDT 
Table 2-14 List of Taqman primers used for PCR 
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2.7.3.2 SYBR Green PCR 
SYBR green PCR was also used to quantify mRNA expression with Power SYBR 
green master mix (Life Technologies) and Quantitect primers from Qiagen (Table 
2-15).  The reaction mix was prepared as shown in Table 2-16, before 10 μl was 
added in triplicate to a 384 well plate. 
Gene 
Name 
Cat no. Company 
IFIT1 QT00201012 Qiagen 
IFIT3 QT00100030 Qiagen 
IFI35 QT00010402 Qiagen 
IFITM1 QT00064246 Qiagen 
OAS1 QT00099134 Qiagen 
MX1 QT00090895 Qiagen 
EIF2AK2 QT00022960 Qiagen 
MT1H QT01004612 Qiagen 
MT1M QT01004626 Qiagen 
MT1X QT00048237 Qiagen 
Table 2-15 List of primers used for SYBR PCR 
 
Component Volume / reaction 
Power SYBR green master mix 17.5 μl 
Primers 3.5 μl 
Template cDNA 1.75 μl 
RNase-free H2O 12.25 μl 
Total Volume = 35 μl 
Table 2-16 Power SYBR green PCR reaction components 
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 Generating PCR standards for absolute quantification of 2.7.4
microRNA 
In order to gain a better understanding of the expression levels of different 
microRNA, we decided to make PCR standards.  For the let-7a control, single 
stranded RNA template was ordered from Integrated DNA Technologies (IDT).  To 
make template for microRNA, 5 µl stock double stranded microRNA mimic (20 
μM) was diluted in 45 μl RNase-free H2O and denatured at 95ºC for 5 minutes. 
This was then immediately placed in ice water to cool.  5 μl of this stock was 
then added to the 15 μl RT reaction, giving 4.013x1011 copies/μl cDNA. 
miRNA copy number was calculated using Avogadro’s Constant as follows: 
 5 μl 20 μM mimic = 0.1 nmoles in a total of 50 μl 
 Copy Number   = Avogadro’s Constant x moles 
     = (6.022 x 1023) x (1 x 10-10) 
     = 6.022x1013 copies in 50 μl 
     = 1.204x1012 copies/μl 
In microRNA cDNA reactions we use 0.6 μl template cDNA per well, so we need 
to achieve the desired concentration of standard template in 0.6 μl. To obtain a 
standard curve, standards were serial diluted to give copy numbers in the range 
of 1x109 to 1x103. 
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 Microarray 2.7.5
In order to investigate pathways regulated by miR-34a in monocytes, PB CD14+ 
cells were transfected with either miR-34a or a control miRNA mimic (20 nM) for 
24 hours.  RNA was then isolated and sent to the Glasgow Polyomics facility to 
perform an mRNA microarray (GeneChipHG-u133 plus 2; Affymetrix).  Data were 
analysed using GeneSpring and Ingenuity Pathway analysis softwares.  To 
minimalize systemic non-biological differences, Robust Multichip Analysis (RMA) 
was used, followed by quantile normalization with baseline transformation to 
the median of all samples.  Entities were filtered based on their signal intensity 
value and retained if they achieved a value within the range (percentile cut off: 
20-100) for at least one sample out of 10.  To identify differentially expressed 
genes, Mann Whitney test and 2 fold cut off was applied.  To identify direct miR-
34a targets, all genes (regardless of fold change) that were down-regulated in 
miR-34a mimic transfected cells were ranked and checked against miR-34a 
predicted targets proposed by TargetScan prediction algorithm. 
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 In situ hybridisation 2.8
An in situ staining protocol was developed using the miRCURYTM microRNA ISH 
Optimization Kit (Exiquon) using the manufacturer’s guidelines.  Detailed below 
is the final protocol used.  Unless otherwise stated reagents were provided with, 
or recommended for use with the optimisation kit. 
 Standard non-fluorescent protocol 2.8.1
For the staining of tissue sections, samples first had to be deparaffinised in 
xylene and ethanol as outlined in Table 2-17. 
Step Solvent Duration 
1 
Xylene 
5 minutes 
2 5 minutes 
3 5 minutes 
4 
99.9% 
Ethanol 
Immerse 10 times 
5 Immerse 10 times 
6 5 minutes 
7 
96% Ethanol 
Immerse 10 times 
8 5 minutes 
9 
70% Ethanol 
Immerse 10 times 
10 5 minutes 
11 PBS 5 minutes 
Table 2-17 In situ hybridisation - Steps used to deparaffinise tissue sections 
 
Slides were then incubated with 15 μg/ml Proteinase-K for 10 minutes at 37ºC, 
before being washed twice in PBS and dehydrated as shown in Table 2-18. 
Step Solvent Duration 
1 
70% Ethanol 
Immerse 10 times 
2 1 minute 
3 
96% Ethanol 
Immerse 10 times 
4 1 minute 
5 
99.9% Ethanol 
Immerse 10 times 
6 1 minute 
Table 2-18 In situ hybridisation - Steps used to dehydrate slides 
 
Slides were then allowed to air dry for approximately 15 minutes before the 
double digoxigenin (DIG) labelled LNATM probe (miR-34a or scrambled) was 
applied and the slides incubated for a further 1 hour at 55ºC on a heated plate 
hybridiser. To avoid evaporation of liquids and slides drying out coverslips were 
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placed over the slides, and these were sealed using fixogum.  After the 1 hour 
incubation the cover slips were removed and slides washed in SSC buffers as 
outlined in Table 2-19. 
Step Buffer Duration Temperature 
1 5 x SSC 5 minutes 55ºC 
2 1 x SSC 5 minutes 55ºC 
3 1 x SSC 5 minutes 55ºC 
4 0.2 x SSC 5 minutes 55ºC 
5 0.2 x SSC 5 minutes 55ºC 
6 0.2 x SSC 5 minutes RT 
Table 2-19 In situ hybridisation - Steps used to wash slides 
 
A hydrophobic barrier was then applied to the slides by placing them in PBS, 
before a blocking solution was applied for 15 minutes at room temperature. The 
blocking solution is made up by diluting a 10 x blocking solution in 1 x Maleic 
acid. When the blocking solution is removed, an anti-DIG-alkaline phosphatase 
(AP) was applied and the slides incubated in a humidified chamber at room 
temperature for one hour. To help reduce non-specific binding this was diluted 
1:800 in blocking solution containing 2% sheep serum. After the one hour 
incubation, slides were washed three times in PBS-Tween and incubated in AP 
substrate for a further 2 hours at 30ºC in a humidified chamber in the dark. 
Slides were then incubated with KTBT buffer for two 5 minute incubations to 
stop the reaction before being washed in water. If Nuclear Fast Red was added, 
it was added for 1 minute at this stage, before slides were washed in tap water. 
Slides were then dehydrated once again (procedure as detailed in Table 2-18) 
and mounted using Vectamount hard set. 
 Double fluorescent in situ hybridisation with miR-34a and 2.8.2
CD68 
When fluorescent in situ hybridisation was required to allow double staining with 
CD68, the protocol was identical until the addition of the anti-DIG antibody. For 
fluorescent staining at this stage a specific anti-DIG fluoresceine antibody was 
used (again diluted in blocking solution containing 2% sheep serum to avoid non-
specific binding). After one hour slides were washed in PBS-Tween before a 
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mouse anti-human CD68 or control IgG antibody was added at 1 μg/ml and slides 
were incubated at 4ºC overnight in the dark. 
The following day, slides were washed in PBS-T, and a secondary biotinylated 
horse anti-mouse antibody was added to the sections for 30 minutes at room 
temperature (1:200 with blocking solution). Slides were once again washed in 
PBS-T before Avid D-Texas Red (1:500) was added for a further 30 minutes. To 
mount slides for viewing, 1 drop of Vectamount hard set containing DAPI was 
added to each section, a coverslip placed on top and sealed with clear nail 
varnish. 
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 Luciferase Assays 2.9
Luciferase assays were used to determine whether a microRNA was capable of 
physically binding to a given predicted target.  
 Generation of target insert 2.9.1
For each predicted target, primers were designed that would allow amplification 
of a section of the 3' untranslated region (3'UTR) containing the potential 
microRNA binding site.  In this project luciferase assays were carried out to 
assess whether microRNA-34a was capable of binding to its predicted binding 
sites in Notch1, CSF1-R, IRF1 and MTF1 - which had two separate binding sites 
that were tested individually (MTF1 (1) and MTF1 (2)).  All primers used in this 
project are shown in Table 2-20.  All primers were ordered from IDT and made 
up to 100 μM in RNase free water.  Working stocks were then made with 5 μl of 
each of the forward and reverse primers and 90 μl RNase-free water.  These 
primers were used to amplify the required insert from a genomic DNA (gDNA) 
template.  An example PCR reaction is shown in Table 2-21, and the thermal 
cycler profile is shown in Table 2-22. 
Target Forward Primer Reverse Primer 
Notch1 AGTTTAAACGTCTGTGTGCGCTCTGT AGTCGACGAGCATCTTCTTCGGAACCT 
CSF1-
R 
AGTTTAAACATCAGTTCTGCTGAGGAG 
TTG 
AGTCGACTGAAGGAGGGAAGGAAAGA 
AAG 
IRF1 
AGTTTAAACTCTGAAGAACATGGATGC 
CACCTG 
AGTCGACGCCCTGGGATTGGTGTT 
ATGCTT 
MTF1 
(1) 
AGTTTAAACTGCTCAGGGCCAGCCAAG 
ATATTA 
AGTCGACAATCCCAGCACTTTGGG 
AGACTG 
MTF1 
(2) 
AGTTTAAACTTTAGGGAGAGAGGGAAA 
CAGTCC 
AGTCGACAAGGGCAAGAGAAAGCCT 
CTGACT 
Table 2-20 Primers used for luciferase assays 
 
Component Volume / reaction 
2 x GoTaq Master Mix 
(Promega) 
25 μl 
Primers (working stock) 2.5 μl 
gDNA 2 μl 
H2O 20.5 μl 
Total Volume = 50 μl 
Table 2-21 PCR reaction components used for generation of candidate 3'UTR amplicons 
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Temperature Time Stage 
94ºC 2 mins 1 
94ºC 20 secs 2 
(Repeat x 35) 56ºC 20 secs 
72ºC 40 secs 
72ºC 10 mins 3 
Table 2-22 Thermal cycler profile used for generation of luciferase insert 
 
PCR products were initially run out on 0.8% (W/V) TAE agarose gels to confirm 
the size and specificity of amplifications.  Bands of the correct predicted sizes 
were excised from the gel and gel purified using the QIAquick Gel Extraction kit 
(Qiagen).  The purified DNA fragment was then inserted into pCR2.1 TOPO vector 
(Invitrogen) following the manufacturer’s instructions. This vector takes 
advantage of Taq DNA polymerases ability to add non-template dependent 
terminal deoxy-adenosines to the 3' ends of amplified products.   
Reactions were transformed into competent XL1-Blue cells and plated out onto 
LB agar plates containing 50 μg/ml ampicillin and grown overnight at 37ºC.  The 
following day colonies were picked and used to inoculate 5 ml cultures of LB plus 
50 μg/ml ampicillin.  The cultures were grown overnight at 37ºC in a shaking 
incubator.  The following day plasmid DNA was prepared from 1.5 mls of 
bacterial culture using the Qiaprep Spin miniprep kit (Qiagen).  Plasmids 
containing the correct inserts were confirmed by performing a double digest 
using the restriction enzymes PmeI and SalI (New England Biolabs – NEB).  
Digested plasmids were run out on 0.8% TAE agarose gel next to a 1kB (+) DNA 
ladder (Invitrogen).  This digest served to identify clones with the correct insert, 
but also generated insert fragments that could be gel purified and cloned into 
PmeI/SalI sites in the pmiRGLO reporter as described below. 
 Preparation of luciferase vector 2.9.2
The pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega) was 
used as the reporter vector in these experiments.  As demonstrated in Figure 
2-1, the vector contains a multiple cloning site (MCS) 3' of a firefly luciferase 
reporter gene (luc2), and also a humanized Renilla luciferase-neomysin 
resistance cassette (hRluc-neo), which functions as a reporter gene for the 
normalisation of luciferase activity. 
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Figure 2-1 pmirGLO Dual-Luciferase miRNA Target Expression Vector 
 
Prior to ligation of the vector and insert, the vector must be linearized with 
appropriate restriction enzymes. These are chosen depending on the insert, and 
are used to create complimentary overhangs between the insert and vector to 
allow later annealing. An example of the reaction used for vector digestion is 
shown in Table 2-23. This mixture was incubated at 37ºC for 2 hours. 
Component Volume / reaction 
10 x Buffer 4 (NEB) 5 μl 
plasmid 20 μl 
PmeI (NEB) 1 μl 
SalI (NEB) 1 μl 
H2O 23 μl 
Total Volume = 50 μl 
Table 2-23 Reaction setup for digestion of pmirGLO vector for luciferase assay 
 
 Ligation of target insert and luciferase vector 2.9.3
The next step is ligation of the insert (containing the predicted microRNA 
binding site) and vector. The components of the ligation mixture are outlined in 
Table 2-24. The components were all mixed in an eppendorf and incubated at 
room temperature for 10 minutes, creating the pmirGLO vector with the desired 
insert containing the predicted microRNA binding site. 
  
  112 
 
 
Component Volume / reaction 
10 x T4 ligase buffer 
(NEB) 
2 μl 
Vector (cut pmirGLO) 3 μl 
Insert 14 μl 
T4 DNA ligase 1 μl 
Total Volume = 20 μl 
Table 2-24 Components of ligation reaction for pmirGLO vector and target insert 
 
 Transformation of competent cells 2.9.4
In order to transform the ligated pmirGLO vector into competent cells, 3 μl of 
the assembled product was placed in a microcentrifuge tube, and 50 μl of 
competent cells added to the tube.  This mixture was left on ice for 30 minutes, 
before cells were heat-shocked at 42ºC for 30 seconds and placed back on ice for 
2 minutes.  300 μl of Luria-Berta (LB) broth was then added and the cells 
allowed to recover for 60 minutes at 37ºC in a shaker (approx. 200 – 250 rpm).  
200 μl of the competent cells were then spread on an LB-Amp plate and placed 
in a 37ºC incubator overnight. 
The following day three colonies from each plate were picked and placed in 
individual universals containing 5 mls LB-AMP broth. These were cultured 
overnight at 37ºC in a shaker (approx. 200 – 250 rpm).  The following day plasmid 
DNA was extracted from 1.5 mls of the culture using a QIAprep Spin Miniprep Kit 
(Qiagen).  These samples were routinely sent for sequencing to validate correct 
target insert. 
 
 Transfection of cells with luciferase vector 2.9.5
Luciferase experiments were performed in Human embryonic kidney (HEK)-293 
cells. Shortly before transfection of the cells, they were seeded at 1 x 105 cells 
per well of a 24 well plate in 500μl complete DMEM, and placed under normal 
growth conditions (37ºC, 5% CO2) to allow cells to adhere. In the meantime the 
transfection mix was made using Attractene transfection reagent (Qiagen). 
Reaction components are shown in Table 2-25. Transfection mixtures were 
incubated at room temperature for 20 minutes to allow the formation of 
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transfection complexes. After this time the mixture was added drop-wise onto 
cells to assure uniform distribution of complexes.  
Component Volume / reaction 
DNA (200 ng/μl) 2 μl 
5 μM control or 
microRNA mimic 
2.8 μl 
Attractene 1.5 μl 
Optimem (Invitrogen) 60 μl 
Total Volume 66.3 μl 
Table 2-25 Attractene mixture components for luciferase assay 
 
After 24 hours adherent cells were washed with PBS, then 200 μl 1 x passive lysis 
buffer was added per well (5 x lysis buffer provided with Promega’s Dual-
Luciferase® Reporter Assay, diluted in distilled water). The plate was left to 
gently rock for 15 minutes at room temperature, before the lysates were diluted 
1 in 200 in the 1 x passive lysis buffer. 50 μl of the diluted lysate was added in 
triplicate to white 96 well flat bottomed plates (Greiner). 50 μl of diluted 
luciferase assay substrate was then added to each well, and firefly luciferase 
activity measured on a luminometer. 50μl of Stop & Glo® Reagent was then 
added to each well, and Renilla luciferase activity measured on the 
luminometer. (all reagents and buffers provided in Promega’s Dual-Luciferase® 
Reporter Assay kit). 
 Calculating the results 2.9.6
miRNA knock down was calculated as a percentage of normalised miRNA treated 
sample compared to scrambled control.  In brief the luciferase activity of all 
samples were normalised to the renilla activity by dividing luciferase/renilla. 
The normalised value obtained for the specific miRNA treated samples were then 
expressed as a percentage of the scrambled control samples. 
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 Statistical Analysis 2.10
All statistical analyses were performed using GraphPad Prism 5, except 
correlation statistics which were carried out in Minitab 17 statistical software.  
All results are displayed as mean ± standard error of the mean.   
The particular statistical test used depended on the given experiment, and is 
indicated in the figure legend for each graph.  Where there was an n ≥ 8, a 
normality test was used (D'Agostino-Pearson normality test) to determine 
whether data displayed a Gaussian distribution. 
A p value of < 0.05 was considered statistically significant.  Where significance 
was reached asterisk on the graph indicate the level of significance.  * = p <0.05, 
** = p < 0.01, *** = p < 0.001. 
 
  
 
 
Chapter 3 – microRNA-34 Family Expression and 
Regulation 
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 Introduction and Aims 3.1
Rheumatoid arthritis is a chronic inflammatory disorder, whereby synovial 
inflammation ultimately results in joint destruction and impaired function of 
affected joints.  Although disease processes are not fully understood, one cell 
type known to be a key player in the perpetuation of this inflammation is the 
macrophage.  These cells are recruited to the synovium in large numbers, where 
they are capable of producing substantial quantities of inflammatory cytokines; 
including TNF-α, IL-6 and IL-1β.  The mechanisms underlying this inflammatory 
gene expression in macrophages are yet to be fully dissected, but a better 
understanding of this could allow the development of new treatments targeting 
known, as well as completely novel disease-driven pathways. 
One area of research which could provide such new treatment targets comprises 
the RNA interactome – especially the potential role of microRNA.  These are a 
recently discovered class of post-transcriptional regulators known to be involved 
in the regulation of many cellular processes – including cell cycle, apoptosis and 
inflammatory cytokine production.  They are demonstrated to be dysregulated in 
a variety of diseases.  Since they can be readily detected in cells and in the 
soluble phase, they could be useful as biomarkers, or even in the generation of 
new therapies.  Certainly since they cross regulate a variety of functionally 
linked pathways, their elucidation is likely to prosper our understanding of the 
underlying pathogenetic events subserving the target lesion in the RA synovium. 
Previous experiments from our laboratory set out to determine the differential 
transcript expression between CD14+ cells derived from the peripheral blood (PB) 
and synovial fluid (SF) of RA patients.  In order to achieve this, a microarray was 
performed on RNA isolated from patient samples.  As well as developing an 
mRNA signature for these cells, the array also highlighted a few microRNA that 
were differentially expressed.  As demonstrated in Figure 3-1, the microarray 
data showed that miR-155 and miR-34a were expressed higher in the SF CD14+ 
cells, while miR-223 was significantly lower in the SF cells.  Our group have 
already generated data examining the expression and regulation of miR-155 
[300] and miR-223 [342], and I set out to establish a similar potential role for 
miR-34a in the same context.  
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microRNA-34a is already known to have a role in several disease states, and in 
particular has been extensively studied in cancer and heart disease.  In mouse 
models of heart disease, it has been shown that miR-34 inhibition attenuated 
cardiac remodelling and improved systolic function [343].  Furthermore, in the 
cancer field many studies have shown that miR-34a acts as a tumour-suppressor 
by targeting numerous genes related to proliferation, apoptosis and invasion 
(reviewed in [344]).  miR-34a replacement therapy is already in phase I clinical 
trials for the treatment of liver cancer [331].  Given the many confirmed roles of 
miR-34a in cellular regulation, its differential expression in RA could be 
significant, so I sought to dissect its possible role in the inflammatory phenotype 
seen in monocytes and macrophages in RA.  In this chapter I examined the 
expression of this microRNA in both the periphery and synovium of RA patients, 
and also set out to establish those factors that regulate miR-34a expression. 
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Figure 3-1 Expression of miR-155 and miR-34a is up-regulated, while miR-223 is down-
regulated in CD14
+
 cells isolated from the synovial fluid of RA patients compared to 
matched peripheral blood samples 
CD14
+
 cells were isolated from the peripheral blood (PB) or synovial fluid (SF) of RA patients 
before a microarray was used to compare transcript expression between these populations.  As 
well as generating an mRNA signature for the cells, the microarray highlighted three microRNA that 
were differentially expressed – miR-155, miR-34a and miR-223.  The PB expression for each donor 
was normalised to 1, with SF expression shown as relative fold change.  Data presented as mean 
plus standard error of the mean.  Wilcoxon matched-pairs signed rank test; * P < 0.05. n = 7.  This 
microarray was analysed by my supervisor – Dr Kurowska-Stolarska – prior to the beginning of my 
PhD, and served as the pilot data on which my project was based. 
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 Expression of the microRNA-34 family in health and 3.2
disease 
In order to validate the results from the microarray, fresh samples were 
obtained from RA patients.  CD14+ cells were isolated from the matched PB and 
SF samples and Taqman PCR performed to measure the expression of miR-34a.  
As shown in Figure 3-2, these experiments show that miR-34a is expressed at 
significantly higher levels in the CD14+ cells isolated from RA SF compared to PB 
samples.  As such they confirmed the preliminary analysis on which my project 
was predicated and served to encourage further investigation.  As miR-34a 
belongs to a family of microRNA, we also measured the expression of the other 
family members – miR-34b and miR-34c – which were not differentially expressed 
between the PB and SF CD14+ cells. 
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Figure 3-2 miR-34a, but not miRs 34b/c, is up-regulated in CD14
+
 cells isolated from the 
synovial fluid of RA patients compared to matched peripheral blood samples 
CD14
+
 cells were isolated from the peripheral blood (PB) or synovial fluid (SF) of RA patients 
before Taqman PCR was used to quantify microRNA levels compared to the housekeeping control 
U6.  The expression of microRNA-34a, b and c was measured.  The PB expression for each donor 
was normalised to 1, with SF expression shown as relative fold change.  Data presented as mean 
plus standard error of the mean.  Paired t test; ** P < 0.01.  n = 10. 
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 Developing standards to quantify miR-34a expression 3.2.1
Although the expression of miR-34b and miR-34c is equivocal in the PB and SF 
CD14+ cells, it was important to gain a better understanding of their expression 
levels.  miRs-34b and 34c share the same seed region as miR-34a, and as a 
consequence share a number of the same targets.  I therefore set out to 
determine whether they are present in our cells and likely to interfere with 
future experiments.  In order to do this we aimed to develop PCR standards.  For 
several reasons, at this stage we decided to switch from our previous PCR 
housekeeping (small nuclear RNA U6), to let-7a.  U6 is larger in size than miRNA, 
and we were also unsure which part of U6 was amplified by our TaqMan PCR 
primers – making it difficult to design standards.  After searching the literature 
we found that let-7a microRNA was often used as a house-keeping control [345, 
346].  We therefore sought to determine and compare the expression levels of 
U6 and let-7a in our cells, and ensure their expression was stable.   We chose to 
check the expression during the M-CSF maturation of CD14+ cells, and also after 
stimulation of macrophages with various TLR ligands.  Taqman PCR was used to 
measure U6 and let-7a expression where samples had been normalised to the 
same starting RNA concentration in each reaction.  Figure 3-3 shows the CT 
values for U6 expression, and confirms that it’s expression is indeed stable 
during both the M-CSF maturation of CD14+ cells and their subsequent 
stimulation via TLR ligands.  Figure 3-4A demonstrates that let-7a expression 
remains constant in CD14+ cells freshly isolated from buffy coat samples, and 
after M-CSF maturation for 3 or 7 days.  Let-7a expression also remains stable 
after stimulation of M-CSF matured macrophages with various TLR ligands 
(Figure 3-4B).  We therefore concluded that it was a suitable housekeeping 
control for normalisation of transcript expression in future experiments.  
PCR standards for let-7a and miRs 34a, b and c were developed as described in 
section 2.7.4 in the materials and methods.  Figure 3-5 shows a representative 
standard curve and amplification plot for the miR-34a standards, and show 
successful detection of the miRNA between 103 and 109 copies per PCR reaction. 
Thus we continued to run these standards and use absolute quantification for 
future microRNA PCR. 
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Using these standards, Taqman PCR was repeated on the same PB and SF 
samples from RA patients used in Figure 3-2.  As demonstrated in Figure 3-6, 
again miR-34a is expressed at a higher level in the SF CD14+ cells of RA patients 
compared to matched PB cells.  Also clear is that miR-34b and miR-34c are 
barely detectable, or expressed at very low levels in both the PB and SF cells, 
and there was no difference in the magnitude of expression between PB and SF 
cells.  This gave us confidence that these microRNA would not interfere with our 
future results, and from this point onwards we chose to focus solely on miR-34a. 
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Figure 3-3 U6 expression is stable across monocyte maturation and subsequent TLR ligand 
stimulation 
As we have used U6 as a housekeeping control for the normalisation of transcript expression after 
PCR, we sought to determine whether its expression was stable across our frequently used 
conditions.  CD14
+
 cells were isolated from buffy coat samples and their U6 expression measured 
at day 0 (d0), and after 3 (d3) and 7 (d7) days 50 ng/ml M-CSF-induced maturation.  Panel A 
shows the CT values for each condition, where experiments were normalised for the same starting 
concentration of RNA.  The CT values are also shown after stimulation of these 7 day M-CSF 
matured cells with various TLR ligands (B).  Data presented as mean plus standard error of the 
mean.  n = 3. 
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Figure 3-4 Let-7a expression is stable across monocyte maturation and subsequent TLR 
ligand stimulation 
Before using let-7a as a house keeping control for PCR normalisation, we sought to determine 
whether its expression was stable across our frequently used conditions.  CD14
+
 cells were 
isolated from buffy coat samples and their let-7a expression measured at day 0 (d0), and after 3 
(d3) and 7 (d7) days 50 ng/ml M-CSF-induced maturation.  Panel A shows the CT values for each 
condition, where experiments were normalised for the same starting concentration of RNA.  The 
CT values are also shown after stimulation of these 7 day M-CSF matured cells with various TLR 
ligands (B).  Data presented as mean plus standard error of the mean.  n = 3. 
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Figure 3-5 Double stranded microRNA mimics can be used to develop PCR standards for 
microRNA 
microRNA standards were generated from double stranded microRNA mimics as described in the 
materials and methods.  The figure shows a representative standard curve and amplification plot 
for 10
3
 to 10
9
 miR-34a copies / reaction. 
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Figure 3-6 miR-34a, but not miRs 34b/c, is highly expressed in SF CD14
+
 cells 
CD14
+
 cells were isolated from the peripheral blood (PB) and synovial fluid (SF) of RA patients, 
and PCR standards were used to determine the absolute copy number of microRNA-34a, b and c 
by TaqMan PCR.  Data presented as mean plus standard error of the mean.  Wilcoxon matched-
pairs signed rank test; *** P < 0.001.  n = 11. 
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 miR-34a expression in synovial tissues 3.2.2
Next, we set out to determine whether microRNA-34a was differentially 
expressed in the synovial tissue of RA patients.  To investigate this possibility, 
we performed in situ hybridisation for miR-34a in synovial tissues derived from 
RA patients and compared it to tissues from inflammatory (iOA) and non-
inflammatory (niOA) osteoarthritis patients.  This in situ staining protocol was 
originally worked up in the lab by Stefano Alivernini, who also performed a lot of 
the tissue staining.  Figure 3-7 shows representative staining pictures for one RA 
(A) and one niOA (B) tissue stained using a miR-34a probe, as well as an RA 
tissue stained with a scramble microRNA probe (C).  A staining score was 
developed based on the percentage of cells positive for miR-34a, and an average 
from four fields of view taken per section.  As shown in Figure 3-8, RA tissues 
contain a significantly higher percentage of miR-34a positive cells compared to 
both iOA and niOA. 
In order to establish whether any of these miR-34a positive cells were 
macrophages, we performed in situ staining for miR-34a, followed by fluorescent 
staining for CD68.  The orange staining in Figure 3-9 demonstrates that a 
proportion of cells in the RA synovium are positive for both miR-34a and CD68, 
suggesting macrophages in the RA joint express miR-34a.  Equally a significant 
number of cells were miR-34a positive but CD68 negative, and thus are likely not 
macrophages.   The focus of my project, however, was the role of miR-34a in 
macrophage activation and for this reason I chose to continue to examine the 
biology of miR-34a in this lineage. 
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Figure 3-7 In situ hybridisation staining for miR-34a in RA and OA synovial tissues 
Synovial tissues from rheumatoid arthritis (RA) and osteoarthritis (OA) tissues were stained for 
miR-34a expression using in situ hybridisation.  Representative staining is shown here for one RA 
(A) and one OA (B) sample.  Also shown is an RA tissue stained using a miRNA scramble probe 
(C).  In the OA tissue and where the scramble probe was used, nuclear red was used for clarity of 
tissue integrity.  For each tissue one 10x magnification and one 40x magnification image is shown 
(annotated on pictures). 
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Figure 3-8 miR-34a in situ hybridisation score in RA and OA synovial tissues 
Synovial tissues from rheumatoid arthritis (RA) and both non-inflammatory (niOA) and inflammatory 
(iOA) osteoarthritis tissues were stained for miR-34a expression using in situ hybridisation.  The 
level of staining was quantified using the staining score shown.  Each dot on the graph represents 
the average staining score given for a particular sample.  Data points represent the average taken 
from four fields of view, line represents the average of all samples.  One-way ANOVA with 
Bonferroni post test; ** P < 0.01, *** P < 0.001.  n = 6/7 samples per group.  Scoring of tissues 
performed by Stefano Alivernini. 
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Figure 3-9 Double fluorescent staining shows macrophages in the RA synovium express 
miR-34a 
Fluorescent in situ hybridisation staining for miR-34a (green) was performed, followed by 
fluorescent staining for CD68 (red). DAPI was also used to stain the nuclei (blue). The orange 
staining visible in figure (C) shows the overlap of red and green, representing miR-34a positive, 
CD68-expressing macrophages in the synovium. 
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 miR-34a expression in peripheral blood CD14+ cells 3.2.3
We next wished to compare the expression of miR-34a in the peripheral blood 
compartment of RA patients versus healthy controls.  To achieve this, cells were 
isolated from the blood of healthy controls, as well as three different RA patient 
subgroups: those responding well to cDMARD treatment (DMARD good 
responders), those currently not responding to cDMARDs (DMARD-resistant) and 
patients who had now failed multiple conventional and biologic therapies 
(biologic resistant).  Taqman PCR was then used to quantify miR-34a expression.  
As shown in Figure 3-10A, those patients which were classed as “biologic-
resistant” have significantly higher miR-34a expression in their PB CD14+ cells 
compared to healthy controls.  Figure 3-10B shows the patient demographics; 
although age and smoking status did vary between groups, these had no effect 
on miR-34a expression levels (Figure 3-10C and D, respectively).   
We went on test whether miR-34a expression correlated with disease duration or 
other clinical markers of disease activity; RF titre (IU/ml), HS CRP (mg/dl), ESR, 
DAS28 ESR, tender joint count (TJC) and swollen joint count (SJC).  These 
correlations are shown in Figure 3-11, and demonstrate that only the SJC of 
patients showed a positive correlation with miR-34a expression.  Given multiple 
comparisons it is not clear whether this carries any significance, and future 
replication will be important.  We also wanted to determine whether miR-34a 
expression was simply a marker of the degree of on-going inflammation.  To test 
this we performed a luminex on the serum of all blood donors, and checked to 
see if any of the cytokines measured correlated with miR-34a expression.  Figure 
3-12 shows the correlations for cytokines that were detectable in the majority of 
samples.  miR-34a expression did not correlate with the serum expression of IL-
1RA, IL-2R, IL-7, IL-12, IFN-α, MCP-1, MIP-1β or MIG.   
Thus, I have identified the differential expression of a microRNA in circulating 
monocytes in RA patients that suggests the state of disease in a cohort of 
multiple drug resistant patients may be altered, despite otherwise similar levels 
of intercurrent inflammation.  If macrophages are a critical perpetuator cell 
lineage in RA then this would be compatible with the hypothesis that miR-34a 
dysregulation is associated with chronic synovial inflammation and that the 
peripheral monocyte pool is not ‘normal’.  
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Figure 3-10 miR-34a is expressed higher in CD14
+
 cells isolated from the peripheral blood of 
biologic-resistant RA patients compared to controls  
miR-34a expression was measured in CD14
+
 cells isolated from the peripheral blood of healthy 
controls and three different RA patient subgroups: those responding well to cDMARD treatment 
(DMARD good responders), those currently not responding to cDMARDs (DMARD-resistant) and 
patients who had now failed multiple conventional and biologic therapies (biologic resistant).  miR-
34a expression is shown in panel A.  Data shown as mean plus standard error of the mean. 
Kruskal-Wallis test with Dunn’s multiple comparison; * P < 0.05. n = 19 – 30 / group. (B) Patient 
demographics show age and smoking status were not comparable between the groups (P value 
highlighted by a red circle on the table), but these do not influence miR-34a expression levels, (C) 
and (D) respectively. 
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    Healthy 
Controls 
DMARD 
Responders 
DMARD 
Resistant 
Biologic 
Resistant 
P value 
Number n= 26 19 23 30   
Age (years) Mean 
(StDev) 
48.38     
(7.74) 
62.95     
(10.55) 
58.35     
(10.19) 
58.67     
(10.45) 
0.000 
Gender  F:M 22:4 12:7 18:5 26:4 0.211 
Height Mean 
(StDev) 
1.6350  
0.0776 
1.6389  
0.1104    
1.6691  
0.0990                
1.6276  
0.0847   
0.410 
Weight Mean 
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(14.53)            
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(23.64)             
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(18.02)                    
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(13.98)    
0.106 
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(5.72) 
0.406 
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Figure 3-11 miR-34a expression correlated with clinical measures of disease 
CD14
+
 cells were isolated from the blood of RA patients and miR-34a expression measured by 
PCR.  Correlations were then performed to determine whether increased miR-34a expression 
could be influenced by disease state.  Scatterplots are shown for miR-34a expression (raw data 
was per 10,000 let-7a) against disease duration or other clinical markers of disease activity; 
rheumatoid factor (RF) titre (IU/ml), HS CRP (mg/dl), ESR, DAS28 ESR, tender joint count (TJC) 
and swollen joint count (SJC). 
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Figure 3-12 miR-34a expression correlated with serum cytokine levels 
CD14
+
 cells were isolated from the blood of RA patients and miR-34a expression measured by 
PCR.  From the same samples, serum was stored for luminex analysis to measure cytokine 
expression.  Correlations were then performed to determine whether increased miR-34a 
expression could be influenced by the general peripheral inflammatory state.  Scatterplots are 
shown here for miR-34a expression (raw data was per 10,000 let-7a) against IL-1RA, IL-2R, IL-7, 
IL-12, IFN-α, MCP-1, MIP-1β and MIG. 
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 miR-34a expression in monocyte subsets 3.2.4
When measuring miR-34a expression in the PB of RA patients and healthy 
controls, it would have been useful to further phenotype the CD14+ cells.  It is 
already well documented that monocytes from the peripheral blood of RA 
patients show clear signs of activation.  For example, they produce increased 
quantities of cytokines such as IL-1 and IL-6 [347, 348], and a greater proportion 
of CD14+ cells from RA patients also express CD16 [219, 349]; with more recent 
data suggesting they also have increased expression of CD56 [350]. This 
population of CD14+ cells produce more TNF-α and IL-23 compared to that of 
CD56- monocytes, so we wished to check if different monocyte populations 
expressed different levels of miR-34a – which could be in part responsible for the 
differential miR-34a expression seen in RA patients.  To do this we obtained 
healthy peripheral blood samples, and sorted the monocytes on an Aria FACS 
machine.   Figure 3-13 shows the gating strategy used, which was based on that 
used by Cros et al [204].  Live, single cells were gated based on HLA-DR 
positivity, and being negative for other cellular markers – namely CD2, CD15, 
CD19, CD56 and NKp46.  The remaining cells were gated into the three major 
monocyte populations based on their expression of CD14 and CD16 – CD14hi CD16-
, CD14hi CD16+ and CD14dim CD16+.  The miR-34a expression of these cells was 
then measured by Taqman PCR, and showed no significant differences between 
the expression of miR-34a in these cell subsets. 
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Figure 3-13 Gating strategy and miR-34a expression in sorted monocyte populations from 
healthy peripheral blood 
PBMCs were isolated from healthy blood donors and stained for FACS.  Cells were first gated on 
forward / side scatter (A), before doublets (B) and dead cells (C) were excluded.  Next, cells were 
gated for HLA-DR positivity, and negative for other lineage markers (CD2, CD15, CD19, CD56 and 
NKp46) (D).  The three major monocyte populations were then sorted based on their expression of 
CD14 and CD16 – CD14
hi
 CD16
-
, CD14
hi
 CD16
+
 and CD14
dim
 CD16
+
 (E).  RNA was extracted from 
these cells and PCR used to quantify miR-34a expression (F). Data points represent the miR-34a 
expression of a single healthy donor; data points from the same donor are linked by a line. 
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 Regulation of microRNA-34a expression 3.3
Having established miR-34a up-regulation in monocytes and macrophages in both 
the joint and periphery of RA patients, we next wished to determine what the 
possible causes of this up-regulation could be.  First, we wanted to determine 
whether the basal maturation state could have an effect on miR-34a expression.  
In order to evaluate this, miR-34a expression was measured by PCR in CD14+ cells 
freshly isolated from buffy coats, and compared to the levels seen after 3 and 7 
days M-CSF or GM-CSF maturation (50 ng/ml).  As seen in Figure 3-14, miR-34a 
expression was up-regulated during maturation with M-CSF, and also to a lesser 
extent with GM-CSF.  In order to attain a more accurate time scale for this up-
regulation, cells were cultured with M-CSF and miR-34a expression checked at 
the earlier time points of 2, 6 and 24 hours.  As seen in Figure 3-14C, there was 
no change in expression up until 6 hours, with a trend towards increased 
expression seen after 24 hours.  Significant up-regulation of miR-34a, however, 
was not seen until the 72 hour time point, suggesting that there are indirect 
regulatory steps required to drive its expression. 
Due to the constraints of working with primary cells, particularly in terms of 
manipulation of gene expression, I next wished to assess whether a monocytic 
cell line (THP-1 cells) could be used to investigate miR-34a regulation.  Firstly, 
we wanted to establish whether these cells also up-regulate miR-34a during 
maturation, so cultured them in M-CSF for 3 or 7 days.  As seen in Figure 3-15A, 
no change in miR-34a expression was observed across the time points.  Next, we 
used the well-established method of maturing THP-1 cells with PMA, but again 
saw no increase in miR-34a expression (Figure 3-15B), whereas differences were 
observed in another maturation induced microRNA – miR-22 (Figure 3-15C).  
These experiments established that only primary cells would permit addressing 
the questions of relevance, and I proceeded with these alone. 
We hypothesised that the increased relative expression of miR-34a seen in SF 
CD14+ cells was due to exposure of monocytes to the inflammatory 
microenvironment in the inflamed synovium, leading to maturation and 
presumably also an enhanced activation state.  In order to test this, CD14+ cells 
isolated from buffy coats were cultured for 24 hours in media alone, or with 10% 
SF extracted from 6 different RA patients.  As shown in Figure 3-16A, when miR-
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34a levels were averaged across the different SF cultures, a trend towards 
higher miR-34a expression was seen, but when the expression was measured 
individually for each SF (Figure 3-16B) it is obvious that not all synovial fluids 
stimulate monocyte miRNA expression in the same way.  This likely reflected the 
distinctive composition of individual patient derived SFs, and in this sense was 
unsurprising.  
We next wished to determine if stimulation of monocytes or macrophages could 
alter miR-34a expression.  In order to establish this we took CD14+ cells isolated 
from buffy coats and stimulated them with various TLR ligands.  We also 
performed the same stimulations with cells which had been matured with M-CSF 
for 7 days prior to addition of the stimuli.  Cells were stimulated for 2, 6 and 24 
hours, and miR-34a expression was later measured by Taqman PCR.  The 
supernatants from the 24 hour time point were also taken to establish TNF-α 
levels by ELISA as a measure of successful stimulation.  As shown in Figure 3-17, 
no difference was seen in the miR-34a expression of stimulated monocytes (A) or 
M-CSF-matured macrophages (C) although cells displayed increased TNF-α 
production (B – monocytes, D - M-CSF matured macrophages).  We therefore 
concluded that stimulation of myeloid cells by endogenous TLR ligands in the RA 
synovium was unlikely to be the cause of their increased miR-34a expression. 
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Figure 3-14 miR-34a expression is increased in CD14
+
 cells from buffy coats during M-CSF 
and GM-CSF maturation 
To determine the effect of maturation on miR expression, miR-34a was measured in freshly 
isolated CD14
+
 cells (d0), and compared to cells after 3 or 7 days maturation with M-CSF or GM-
CSF (50 ng/ml) – panel A and panel B, respectively.   In order to determine a more precise 
timescale for miR-34a up-regulation, cells were cultured with M-CSF and taken off at earlier time 
points. Data shown as mean plus standard error of the mean. n = 4, Repeated Measures ANOVA 
with Bonferroni’s multiple comparison test; ** p < 0.01, *** p < 0.001. 
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Figure 3-15 miR-34a expression is not up-regulated by THP-1 cells during maturation 
miR-34a expression was measured after culture of THP-1 cells with 50 ng/ml M-CSF (A - n = 2 
independent experiments) and after 100 ng/ml PMA had been used for 3 days to induce 
differentiation and adherence (B).  Data are also shown for the expression of miR-22 – another 
microRNA known to be regulated by maturation (C). Data presented as mean plus standard error 
of the mean. Paired T test; *** P < 0.001. 
  
miR-34a  Expression
Cells Alone +PMA
0
100
200
300
400
C
o
p
y
 N
u
m
b
e
r
(p
e
r 
1
0
,0
0
0
 l
e
t-
7
a
)
m iR -2 2  E x p r e s s io n
Cells Alone +PMA
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
* * *
C
o
p
y
 
N
u
m
b
e
r
(
p
e
r
 
1
0
,
0
0
0
 
l
e
t
-
7
a
)
miR-34a Expression
d0 d3 d7
0
10
20
30
40
C
o
p
y
 N
u
m
b
e
r
(p
e
r 
1
0
,0
0
0
 l
e
t-
7
a
)
A B 
C
  141 
 
 
 
 
Figure 3-16 miR-34a is up-regulated after culture of CD14
+
 cells with some synovial fluid 
samples  
CD14
+
 cells were isolated from buffy coats and cultured alone (CA) or with 10% synovial fluid 
derived from 6 different RA patients (SF1-6).  After 24 hours miR-34a expression was measured by 
PCR.  Panel A represents data where the average of the 6 SF cultures was taken, while panel B 
shows the data for each individual SF separately.  Data shown as mean plus standard error of the 
mean. Kruskal-Wallis test with Dunn’s multiple comparison; * P < 0.05. 
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Figure 3-17 miR-34a expression is not regulated by TLR stimulation 
CD14
+
 cells were isolated from peripheral blood samples and stimulated with various TLR ligands 
for 24 hours before miR-34a expression was measured by qPCR (A).  As a measure of activation, 
TNF-α levels were measured in the supernatants after the 24 hour stimulation by ELISA (B). Cells 
were also M-CSF matured for 7 days prior to stimulations (C), and again TNF-α production after the 
24 hour stimulation used to confirm successful stimulation (D).  Shown in (E) is the colour code 
used for all graphs.  Data shown as mean plus standard error of the mean. n = 3. 
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 Discussion 3.4
Previous data from our laboratory suggested that miR-34a was increased in 
CD14+ monocytes isolated from the SF of RA patients compared to matched PB 
cells.  Therefore, this study set out to confirm this observation, and having 
achieved this, determine whether miR-34a was differentially expressed in RA 
samples compared to controls.  Another key part of this investigation was to 
determine the potential factors driving this dysregulated miR-34a expression. 
My first key observation is that synovial fluid and tissue macrophages do indeed 
express miR-34a.  Moreover, circulating peripheral blood monocytes from 
biologic-resistant RA patients express higher levels of microRNA-34a than were 
observed in matched healthy controls.  These data have some fundamental 
implications.  The key biologic activities of miR-34a thus far include the 
regulation of cell cycle, which proved to be important in miR-34a anti-oncogene 
activity [351]; and it is also associated with accelerated cell aging [336, 352].  
The finding that miR-34a is indeed elevated in the context of synovial tissue in 
RA therefore suggests this as a novel pathway in RA, potentially regulating the 
chronic contribution of macrophages to pathology. 
There were however some obvious limitations to this part of my study.  I was 
hindered by the inability to obtain certain samples from healthy tissue controls.  
Healthy controls could be used when looking at microRNA expression in 
peripheral blood samples, but when looking at synovial fluid cells or synovial 
tissue this was not possible, and appropriate controls had to be determined 
depending on the given sample type.  To look at sites of inflammation in the 
joint, although not ideal, we considered the best control to be patients with 
non-inflammatory and inflammatory joint disease (as determined by H&E 
staining), as these tissues were easily accessible in the lab.  Thus, our 
interpretation cannot truly demonstrate disease specificity.  That said the 
presence of this pathway in itself is pathogenetically informative.  In particular, 
we recognise the challenges inherent in using OA as a control – for this reason I 
have chosen to segregate these tissues into inflammatory and non-inflammatory 
subgroups based on histological appearances.  An intriguing side observation is 
therefore that in inflamed OA tissues the presence of miR-34a may have 
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significance – this is outwith the scope of my thesis but will be followed up by 
the host laboratory in due course with Dr Carl Goodyear and Prof William Ferrell. 
The increased miR-34a expression seen in cells isolated from the peripheral 
blood of drug-resistant patients is of particular interest, as it suggests the 
microRNAs increased expression is not solely due to activation and maturation at 
the sites of synovial inflammation.  This said, it is well documented that PB 
monocytes are primed or activated in RA, but the similar miR-34a expression 
seen in the monocyte populations sorted from peripheral blood also suggests 
miR-34a expression in monocytes is not simply a result of maturation status.  A 
study looking at microRNA expression in early RA patients would be useful to 
determine whether these patients have constitutively higher miR-34a 
expression, which could be used as a potential biomarker of non-response to 
therapy, or whether miR-34a levels change in response to the on-going, 
unopposed inflammatory activity in these patients. 
The fact that miR-34a does not correlate with any peripheral measures of 
inflammation, but does correlate with the SJC of patients is also interesting.  
Swollen joints are one of the most characteristic features of RA, and the number 
of swollen joints is directly linked to disease severity.  This could suggest that 
miR-34a expression in PB CD14+ cells is altered in response to localised 
inflammation in the joint, as opposed to the overall cumulative systemic 
inflammatory state.  This said, we were concerned about statistical errors 
introduced by multiple comparison testing – so further validatory analyses would 
be helpful in this regard.  Potentially this could be performed in the PEAC 
consortium cohort of which Glasgow is a part.  An alternate view is that the 
elevated levels of miR-34a in circulating monocytes of patients with drug-
resistant disease are a feature of the chronicity in such patients, rather than 
intercurrent disease activity.  This in one sense makes miR-34a more interesting 
as a molecular factor that could play a fundamental role in maintaining the 
cellular events driven by monocytes. 
The increase in miR-34a expression seen during M-CSF maturation, and lesser 
increase in GM-CSF matured cells is intriguing.  This suggests that miR-34a may 
play a pivotal role in the differentiation and activation of different subtypes of 
macrophages, and potentially dendritic cells.  The latter is currently being 
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studied by others in the lab, so I focused on dissecting the role of miR-34a in the 
biology of M-CSF driven macrophages. 
The increase in miR-34a expression seen in biologic resistant patients, as well as 
the increase in healthy cells cultured in SF suggests that exposure to 
inflammatory stimuli could result in increased miR-34a expression, although the 
lack of response to TLR ligands could suggest otherwise.  It has previously been 
suggested that LPS stimulation actually down-regulates miR-34a expression in 
macrophages, although these experiments were performed in RAW264.7 cells 
[353], and a subsequent study on human monocyte derived macrophages also 
failed to find a significant difference compared to controls [354].  Alternatively, 
M-CSF and / or GM-CSF derived from the sites of inflammation may be 
responsible for the changes seen in miR-34a expression in some RA patients, and 
in the healthy donor monocytes cultured with SF. 
This study, to my knowledge, provides the first evidence that miR-34a is up-
regulated in monocytes and macrophages in both the periphery and sites of 
inflammation in RA.  Future experiments will therefore focus on what affect 
altering miR-34a expression has on monocytes and macrophages, as unravelling 
the pathways regulated by miR-34a in these cells could give clues to why it is 
differentially expressed in RA. 
 
  
 
 
Chapter 4 – Investigating the functional and 
phenotypic consequence of miR-34a   
manipulation in macrophages 
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 Introduction and Aims 4.1
Having established in the previous chapter that miR-34a expression is increased 
in peripheral blood monocytes and synovial macrophages in RA, and knowing it is 
also up-regulated during monocyte to macrophage differentiation, we next set 
out to determine the possible functional role(s) of miR-34a in macrophage 
biology.  The primary roles of macrophages include production of a wide range 
of cytokines, reactive oxygen and nitrogen intermediates and also phagocytosis 
of cellular debris, microorganisms and infected, damaged or antibody-coated 
cells.  RA is characterised by the chronic dysregulated activation of 
macrophages, such that they could contribute to pathogenesis by several or all 
of these mechanisms.  We therefore wished to investigate whether altering miR-
34a expression could affect the ability of macrophages to produce cytokines in 
response to TLR ligands, or change their expression of various surface markers 
involved in macrophage activation and the promotion of phagocytosis. 
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 Effect of miR-34a manipulation on cytokine output 4.2
In order to assess the effect of altering miR-34a levels on the cytokine output of 
macrophages, CD14+ cells were first isolated from buffy coats and then M-CSF-
matured for 7 days.  These cells were then transfected with a control mimic, 
miR-34a mimic, control inhibitor or miR-34a inhibitor for 24 hours prior to 
stimulation with 10 ng/ml LPS for a further 24 hours.  The microRNA mimic used 
here is transfected as a double-stranded RNA molecule, where exclusion of the 
passenger strand (through proprietary mechanisms undisclosed by the company) 
ensures that only the strand of interest is active.  This is intended to “mimic” 
native microRNAs, and allow overexpression of microRNA to aid the discovery of 
potential functional roles of individual microRNA.  The microRNA inhibitors are 
single-stranded RNA molecules, which bind and inhibit endogenous microRNA, 
thereby revealing any consequence of the microRNAs down-regulation / 
absence.  
We initially measured only the TNF-α production by the transfected and 
stimulated macrophages, as this cytokine is known to play a key role in the 
pathogenesis of RA; moreover it is known to be primarily produced by 
macrophages [235, 355].  TNF-α is also thought to have a hierarchical role in the 
RA cytokine milieu, illustrated by the fact that treatment of cultures of synovial 
cells from RA patients with anti-TNF therapy reduces the levels of IL-1, IL-6, IL-8 
and GM-CSF synthesis [62, 356].  It is also known that TNF-inhibitors represent 
some of the most successful biologic therapies currently available in the 
treatment of RA. 
The TNF-α concentration in the supernatants of transfected and stimulated cells 
was measured by ELISA.  As demonstrated in Figure 4-1, cells transfected with 
miR-34a mimic produced significantly less TNF-α when compared to control 
mimic transfected cells.  miR-34a inhibition, however, had no effect on the 
measured TNF-α concentration.  In order to determine whether the over and 
under-expression of miR-34a was successful, PCR was performed to measure 
miR-34a expression in the transfected cells.  As seen in Figure 4-1C, transfection 
of cells with a miR-34a mimic results in the desired increase in miR-34a 
expression.  Transfection of day 7 M-CSF matured cells with a miR-34a inhibitor, 
however, produced no significant change in miR-34a expression detectable by 
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PCR.  We therefore concluded that miR-34a inhibitors had been unsuccessful in 
these cells, and decided to explore other approaches to miR-34a inhibition. 
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Figure 4-1 Effect of miR-34a manipulation on TNF-α production by 7 day M-CSF-matured 
macrophages 
CD14
+
 cells were isolated from buffy coat samples and matured with 50 ng/ml M-CSF for 7 days. 
These cells were then transfected with 25 nM control (Cm) or miR-34a (miR-34am) mimics or 
inhibitors (Ci or miR-34ai) 24 hours before stimulation with 10 ng/ml LPS for a further 24 hours.  
The TNF-α concentration in the supernatants of transfected and stimulated cells was then 
measured by ELISA.  Panel A shows the TNF-α concentration of cells transfected with Cm or miR-
34am, while panel B shows the TNF-α concentration of cells transfected with Ci or miR-34ai.  Shown 
in panels C and D is the miR-34a expression measured by PCR after transfection with control and 
miR-34a mimics and inhibitors, respectively.  The miR-34a expression of control mimic or control 
inhibitor transfected cells was normalised to 1, with the other conditions being expressed as fold 
change.  Data shown as mean plus standard error of the mean.  Paired t test; * P < 0.05. ** P < 
0.01, n = 8. 
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In chapter 3 we demonstrated that miR-34a expression increases significantly 
during the M-CSF maturation of CD14+ cells.  For this reason we hypothesised 
that the miR-34a levels achieved after 7 days maturation in M-CSF were too 
high, and our inhibitor could not effectively reduce its expression at the 
manufacturer’s suggested concentration.  As CD14+ cells already achieve an 
increased level of miR-34a and an adherent macrophage-like morphology after 3 
days in M-CSF, and previous experiments in our group have shown their cytokine 
response to culture with RA synovial fluid or cytokine-activated T cells is 
equivalent to that achieved by cells cultured in M-CSF for 7 days (Jagtar Nijjar, 
PhD thesis), we decided to try using miR-34a mimics and inhibitors in 3 day M-
CSF-matured cells.  As previously, CD14+ cells were isolated from buffy coats, 
but this time they were M-CSF-matured for 3 days prior to 24 hour transfection 
with control or miR-34a mimics or inhibitors.  RNA was isolated from these cells 
and the miR-34a expression determined by PCR.  As shown in Figure 4-2, miR-34a 
was significantly increased in miR-34a mimic transfected cells, and this time 
significant down-regulation of endogenous miR-34a was also observed with the 
use of miR-34a inhibitors.  
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Figure 4-2 miR-34a expression of 3 day MCSF-matured macrophages after transfection with 
miR-34a mimics and inhibitors 
CD14
+
 cells were isolated from buffy coat samples and matured with 50 ng/ml M-CSF for 3 days. 
These cells were then transfected with 25 nM control (Cm) or miR-34a (miR-34am) mimics or 
inhibitors (Ci or miR-34ai) for 24 hours.  The miR-34a expression of mimic and inhibitor transfected 
cells are shown in panel A and B, respectively.  For each donor the control mimic or inhibitor 
expression was normalised to 1, with the other conditions being expressed as fold change.  Data 
shown as mean plus standard error of the mean. Paired t test; ** p < 0.01, *** p < 0.001. n = 8. 
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We therefore decided to use this transfection scheme in all further experiments.  
Accordingly, these 3 day M-CSF-matured cells were left in transfection reagents 
for 24 hours, and then stimulated for 24 hours with the addition of TLR ligands.  
We chose two stimuli, namely LPS and CL097, to demonstrate the effects of both 
extracellular and intracellular stimuli on macrophage cytokine production, and 
also because these two TLRs can utilise different signal transduction pathways to 
mediate their effects. 
Figure 4-3A and Figure 4-3B show the TNF-α concentration after stimulation with 
1 or 10 ng/ml LPS, respectively.  In both instances, significant down-regulation 
of TNF-α was observed with miR-34a over-expression, and a significant up-
regulation observed upon miR-34a inhibition.  As human cytokine production is 
highly variable from donor to donor, we also normalised the data so that the 
control (mimic or inhibitor) for each donor was set to 100%, with the 
experimental condition shown as a percentage.  Both the raw data calculation 
and percentage change from control were similar between the 1 and 10 ng/ml 
LPS stimulation conditions.  LPS stimulation of miR-34a over-expressing cells 
resulted in a mean (SEM) reduction of 18% (±3.89%) in TNF-α production, while in 
miR-34a inhibited cells an increase of 45% (±7.79%) TNF-α production was 
observed.  
miR-34a mimic and inhibitor transfected cells were also stimulated with the 
TLR7/8 ligand Cl097.  Cells were transfected using the aforementioned 
conditions, then stimulated with 1 μg/ml Cl097 for a further 24 hours.  Figure 
4-4A shows the TNF-α concentration in the supernatants as measured by ELISA.  
As with the LPS-stimulated cells, Cl097-stimulated cells demonstrate a 
significant down-regulation of TNF-α with miR-34a over-expression, and a 
significant up-regulation with miR-34a inhibition.  Again data are also displayed 
as percentage change.  Cl097 stimulation exhibited 24% (±11.03%) reduction in 
TNF-α production following miR-34a over-expression (Figure 4-4B), and a 68% 
(±18.75%) increase in TNF-α production following miR-34a inhibition (Figure 4-4C). 
These data demonstrate that miR-34a has a likely role in the negative regulation 
of TNF-α production in response to both LPS and Cl097 stimulation. 
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Figure 4-3 Effect of miR-34a manipulation on LPS-induced TNF-α production of 3 day M-
CSF-matured macrophages 
CD14
+
 cells were isolated from buffy coats and matured for 3 days in 50 ng/ml M-CSF. Cells were 
then transfected with 25 nM control (Cm) or miR-34a mimic (miR-34am) or inhibitors (Ci or miR-34ai) 
prior to a 24 hour stimulation with LPS.  The concentration of TNF-α in the cell supernatants was 
then measured by ELISA.  Panel A and B show the TNF-α concentration after stimulation with 1 or 
10 ng/ml LPS, respectively.  Wilcoxon matched-pairs signed rank test; ** P < 0.01.  n = 8.  Also 
shown are the normalised TNF-α production values for the same samples.  For each donor the 
control mimic or inhibitor was normalised to 100%, with miR-34a being shown as a percentage of 
control.  The miR-34a over-expression data are shown for 1 ng/ml and 10 ng/ml LPS stimulated 
cells in panels C and D respectively, while inhibitor data are shown in E and F.  Data shown as 
mean plus standard error of the mean.  Paired t test; ** P < 0.01.  n = 8. 
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Figure 4-4 Effects of miR-34a manipulation on Cl097-induced TNF-α production of 3 day M-
CSF-matured macrophages 
CD14
+
 cells were isolated from buffy coats and matured for 3 days in 50 ng/ml M-CSF.  Cells were 
then transfected with 25 nM control (Cm) or miR-34a mimic (miR-34am) or inhibitors (Ci or miR-34ai) 
prior to a 24 hour stimulation with Cl097.  The concentration of TNF-α in the cell supernatants was 
then measured by ELISA.  Panel A shows the TNF-α concentration after stimulation with 1 ug/ml 
Cl097.  Wilcoxon matched-pairs signed rank test; * P < 0.05, ** P < 0.01.  n = 8.  Also shown are 
the normalised TNF-α production values for the same samples.  For each donor the control mimic 
or inhibitor was normalised to 100%, with miR-34a being shown as a percentage of control.  Panel 
B shows the normalised data for miR-34a over-expression, while C shows the effect of miR-34a 
inhibition on TNF-α production.  Data shown as mean plus standard error of the mean.  Paired t 
test; ** P < 0.01.  n = 8. 
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Next, in an attempt to gain a better understanding of the effects of altering 
miR-34a expression on macrophage cytokine production, we decided to perform 
a multiplex luminex assay.  This allowed us to determine the concentration of 
many cytokines – both pro- and anti-inflammatory.  Although the TNF-α 
production was similar between cells stimulated with 1 or 10 ng/ml LPS, we 
chose to use the 10 ng/ml LPS stimulation for the luminex, as other cytokines 
may require a higher level of stimulation to generate detectable cytokine 
output.  The samples from transfected cells stimulated with 10 ng/ml LPS and 
those stimulated with 1 μg/ml Cl097 were assayed by a luminex which was 
capable of measuring IL-1RA, IFN-γ, IL-7, IFN-α, IP-10, Eotaxin, MIG, IL-5, IL-6, 
IL-10, MIP-1α, IL-17, IL-8, IL-12 (p40⁄p70), RANTES, MIP-1β, GM-CSF, TNF-α, IL-
1β, IL-2, IL-4, IL-2R, IL-15, MCP-1 and IL-13. All analytes that were detectable 
and in range for all samples are shown in the graphs below. 
For LPS stimulated cells, other than TNF-α, only IL-6 showed reciprocal changes 
upon miR-34a manipulation.  Thus we observed a significant reduction with miR-
34a over-expression and an increase with miR-34a inhibition.  For IL-1β we 
observed only a trend towards reduced expression with miR-34a over-expression 
but we did see a significant increase in expression with miR-34a inhibition 
(graphs shown in Figure 4-5).  Of interest, several cytokines showed significant 
down-regulation in miR-34a over-expressing cells, but no change where miR-34a 
had been inhibited.  As demonstrated in Figure 4-6 these included IFN-γ, MIG, IL-
7, IL-15 and IL-1RA.  Figure 4-7 shows all the analytes whose expression 
remained consistent between all four conditions; namely IL-10, IL-12, IL-2R and 
IFN-α. 
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Figure 4-5 Analytes whose LPS-induced production was influenced by miR-34a over and 
under expression in macrophages 
CD14
+
 cells were isolated from buffy coats and matured for 3 days in 50 ng/ml M-CSF.  Cells were 
then transfected with 25 nM control (Cm) or miR-34a mimic (34am) or inhibitors (Ci or 34ai) prior to a 
24 hour stimulation with LPS.  The concentration of cytokines in the supernatant was then 
measured by luminex.  Shown are the analytes whose expression was detectable in all samples, 
and changes were observed with the use of miR-34a mimics and inhibitors.  Wilcoxon matched-
pairs signed rank test; * p < 0.05, ** p < 0.001.  n = 8.  
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Figure 4-6 Analytes whose LPS-induced production was influenced by miR-34a over 
expression in macrophages 
CD14
+
 cells were isolated from buffy coats and matured for 3 days in 50 ng/ml M-CSF.  Cells were 
then transfected with 25 nM control (Cm) or miR-34a mimic (34am) or inhibitors (Ci or 34ai) prior to a 
24 hour stimulation with LPS.  The concentration of cytokines in the supernatant was then 
measured by luminex.  Shown are the analytes whose expression was detectable in all samples, 
and changes were observed with the use of miR-34a mimics but not inhibitors.  Wilcoxon matched-
pairs signed rank test; * p < 0.05, ** p < 0.001.  n = 8.  
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Figure 4-7 Analytes whose LPS-induced production was not influenced by miR-34a over or 
under expression in macrophages 
CD14
+
 cells were isolated from buffy coats and matured for 3 days in 50 ng/ml M-CSF.  Cells were 
then transfected with 25 nM control (Cm) or miR-34a mimic (34am) or inhibitors (Ci or 34ai) prior to a 
24 hour stimulation with LPS.  The concentration of cytokines in the supernatant was then 
measured by luminex.  Shown are the analytes whose expression was detectable in all samples, 
but no significant differences were observed by Wilcoxon matched-pairs signed rank test.  n = 8.  
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When transfected cells were stimulated with Cl097, the range of cytokines that 
demonstrated reciprocal changes upon miR-34a manipulation was broader, and 
included IL-1β, IL-6, IL-7, IL-13, IL-15, RANTES and GM-CSF.  These were all 
significantly down-regulated in miR-34a mimic transfected cells, and up-
regulated in miR-34a inhibitor transfected cells (shown in Figure 4-8).  As with 
LPS, Cl097 stimulation also elicited a group of cytokines whose expression was 
affected by miR-34a over-expression, but not miR-34a inhibition, including IL-
1RA, IL-2R, IL-12 and IFN-α (Figure 4-9).  Figure 4-10 shows the analytes whose 
expression remained consistent in all 4 conditions after Cl097 stimulation.  Of 
those that could be detected namely IL-10 and IP-10.  In summary, miR-34a 
seems to inhibit overall macrophage activation, manifest by the altered 
production of a broad range of cytokines, particularly in response to stimulation 
with the intracellular TLR, TLR7. 
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Figure 4-8 Analytes whose Cl097-induced production was influenced by miR-34a over and 
under expression in macrophages 
CD14
+
 cells were isolated from buffy coats and matured for 3 days in 50 ng/ml M-CSF.  Cells were 
then transfected with 25 nM control (Cm) or miR-34a mimic (34am) or inhibitors (Ci or 34ai) prior to a 
24 hour stimulation with Cl097.  The concentration of cytokines in the supernatant was then 
measured by luminex.  Shown are the analytes whose expression was detectable in all samples, 
and changes were observed with the use of both miR-34a mimics and inhibitors. Wilcoxon 
matched-pairs signed rank test; * p < 0.05, ** p < 0.001. n = 8.  
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Figure 4-9 Analytes whose Cl097-induced production was influenced by miR-34a over 
expression in macrophages 
CD14
+
 cells were isolated from buffy coats and matured for 3 days in 50 ng/ml M-CSF.  Cells were 
then transfected with 25 nM control (Cm) or miR-34a mimic (34am) or inhibitors (Ci or 34ai) prior to a 
24 hour stimulation with Cl097.  The concentration of cytokines in the supernatant was then 
measured by luminex.  Shown are the analytes whose expression was detectable in all samples, 
and changes were observed with the use of miR-34a mimics but not inhibitors.  Wilcoxon matched-
pairs signed rank test; * p < 0.05, ** p < 0.001. n = 8.  
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Figure 4-10 Analytes whose Cl097-induced production was not influenced by miR-34a over 
or under expression in macrophages 
CD14
+
 cells were isolated from buffy coats and matured for 3 days in 50 ng/ml M-CSF.  Cells were 
then transfected with 25 nM control (Cm) or miR-34a mimic (34am) or inhibitors (Ci or 34ai) prior to a 
24 hour stimulation with Cl097.  The concentration of cytokines in the supernatant was then 
measured by luminex. Shown are the analytes whose expression was detectable in all samples, 
but no significant differences were observed by Wilcoxon matched-pairs signed rank test. n = 8.  
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Both we (to be discussed in chapter 5) and others have demonstrated that miR-
34a can target the MCSF receptor CSF1R [357].  There are several studies 
suggesting that M-CSF can induce TNF-α mRNA and protein expression, and even 
act synergistically with LPS stimulation to cause increased TNF-α production 
[358-361].  For this reason, and because we supplement our cultures with M-CSF 
(potentially acting as a “co-stimulant” with TLR agonism), we wanted to test 
whether reduced CSF1-R expression by our miR-34a mimic transfected cells could 
be responsible for the reduced TNF-α expression.  To test this, as previously 
described, CD14+ cells were isolated from buffy coats and cultured with M-CSF 
for 7 days, however, when changing the media of these already differentiated 
cells prior to transfection, they were replenished with fresh complete medium 
with no M-CSF supplementation, or with 5 or 50 ng/ml M-CSF.  Cells were 
transfected for 24 hours as before, then stimulated with 10 ng/ml LPS for a 
further 24 hours.  The TNF-α concentration in the supernatants was then 
measured by ELISA.  Figure 4-11 shows the results, and while data are variable 
(as expected with human cells) and from only three donors, regardless of the M-
CSF concentration, the LPS-induced TNF-α production was consistently lower in 
the miR-34a mimic transfected cells.  Thus miR-34a targeting of CSF1R is unlikely 
to explain the reduced TNF production we observed in miR-34a mimic 
transfected cells. 
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Figure 4-11 The effect of different M-CSF concentrations on LPS-induced TNF-α production 
by miR-34a-transfected macrophages 
CD14
+
 cells were isolated from buffy coat samples and matured with 50 ng/ml M-CSF for 7 days. 
These cells were then transfected with 25 nM control (Cm) or miR-34a (miR-34am) mimics in the 
absence of M-CSF, or in the presence of 5 or 50 ng/ml M-CSF for 24 hours prior to a further 24 
hour stimulation with 10 ng/ml LPS.  The TNF-α concentration in supernatants was measured by 
ELISA.  Data from cells from the same donor in the same M-CSF condition are linked by a line.  n = 
3. 
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  Effect of miR-34a manipulation on macrophage 4.3
phenotype 
We next wanted to determine whether miR-34a regulates monocyte to 
macrophage differentiation and subsequent activation.  Thus we tested whether 
over-expression or inhibition of miR-34a affected some of the key surface 
markers found on macrophages.  CD14+ cells were isolated from buffy coats and 
matured with M-CSF for 3 days.  These cells were then transfected with a control 
mimic, miR-34a mimic, control inhibitor or miR-34a inhibitor for 24 hours before 
being harvested and stained for FACS analysis.  We chose to look at CD16, CD64 
and HLA-DR.  
CD64 and CD16 are Fc receptors (FcRs); FcγRI and FcγRIII respectively.  FcγRs 
bind IgG in many forms, including monomeric IgG, immune complexes and 
antibody-coated or opsonized particles or cells.  These two specific receptors 
associate with the FcR common γ-chain that contains immunoreceptor tyrosine-
based activation motifs (ITAMs).  Upon binding of the receptors by IgG, these 
ITAMs activate signalling cascades, with subsequent functional outcomes 
depending on the type of IgG bound.  Binding of opsonized pathogens or infected 
cells results in increased uptake by phagocytosis, ultimately resulting in 
pathogen killing or antibody-dependant cell-mediated cytotoxicity (ADCC), 
whereas binding of immune complexes can increase cytokine production and 
alter the activation state of the macrophage.  These markers are also often 
altered during macrophage differentiation and activation.  CD64 for example is 
up-regulated upon macrophage activation, and is frequently used as an “M1” 
macrophage marker [362, 363].  Fc receptors are also important in the context 
of RA, where ACPA containing immune-complexes binding to FcγRs are thought 
to be one of the mechanisms responsible for the activation of synovial 
macrophages.   HLA-DR is an MHC class II molecule, whose primary role is to 
present antigens to T cells, which is often up-regulated during cell activation 
[364].  We therefore chose to measure the expression of these three cell surface 
markers as changes in their expression could indicate differences in the 
maturation or activation state of the miR-34a mimic or inhibitor transfected 
cells. 
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Figure 4-12 shows representative histograms for cells from one donor stained 
with these markers.  The majority of cells in all conditions stained positive for 
all markers, but no differences were seen between the control or miR-34a mimic 
or inhibitor transfected cells.  Figure 4-13 shows the percentage of positive cells 
compared to the fluorescence minus one (FMO) control and also the geometric 
mean fluorescence intensity (gMFI).  These data suggest that miR-34a does not 
regulate the expression of macrophage cell surface markers during maturation in 
an obligate manner. 
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Figure 4-12 Histograms showing representative FACS staining of miR-34a mimic and 
inhibitor transfect macrophages  
CD14
+
 cells were isolated from buffy coats and matured for 3 days in 50 ng/ml M-CSF.  Cells were 
then transfected with 25 nM control (Cm) or miR-34a mimic (miR-34am) or inhibitors (Ci or miR-34ai) 
and cells taken for FACS staining 24 hours later.  Shown in panel A is the colour key used for all 
histograms.  Panels B, C and D show representative histograms for one donor stained with CD64, 
CD16 and HLA-DR respectively. 
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Figure 4-13 Analysis of CD64, CD16 and HLA-DR expression in miR-34a mimic and inhibitor 
transfected macrophages 
CD14
+
 cells were isolated from buffy coats and matured for 3 days in 50 ng/ml M-CSF.  Cells were 
then transfected with 25 nM control (Cm) or miR-34a mimic (34am) or inhibitors (Ci or 34ai) and cells 
taken for FACS staining 24 hours later.  Shown are the percentage of positive cells and geometric 
mean fluorescence intensity (gMFI) for CD64 (A), CD16 (B) and HLA-DR (C).  Data shown as 
mean plus standard error of the mean.  n = 4.  
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 Discussion 4.4
We have previously shown that the expression of miR-34a is increased in the 
synovium of RA patients, and also in circulating monocytes from patients with 
drug resistant disease.  Therefore, this part of the study set out to determine 
the possible functional consequences of dysregulated miR-34a expression.  
My first key observation is that even in 7 day M-CSF-matured macrophages, 
whose miR-34a expression is quite high (shown in chapter 3), further up-
regulation of this microRNA can cause a significant decrease in the TNF-α 
production in response to LPS stimulation.  However, possibly due to the high 
levels of miR-34a found in 7 day M-CSF-matured cells, miR-34a inhibition was not 
bioactive in these cells.  We therefore chose to look at over and under-
expression of miR-34a in CD14+ cells matured with M-CSF for 3 days because 
these cells express intermediate levels of miR-34a, and as such represented a 
system in which the reciprocal activities of miR-34a mimic and inhibitors could 
be formally tested.  Moreover, while we have demonstrated that synovial fluid 
CD14+ cells from RA patients show increased miR-34a expression, these levels 
are not as high as those observed in cells matured with M-CSF for 7 days.  
Finally, as noted earlier, 3 day M-CSF matured cells do not differ phenotypically 
or functionally (at least in terms of cytokine production) from the standard 7 day 
matured cells. 
When day 3 M-CSF-matured cells were examined, a significant reduction in TNF 
with miR-34a over-expression, and a reciprocal increase with miR-34a inhibition 
was found in both LPS and Cl097 stimulated cells.  Consistent with this finding, 
another paper was recently published subsequent to my performing this work 
showing that miR-34a affects TNF-α production by human M-CSF-matured 
macrophages [354].  Interestingly, while we only studied the “functional” miR-
34a strand (miR-34a-5p), this paper looked at the effect of both the 5p and 3p 
strands of miR-34a on TNF production.  They demonstrated that over-expression 
of both strands individually could reduce TNF mRNA and protein, while over-
expression of both strands together resulted in a greater reduction, suggesting 
synergistic effects.  While the authors suggested that miR-34a-5p affected TNF 
production indirectly, the 3p strand actually targeted TNF mRNA directly; which 
they proved using a luciferase reporter assay.  In the initial stages of this project 
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we actually observed increased expression of both strands of miR-34a in synovial 
fluid CD14+ cells from RA patients, but at the time chose to focus on what was 
termed the “functional” strand.  However, in the past two years miR-34a-3p has 
been proven to be a functional microRNA in its own right.  In this study its role in 
TNF production of monocyte-derived macrophages is highlighted.  In an earlier 
study miR-34a-3p expression was found to be reduced in fibroblasts from RA 
patients where it could promote the increased expression of an inhibitor of 
apoptosis, thereby aiding the expansion of FLSs [254].  These studies suggest 
that the increased miR-34a-3p expression in RA SF CD14+ cells could indeed be 
important, and warrant further study. 
In order to obtain a clearer picture of what was going on in our cells after miR-
34a manipulation, we performed a luminex assay to observe a broader cytokine 
profile.  The most interesting results are those that move in reciprocal directions 
with the use of microRNA-34a mimics and inhibitors.  There are many cytokines 
whose expression was unchanged in either condition, or that changed only with 
miR-34a mimics.  The latter results are harder to interpret on their own, 
because the supraphysiological levels of microRNA achieved after transfection 
with microRNA mimics likely causes targeting of pathways that would not occur 
under physiological conditions.  Therefore, microRNA mimics are useful for 
understanding the potential of what a microRNA has the capability of targeting, 
but microRNA inhibitors give a more accurate representation of the role of a 
given microRNA in the cell at that time [365].  For this reason we are more 
engaged with the notion that cytokines that were reciprocally regulated 
represent functionally relevant output from this experimental series.  
The only cytokine, other than TNF-α, which was significantly down-regulated 
with miR-34a over-expression, and up-regulated with miR-34a inhibition under 
both LPS and Cl097 stimulation conditions was IL-6.  IL-1β, however, was 
significantly altered by Cl097 stimulation in both conditions, and significantly 
up-regulated after LPS stimulation of miR-34a inhibited macrophages, with a 
trend towards lower expression seen in the miR-34a mimic transfected cells.   
This is intriguing since TNF-α, IL-6 and IL-1 are considered three of the most 
important cytokines in RA disease pathogenesis.  Treatments opposing their 
actions are licenced for the treatment of RA, and all three are up-regulated in 
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both the serum and SF of RA patients where they correlate with various 
parameters of disease activity [366-369].  They are all involved in multiple levels 
of regulation of immune responses and have many over-lapping and distinct 
functions [370].  
Interestingly, miR-34a inhibited the production of a broader range of cytokines 
in the presence of CL097 stimulation.  These include GM-CSF, IL-15 and IL-7.  
GM-CSF is known to regulate the production, differentiation and activation of 
myeloid cells.  It is found at high levels in the synovium of RA patients, where it 
is thought to play a role in driving local inflammatory responses.  Increased GM-
CSF in RA could be involved in promoting an inflammatory phenotype in 
macrophages [371], and also play a role in promoting the generation and survival 
of pathogenic Th17 cells [153].  IL-15 is also increased in expression in both the 
serum and synovial fluid of RA patients, where it correlates with disease severity 
[372].  Initially described as T cell growth factor, it is now known that IL-15 is 
involved in regulating the activation and proliferation of T cells and NK cells, 
and promoting the survival of memory T cells [373].  It is also capable of 
promoting osteoclastogenesis [374], while blocking IL-15 activity reduced the 
destruction of cartilage and bone in the murine CIA model [375].  The expression 
of IL-7 in the serum of RA patients is still controversial, with conflicting reports 
suggesting it could be up or down-regulated compared to controls, but it is 
known to be up-regulated in the synovial fluid of RA patients compared to OA 
patients [376, 377].  IL-7 has been shown to promote osteoclastogenesis in RA 
CD14+ cells [378], and like IL-15, it also has a role preventing apoptosis of naïve 
T cells [379] and promoting the survival and expansion of memory T cells [380, 
381].  The fact that many of these cytokines are up-regulated in the serum and 
synovial fluid of RA patients, while miR-34a is up-regulated in monocytes and 
macrophages in the periphery and synovium could suggest that miR-34a is 
actually unsuccessfully trying to dampen the on-going inflammation. 
The results from these experiments leave two particularly interesting questions; 
what causes miR-34a’s negative regulation of macrophage cytokine production, 
and why are the differences seen with Cl097 stimulation more profound than 
those seen with LPS stimulation. 
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Firstly, what causes miR-34a’s negative regulation of macrophage cytokine 
production?  As mentioned previously, miR-34a overexpression down-regulates 
CSF1-R, which is a predicted and verified target of miR-34a.  M-CSF is crucial for 
macrophage differentiation and can synergise with other stimuli to promote 
macrophage activation.  Thus, one possible hypothesis we had was that miR-34a 
targeting of CSF1R had a negative effect on macrophage activation and 
therefore reduced cytokine production in response to TLR stimulation (by 
diminution of the combinatorial effect of CSFR1 and TLR signalling).  This did not 
appear to be the case, however, as all macrophage maturation markers tested 
were not affected by miR-34a manipulation, and altering the M-CSF 
concentration didn’t affect the reduced TNF-α production in miR-34a over-
expressing cells in response to LPS stimulation.  Though to formally exclude 
autocrine M-CSF release mediating this effect it would be necessary to add a 
neutralising anti-MCSF antibody to the culture.  
When using ingenuity pathway analysis and using predicted miR-34a targets to 
look for other potential ways by which miR-34a could negatively influence TNF-α 
production, interleukin-1 receptor-associated kinase (IRAK) -2 and IRAK-4 came 
up as interesting potential miR-34a targets.  The IRAK family has four members, 
IRAK-1, 2, 3 and 4, which are implicated in the downstream signalling of the TLR 
and IL-1R family molecules.  Both IRAK-2 and IRAK-4 have two potential miR-34a 
binding sites in their 3’-UTR, but to my knowledge no studies have confirmed 
miR-34a targeting of these mRNAs [382].  Another interesting potential miR-34a 
target that could be involved in altering cytokine production after miR-34a over-
expression and inhibition is mitogen-activated protein kinase kinase kinase 14 
(MAP3K14), also known as nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-κB) -inducing kinase (NIK).  MAP3k14 is crucial in the non-canonical 
NF-κB pathway.  This serine/threonine protein-kinase binds to TNF receptor-
associated factor 2 (TRAF2) and stimulates NF-κB activity.  It participates in an 
NF-κB-inducing signalling cascade common to the TNF and IL-1 type 1 receptors 
[383].  These three predicted targets therefore represent novel and interesting 
pathways by which miR-34a could regulate macrophage cytokine production. 
The second question this study poses is why are the differences seen with Cl097 
stimulation more profound than those seen with LPS stimulation.  As well as 
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TNF-α, IL-1β and IL-6, in the Cl097-stimulated cells IL-7, IL-13, IL-15, RANTES 
and GM-CSF are also significantly down-regulated following miR-34a mimic 
transfection and up-regulated with miR-34a inhibition.  LPS activates cells by 
binding and signalling through TLR-4, while Cl097 does so via TLR-7/8 signalling.  
These data could suggest that manipulation of miR-34a has more profound 
effects on TLR-7/8 induced cytokine production than TLR-4 induced cytokine 
production.  Interestingly, IRAK-2 and IRAK-4 are only involved in MyD88-
dependent TLR signalling – which is the only pathway utilised by TLRs 7 and 8.  
TLR-4, on the other hand, can signal through both MyD88-dependant and 
independent pathways.  miR-34a targeting of IRAK-2 and IRAK-4 could, 
therefore, explain the more profound differences seen here with Cl097 
stimulation versus LPS stimulation. 
There was no time to further explore these hypotheses within this body of work, 
but given more time there are several experiments that would help determine 
whether IRAK-2, IRAK-4 or MAP3k14 do indeed target miR-34a, and whether this 
is in part responsible for the differences in cytokine production described here.  
Firstly, a luciferase assay could confirm whether miR-34a is capable of actually 
binding to the 3’-UTR of these potential targets.  The next step would be to use 
target protectors and see if protecting the binding sites in one or more of these 
mRNA molecules prevented the changes in cytokine production. 
The main limitation in this study is the inability to say without doubt what these 
results infer about the altered miR-34a expression in RA synovial fluid CD14+ 
cells.  These RA cells are neither peripheral blood CD14+ cells, nor M-CSF 
matured macrophages.  microRNA targeting experiments are very susceptible to 
differences in the mRNA expression in a cell at the given time, therefore, if 
given the extra time I would have liked to perform similar experiments on 
patient derived synovial fluid CD14+ cells. 
In summary, this chapter demonstrated that miR-34a negatively regulates TLR-
induced cytokine production by human primary monocyte-derived macrophages 
from the PB of healthy donors.  Further studies in the lab will be conducted to 
test whether miR-34a exhibits the same potential in RA synovial fluid 
macrophages and RA monocyte derived macrophages. 
 
  
 
 
Chapter 5 – Identification of targets and pathways 
regulated by microRNA-34a in monocytes 
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 Introduction and Aims 5.1
microRNA mediate their effects on protein expression by binding to target mRNA 
molecules, ultimately resulting in translation inhibition or mRNA degradation.  In 
plants, miRNA : mRNA binding usually involves perfect complementarity upon 
binding, which often results in direct Argonaute2-catalysed endonucleolytic 
cleavage of the target [257, 258].  In mammals however, direct complementarity 
is rare, and more often miRNAs recognise and bind their targets through the 
“seed sequence”.  This is generally contained in nucleotides 2 – 8 in the 5’ 
region of the microRNA – which is often the most conserved region of microRNA 
[384, 385].  In most cases it is thought that this seed sequence binds 
complementary sequences in the 3’-UTR of target mRNA molecules.  An example 
of these complementary sequences is presented for miR-34a and one of its well-
established targets, Sirtuin (SIRT) 1, in Figure 5-1.  Shown is a section of the 
SIRT1 3’-UTR which contains a six nucleotide sequence complementary to six 
nucleotides of the miR-34a seed sequence. 
 
 
Figure 5-1 Mature hsa-miR-34a binding to the 3’-UTR of SIRT1 
The diagram above shows a small portion of the SIRT1 3’-UTR, which contains a binding site (in 
blue) for miR-34a.  Also shown is the mature sequence of miR-34a, with the seed sequence 
highlighted in red.  Complementary binding sites between the miR-34a seed sequence and SIRT1 
3’-UTR are linked by a line. 
 
A number of prediction programmes are now freely available to aid the discovery 
of potential microRNA targets; these include TargetScan, PicTar, RNA22 and 
miRanda, among others.  These programmes use algorithms to detect potential 
microRNA binding sites, primarily based on the presence of complementary 
binding sites.  The targets of a given microRNA, however, are likely to depend 
on a number of factors.  These include, but are not restricted to, the expression 
Position 891-897 
of SIRT1 3' UTR
5’…UUCCACAAGUAUUAAACUGCCAA…
||||||
3’ UGUUGGUCGAUUCUGUGACGGU  Mature 
hsa-miR-34a
Complimentary binding sequence
miR-34a seed sequence
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level of the particular microRNA, the expression level of other microRNA that 
could target the same mRNA, and also the expression level of competing 
endogenous mRNA within a cell at the given time.  Many of these factors cannot 
be taken into account using these simple prediction algorithms, therefore it 
becomes clear that the use of prediction algorithms alone to find targets would 
result in a significant number of false positive and false negative results.  For 
these reasons, although prediction algorithms are useful in the search for 
candidate targets, experimental techniques and target validation are required 
for confirmation of potential miRNA targets [386, 387]. 
There are a number of experimental techniques frequently used to help 
elucidate the potential role of particular microRNA, and work out the targets 
whereby such function is mediated (reviewed in [388]).  These include under and 
over expression of the candidate microRNA of interest.  This is generally 
followed by PCR or microarray to look at changes at the mRNA level, and/or 
western blot or large-scale proteomics to look at changes in protein expression.  
These strategies can generate a list of potential targets of interest, but does not 
give an insight into whether these candidates are direct targets of the 
microRNA, or are differentially regulated as a result of indirect effects.  For this 
reason luciferase reporter assays are often used.  In this technique the candidate 
sequence containing the potential miRNA binding site is cloned into an 
expression vector downstream from a luciferase reporter gene.  This is then 
transfected into cells in the presence or absence of the targeting microRNA, and 
luminescence is measured to determine whether binding occurs - which in 
consequence will modulate the level of luciferase expression, hence reporting 
functional interactions [389].  
Here we have used some of the techniques documented above to investigate the 
potential role(s) of microRNA-34a in myeloid cell biology.  
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 Pathway Discovery 5.2
The first question we wanted to address was what pathways could be regulated 
by miR-34a in monocytes?  Understanding this profile should build an 
understanding of the potential consequences of miR-34a up-regulation in RA.  In 
order to address this, we chose to use an overexpression system.  CD14+ cells 
were isolated from the peripheral blood of healthy donors, then transfected with 
a control or synthetic miR-34a mimic.  We chose to use monocytes for this part 
of the study, as this could replicate what happens in RA when peripheral blood 
monocytes (which we have shown express relatively low levels of miR-34a) 
migrate to the sites of inflammation and up-regulate miR-34a (possibly due to 
interactions with synovial tissue enriched for M-CSF / GM-CSF expression).  24 
hours after transfection of monocytes with a control or miR-34a mimic, RNA was 
purified, and a microarray (GeneChip® Human Genome U133 Plus 2.0 Arrays) 
performed to determine differentially expressed transcripts.  
We chose to perform a microarray as it would allow the simultaneous 
measurement of thousands of transcripts.  This technology also adopted 
experimental and analysis techniques that were already well established in the 
laboratory.  Early microRNA research suggested that a proteomic approach may 
be better for looking at microRNA targets, but increasingly the field is showing 
that most of the protein reductions (recently estimated at 84% [390]) caused by 
microRNA are a consequence of mRNA destabilisation – giving us the confidence 
to move forward with this method [391, 392]. 
Following some initial problems with low transfection efficiency and high cell 
death of transfected monocytes, the conditions were optimised for the best cell 
density, time of transfection and FBS concentration in the culture.  Once these 
conditions were determined, cells from 8 different donors were transfected and 
a number of factors considered before 5 donors were chosen for the microarray 
analysis (discussed below).  
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 Viability and transfection efficiency of monocytes following 5.2.1
transfection with a miR-34a mimic 
Firstly, we wanted to determine cell viability after the 24 hour transfection.  To 
do this, cells were stained with 7-AAD and analysed by flow cytometry.  Figure 
5-2A shows a representative flow cytometry plot with dead cells staining positive 
for 7-AAD.  This plot also shows the gating strategy used to quantify the 
percentage of live cells in the culture.  The graph in Figure 5-2B shows the 
viability for all the different transfection conditions and 8 different transfected 
blood donors.  As shown on the graph no significant differences were seen in cell 
viability after monocytes were cultured for 24 hours in complete media, with 
transfection reagents, or with the addition of control or miR-34a microRNA 
mimics. 
Next, we wanted to ensure successful transfection of the cells was achieved. For 
this a labelled control mimic (Cm547) was transfected into cells from each 
donor.  Uptake of Cm547, as measured by increased fluorescence, was then 
analysed by flow cytometry and used to estimate the transfection efficiency.  
Figure 5-3A shows a representative histogram of cells transfected using the 
labelled mimic, compared to the standard unlabelled control mimic, while 
Figure 5-3B shows the percentage of cells which have taken up the labelled 
mimic for each donor. 
This data concerning cell viability and transfection efficiency, together with the 
RNA concentration and RNA Integrity Number (RIN), were used to choose samples 
from 5 of the 8 donors for microarray analysis. 
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Figure 5-2 Monocyte cell viability after transfection  
Monocytes were isolated from buffy coat samples and cultured for 24 hours in complete media 
alone (CA), with transfection reagents (TR), or with the control (Cm) or miR-34a (miR-34am) 
microRNA mimics before flow cytometry was performed to assess cell viability.  Panel A shows a 
representative flow cytometry plot for cells stained with 7-AAD.  The gate used to determine the 
percentage of live cells is also shown.  The graph shown in panel B displays the cell viability for all 
conditions with the 8 individual donors. Each data point represents one donor.  Data shown as 
mean plus standard error of the mean. 
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Figure 5-3 Transfection efficiency for monocytes as determined by uptake of a fluorescent-
labelled mimic 
CD14
+
 monocytes were isolated from buffy coat samples and transfected with a regular control 
(Cm) or labelled control (Cm547) microRNA mimic.  After 24 hours the cells were analysed via flow 
cytometry to measure uptake of the labelled mimic by the cells.  Panel A shows a representative 
histogram where cells transfected with the unlabelled mimic are represented in grey and Cm547 
transfected cells are represented in purple.  The gate used to determine the percentage of 
transfected cells (Cm547+) is also shown.  The graph shown in panel B displays the transfection 
efficiency for all 8 donors. Each data point represents one donor.  Data shown as mean plus 
standard error of the mean. 
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 Microarray and pathway analysis of control mimic and miR-5.2.2
34a mimic transfected monocytes. 
RNA from the 10 chosen samples (5 control mimic transfected and 5 miR-34a 
mimic transfected) was sent to the Glasgow Polyomics Facility (GPF) where a 
microarray was performed to determine differentially expressed transcripts 
(GeneChip® Human Genome U133 Plus 2.0 Arrays were used).  
The data generated by the GPF (CEL files) was analysed using GeneSpring.  First 
we wanted to determine potential genes and pathways regulated by miR-34a.  
We performed Mann-Whitney test analysis that resulted in 4482 differentially 
expressed genes with p value less than 0.05 between control mimic and miR-34a 
mimic transfected cells.  To narrow this down we chose to look at all transcripts 
greater than 2 fold up or down regulated in miR-34a transfected cells compared 
to control mimic transfected cells.  This created a list of 117 differentially 
expressed transcripts.  These transcripts are shown in the heat map in Figure 
5-4, which was generated through unbiased clustering based on both the entities 
(genes) and conditions.  This heat map groups genes and conditions based on the 
similarity of their expression profile and shows that indeed conditions (miR-34a 
mimic vs control mimic) segregate separately.  Table 5-1 lists all of these 
transcripts and shows the exact fold change determined by the microarray 
analysis. 
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Figure 5-4 Heat map of transcripts differentially expressed after miR-34a over-expression 
CD14
+
 cells from 5 buffy coat donors were isolated and transfected with a control (Cm) or miR-34a 
(miR-34am) mimic for 24 hours.  A microarray was performed on the isolated RNA, and a heat map 
was generated for all transcripts up or down-regulated 2 fold or greater (heat map was generated in 
GeneSpring using Pearson un-centred correlation with unbiased clustering). 
Cm miR-34am
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Table continued on next page… 
Symbol Entrez Gene Name Fold Change 
IFI44L interferon-induced protein 44-like -15.169 
RSAD2 radical S-adenosyl methionine domain containing 2 -14.631 
CCL8 chemokine (C-C motif) ligand 8 -13.250 
IFIT1 interferon-induced protein with tetratricopeptide repeats 1 -12.865 
CMPK2 cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial -11.966 
APOBEC3A apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A -10.449 
MX1 MX dynamin-like GTPase 1 -9.731 
IFIT2 interferon-induced protein with tetratricopeptide repeats 2 -8.401 
CXCL10 chemokine (C-X-C motif) ligand 10 -7.744 
IFIT3 interferon-induced protein with tetratricopeptide repeats 3 -7.564 
ISG15 ISG15 ubiquitin-like modifier -6.560 
HERC5 HECT and RLD domain containing E3 ubiquitin protein ligase 5 -6.260 
IFI44 interferon-induced protein 44 -6.207 
IFITM1 interferon induced transmembrane protein 1 -5.520 
OAS2 2'-5'-oligoadenylate synthetase 2, 69/71kDa -5.418 
CCL7 chemokine (C-C motif) ligand 7 -5.360 
SIGLEC1 sialic acid binding Ig-like lectin 1, sialoadhesin -5.166 
IFI27 interferon, alpha-inducible protein 27 -5.123 
MX2 MX dynamin-like GTPase 2 -5.106 
OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa -4.925 
LAMP3 lysosomal-associated membrane protein 3 -4.765 
XAF1 XIAP associated factor 1 -4.731 
MT1M metallothionein 1M -4.715 
IFITM3 interferon induced transmembrane protein 3 -4.677 
OAS1 2'-5'-oligoadenylate synthetase 1, 40/46kDa -4.502 
RASGRP1 RAS guanyl releasing protein 1 (calcium and DAG-regulated) -4.491 
EPSTI1 epithelial stromal interaction 1 (breast) -4.265 
DDX60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 -4.171 
IFI6 interferon, alpha-inducible protein 6 -4.062 
SAMD9L sterile alpha motif domain containing 9-like -4.042 
TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 -3.988 
OASL 2'-5'-oligoadenylate synthetase-like -3.823 
CXCL5 chemokine (C-X-C motif) ligand 5 -3.691 
IDO1 indoleamine 2,3-dioxygenase 1 -3.267 
DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 -3.241 
GBP1 guanylate binding protein 1, interferon-inducible -3.200 
CD274 CD274 molecule -3.156 
RTP4 receptor (chemosensory) transporter protein 4 -3.103 
PARP9 poly (ADP-ribose) polymerase family, member 9 -2.941 
ISG20 interferon stimulated exonuclease gene 20kDa -2.932 
IFIT5 interferon-induced protein with tetratricopeptide repeats 5 -2.836 
TNIP3 TNFAIP3 interacting protein 3 -2.834 
TNFAIP6 tumor necrosis factor, alpha-induced protein 6 -2.803 
HSD11B1 hydroxysteroid (11-beta) dehydrogenase 1 -2.735 
IFIH1 interferon induced with helicase C domain 1 -2.655 
CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) -2.650 
IL7R interleukin 7 receptor -2.611 
STAT1 signal transducer and activator of transcription 1, 91kDa -2.609 
GCH1 GTP cyclohydrolase 1 -2.592 
CXCL11 chemokine (C-X-C motif) ligand 11 -2.578 
AK4 adenylate kinase 4 -2.549 
MT1G metallothionein 1G -2.494 
EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2 -2.477 
TRIM22 tripartite motif containing 22 -2.459 
MSANTD3 Myb/SANT-like DNA-binding domain containing 3 -2.448 
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Symbol Entrez Gene Name Fold Change 
HMGN2P46 high mobility group nucleosomal binding domain 2 pseudogene 46 -2.445 
GBP5 guanylate binding protein 5 -2.418 
HS3ST3B1 heparan sulfate (glucosamine) 3-O-sulfotransferase 3B1 -2.406 
SAMD9 sterile alpha motif domain containing 9 -2.391 
TMEFF1 transmembrane protein with EGF-like and two follistatin-like domains 1 -2.381 
IFI35 interferon-induced protein 35 -2.364 
MT1F metallothionein 1F -2.351 
GJB2 gap junction protein, beta 2, 26kDa -2.345 
TNFSF13B tumor necrosis factor (ligand) superfamily, member 13b -2.320 
FFAR2 free fatty acid receptor 2 -2.319 
MT1H metallothionein 1H -2.287 
CYP27B1 cytochrome P450, family 27, subfamily B, polypeptide 1 -2.277 
UBE2L6 ubiquitin-conjugating enzyme E2L 6 -2.274 
IRF7 interferon regulatory factor 7 -2.261 
PLSCR1 phospholipid scramblase 1 -2.249 
LOC100288911 uncharacterized LOC100288911 -2.247 
LOC644090 uncharacterized LOC644090 -2.242 
OLIG2 oligodendrocyte lineage transcription factor 2 -2.220 
MT1E metallothionein 1E -2.194 
MT2A metallothionein 2A -2.181 
PNPT1 polyribonucleotide nucleotidyltransferase 1 -2.179 
CRIM1 cysteine rich transmembrane BMP regulator 1 (chordin-like) -2.162 
CCL24 chemokine (C-C motif) ligand 24 -2.157 
DDX60L DEAD (Asp-Glu-Ala-Asp) box polypeptide 60-like -2.155 
MT1X metallothionein 1X -2.146 
APOL3 apolipoprotein L, 3 -2.121 
PARP12 poly (ADP-ribose) polymerase family, member 12 -2.118 
WFDC21P WAP four-disulfide core domain 21, pseudogene -2.081 
BATF2 basic leucine zipper transcription factor, ATF-like 2 -2.076 
LY6E lymphocyte antigen 6 complex, locus E -2.060 
SLAMF7 SLAM family member 7 -2.052 
CD80 CD80 molecule -2.050 
TNIK TRAF2 and NCK interacting kinase -2.042 
TXLNB taxilin beta -2.040 
LAP3 leucine aminopeptidase 3 -2.021 
MT1HL1 metallothionein 1H-like 1 -2.005 
EPS8 epidermal growth factor receptor pathway substrate 8 2.040 
SEPP1 selenoprotein P, plasma, 1 2.055 
PALD1 phosphatase domain containing, paladin 1 2.069 
GGTA1P glycoprotein, alpha-galactosyltransferase 1 pseudogene 2.072 
F13A1 coagulation factor XIII, A1 polypeptide 2.205 
FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64) 2.243 
FCGR1B Fc fragment of IgG, high affinity Ib, receptor (CD64) 2.302 
TLR7 toll-like receptor 7 2.327 
FCGR1C Fc fragment of IgG, high affinity Ic, receptor (CD64), pseudogene 2.334 
MS4A6A membrane-spanning 4-domains, subfamily A, member 6A 2.514 
GPR34 G protein-coupled receptor 34 2.881 
Table 5-1 List of transcripts differentially expressed after miR-34a over-expression 
CD14
+
 cells from 5 buffy coat donors were isolated and transfected with a control or miR-34a mimic 
for 24 hours. A microarray was performed on the isolated RNA, and the table above shows all 
transcripts which were differentially expressed two fold or greater in the miR-34a mimic transfected 
cells compared to control mimic transfected cells.  Pathway analysis was performed, and those 
transcripts which are in the highly regulated pathways are highlighted. (green – interferon signalling 
pathway; blue – metallothionein pathway; red – toll like receptor and pattern recognition receptor 
pathways; purple - chemokines) 
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This list of differentially expressed transcripts was then further analysed in 
GeneSpring and Ingenuity pathway analysis software programmes, which came 
up with 3 pathways where it appears several members were differentially 
expressed. One of these was the interferon signalling pathway, where the 
transcription factor STAT1, and also several other IFN-inducible genes were 
down-regulated (highlighted in green in Table 5-1). 
In mammalian cells there are hundreds of IFN-inducible or IFN-stimulated genes 
(ISGs), and while many of these have known roles in inhibiting viral replication, 
the exact function(s) of many of these ISGs remain to be fully elucidated.  OAS1 
is one of a family of 2-5A synthetase enzymes, which are involved in the 
activation of latent RNase L.  Upon its recognition of viral RNA within a cell this 
enzyme becomes activated and results in the degradation of all RNA in the cell 
[393].  IFITM1 is an IFN-γ induced gene that plays a key role in the anti-
proliferative action of IFN-γ [394], and MX1 has been shown to inhibit the 
transcription and replication of a number of viruses, including influenza A and 
hepatitis B [395-397].  Although the precise roles of many of the ISGs aren’t fully 
understood, they are all up-regulated in response to stimulation of cells with 
IFNs, and thought to be involved in the anti-viral response.  The pathway map 
generated in Ingenuity showing the differentially regulated transcripts is shown 
in Figure 5-5.  
In order to validate these findings, PCR was performed on the same 5 samples 
used for the microarray, as well as samples obtained from an additional 6 
donors.  Figure 5-6 shows the results from the PCR, and confirms the microarray 
findings that these transcripts are all significantly down-regulated upon miR-34a 
over-expression in monocytes. 
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Figure 5-5 Many members of the interferon signalling pathway are differentially regulated 
upon miR-34a over-expression 
CD14
+
 cells were isolated from buffy coat samples and transfected with a control or miR-34a mimic 
for 24 hours.  A microarray was performed on RNA samples from 5 donors and differentially 
expressed transcripts were analysed in Ingenuity pathway analysis software.  The interferon 
signalling pathway was highlighted as a pathway with a number of differentially expressed 
members.  Transcripts whose expression was down-regulated two fold or greater are outlined in 
pink. 
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Figure 5-6 PCR validation of the differential expression of members of the IFN pathway upon 
miR-34a over-expression 
CD14
+
 cells were isolated from buffy coat samples and transfected with a control (Cm) or miR-34a 
(miR-34am) mimic for 24 hours.  A microarray performed on RNA samples from 5 donors 
highlighted the differential expression of a number of IFN-inducible molecules.  To validate these 
results PCR was performed on the same samples, plus those from an additional 6 donors.  For 
each donor the transcript expression level of the control mimic transfected cells was normalised to 
1, with miR-34a-transfected cells being shown as average fold change.  Data shown as mean plus 
standard error of the mean.  Paired t test or Wilcoxon matched-pairs signed rank test depending on 
whether data were normally distributed (determined by D’Agostino and Pearson omnibus normality 
test); ** P < 0.01, *** p < 0.001. n=11. 
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When analysing the differentially expressed transcripts in Ingenuity, another 
interesting pathway that was highlighted was the TLR signalling pathway 
(highlighted in red in Table 5-1 and pathway map shown in Figure 5-7).  As 
mentioned in the introduction, pattern recognition receptors, such as TLRs, are 
found on the surface or in the cytoplasm of immune cells.  These receptors are 
crucial for the innate immune response to invading microbial and viral 
pathogens.  They recognise and respond to the presence of PAMPs such as the 
bacterial cell wall components lipopolysaccharide (LPS) and peptidoglycan, and 
also viral DNA and RNA.  Herein, we show that following miR-34a over-
expression, TLR7 appears up-regulated, while a number of other pattern 
recognition receptors are down-regulated.  TLR7 is involved in the recognition of 
single stranded RNA, while RIG-1, MDA-5, PKR and OAS are involved in the 
recognition of double stranded RNA [398]. 
Once again, differentially expressed transcripts from the microarray were 
measured in samples obtained from 11 donors by PCR to validate these findings.  
The results are shown in Figure 5-8.  IRF3 was initially measured as upon first 
glance it appeared highlighted in the pathway map in Figure 5-7.  Upon closer 
inspection, however, it was clear IRF3/7 was highlighted due to down-regulation 
of IRF7, while IRF3 itself was unchanged.  So here IRF3 serves as a negative 
control.  These PCR results clearly demonstrate the differential expression of all 
other transcripts, confirming the results observed from the microarray analysis. 
 
  
 
 
 
 
 
Figure 5-7 Many members of the toll-like receptor (TLR) signalling pathway are differentially regulated upon miR-34a over-expression 
CD14
+
 cells were isolated from buffy coat samples and transfected with a control or miR-34a mimic for 24 hours.  A microarray was performed on RNA samples from 5 
donors and differentially expressed transcripts were analysed in Ingenuity pathway analysis software.  The TLR signalling pathway was highlighted as a pathway with a 
number of differentially expressed members.  Transcripts whose expression was down-regulated two fold or greater are outlined in pink, while transcripts up-regulated 
two fold or great are highlighted and circled in blue.  
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Figure 5-8 PCR validation of the differential expression of members of the TLR signalling 
pathway 
CD14
+
 cells were isolated from buffy coat samples and transfected with a control (Cm) or miR-34a 
(miR-34am) mimic for 24 hours.  A microarray performed on RNA samples from 5 donors 
highlighted the differential expression of a number of members of the TLR signalling pathway.  To 
validate these results PCR was performed on the same samples, plus those from an additional 6 
donors.  For each donor the transcript expression level of the control mimic transfected cells was 
normalised to 1, with miR-34a-transfected cells being shown as average fold change. Data shown 
as mean plus standard error of the mean. Paired t test or Wilcoxon matched-pairs signed rank test 
depending on whether data were normally distributed (determined by D’Agostino and Pearson 
omnibus normality test); ** P < 0.01, *** p < 0.001. n=11. 
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The list of differentially expressed transcripts was also analysed on GeneSpring 
pathway analysis, where the metallothionein pathway was highlighted.  The 
pathway map with transcripts whose expression was down-regulated two fold or 
greater highlighted in blue is shown in Figure 5-9.  Metallothioneins (MT) are a 
family of heavy-metal binding proteins whose primary roles are thought to be in 
maintaining heavy metal homeostasis [399-401] and protection from free radicals 
[402-404].  This said, their pathophysiological roles remain to be fully dissected 
and a number of studies are now suggesting potential roles in the regulation of 
immune responses. 
Confirmatory PCR was performed on the same and additional samples in order to 
validate the findings from the microarray (graphs are shown in Figure 5-10).  The 
results clearly demonstrate that all six metallothionein members measured are 
significantly down-regulated in miR-34a over-expressing monocytes, which 
confirms the results observed from the microarray analysis. 
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Figure 5-9 Many members of the metallothionein family are differentially regulated upon 
miR-34a over-expression 
CD14
+
 cells were isolated from buffy coat samples and transfected with a control or miR-34a mimic 
for 24 hours.  A microarray was performed on the isolated RNA from samples from 5 donors and 
differentially expressed transcripts were analysed in GeneSpring pathway analysis.  The 
metallothionein pathway was highlighted as a pathway with a number of differentially expressed 
members.  Transcripts whose expression was down-regulated two fold or great are outlined in blue. 
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Figure 5-10 PCR validation of the differential expression of members of the metallothionein 
pathway 
CD14
+
 cells were isolated from buffy coat samples and transfected with a control (Cm) or miR-34a 
(miR-34am) mimic for 24 hours.  A microarray performed on RNA from 5 donors highlighted the 
differential expression of a number of members of the metallothionein pathway.  To validate these 
results PCR was performed on the same samples, plus those from an additional 6 donors.  For 
each donor the transcript expression level of the control mimic transfected cells was normalised to 
1, with miR-34a-transfected cells being shown as average fold change.  Data shown as mean plus 
standard error of the mean.  Paired t test; *** p < 0.001.  n=11. 
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In addition to the pathways highlighted above, we also observed significant 
down-regulation of 6 members of the chemokine family (CCL8, CCL7, CCL24, 
CXCL5, CXCL10 and CXCL11 – highlighted in purple in Table 5-1) upon miR-34a 
up-regulation.  This is of particular interest in the context of monocyte 
migration and/or retention at site of inflammation such a synovial tissue.  Due to 
time constraints I was unable to investigate this fully but this lead will be 
followed up by other members of the lab. 
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 Using the microarray to look for direct miR-34a 5.3
targets in monocytes 
Our analysis has demonstrated several pathways and molecules which appear to 
be differentially expressed upon miR-34a up-regulation.  However, this type of 
analysis does not distinguish between direct miR-34a targets and indirect effects 
mediated via downstream effects upon inhibition of upstream regulatory mRNAs.  
In order to establish the direct targets of miR-34a, the microarray data were re-
analysed.  This time looking at only ranked down-regulated transcripts, and 
using a cut-off point of Mann Whitney P value lower than 0.05.  We chose this 
method as many miRNA targets, such as transcription factors, do not need to be 
changed dramatically in expression to have significant effects on the cells.  This 
analysis provided us with 2657 down-regulated transcripts.  We then looked at 
the list of predicted miR-34a targets on TargetScan, and found that there were 
61 transcripts which are down-regulated upon miR-34a over-expression that have 
predicted miR-34a binding sites.  Figure 5-11A shows a Venn diagram displaying 
the overlap of down-regulated transcripts containing predicted miR-34a binding 
sites, while Figure 5-11B shows a heat map of those 61 transcripts. 
Once again we wished to validate the microarray findings, so chose candidate 
transcripts of interest to measure by PCR on the samples.  We chose MTF1 and 
IRF1 because of their link with the dysregulated pathways discussed above (IFN 
and metallothionein pathways, respectively) as well as CSF1R and SIRT6.  We 
were interested in CSF1R as in chapter 3 we demonstrated that miR-34a 
expression was increased during the M-CSF maturation of peripheral blood CD14+ 
cells, and because of its obvious importance in monocyte and macrophage 
biology.  SIRT6 stood out as a potential molecule of importance as it has been 
implicated in regulating NFκB-mediated immune responses [405], and SIRT6 
over-expression in murine CIA resulted in reduced disease severity and a lower 
production of both local and systemic pro-inflammatory cytokines [406, 407].  As 
demonstrated in Figure 5-12, of these four candidate transcripts, IRF1, MTF1 and 
CSF1R were significantly down-regulated by PCR, while the expression of SIRT6 
appeared unchanged. 
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Figure 5-11 61 transcripts significantly downregulated in monocytes upon miR-34a 
upregulation that contain potential miR-34a binding sites 
CD14
+
 cells were isolated from buffy coat samples and transfected with a control (Cm) or miR-34a 
(miR-34am) mimic for 24 hours.  A microarray was performed on the RNA samples from 5 donors 
and the list of down-regulated transcripts compared to the list of potential miR-34a targets on 
TargetScan.  Panel A shows a Venn diagram displaying the overlap of down-regulated transcripts 
containing a predicted miR-34a binding site, while panel B is a heat map of those 61 transcripts. 
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Figure 5-12 PCR validation of potential miR-34a targets 
CD14
+
 cells were isolated from buffy coat samples and transfected with a control (Cm) or miR-34a 
(miR-34am) mimic for 24 hours.  A microarray was performed on the RNA samples, and down-
regulated transcripts compared to the list of potential miR-34a targets on TargetScan.  This gave a 
total of 61 transcripts which contained potential miR-34a binding sites and were also down-
regulated upon miR-34a up-regulation.  Above is the PCR validation of 4 of these transcripts.  For 
each donor the transcript expression level of the control mimic transfected cells was normalised to 
1, with miR-34a-transfected cells being shown as average fold change. Data shown as mean plus 
standard error of the mean.  Paired t test; * p < 0.05, ** p < 0.01. n=5. 
  
SIRT6
Cm miR-34am
0.0
0.2
0.4
0.6
0.8
1.0
ns
F
o
ld
 C
h
a
n
g
e
CD115
Cm miR-34am
0.0
0.2
0.4
0.6
0.8
1.0
 *
F
o
ld
 C
h
a
n
g
e
IRF1
Cm miR-34am
0.0
0.2
0.4
0.6
0.8
1.0
 **
F
o
ld
 C
h
a
n
g
e
MTF1
Cm miR-34am
0.0
0.2
0.4
0.6
0.8
1.0
 **
F
o
ld
 C
h
a
n
g
e
  199 
 
 
Microarray, PCR data and prediction algorithms suggest that IRF1, MTF1 and 
CSF1R could be direct targets of miR-34a.  To validate this functionally, we 
performed luciferase assays.  For each potential target, a section of the 3’UTR 
(containing the predicted binding site for miR-34a) was cloned into expression 
vectors downstream from a luciferase gene.  These constructs were then 
transfected into HEK 293 cells along with 25 nM control or miR-34a mimic, and 
luciferase activity measured 24 hours later to determine whether binding occurs.  
Where miR-34a binds its predicted target a drop in luciferase activity is 
observed.  TargetScan suggests CSF1R and IRF1 have one potential miR-34a 
binding site in their 3’UTR, while MTF1 has two – so two separate plasmids were 
generated for MTF1, each containing one of the binding sites.  A luciferase assay 
was also performed for Notch1 as a positive control, as this has previously been 
validated as a miR-34a target by luciferase assay in several other studies [408-
410].  The results from the luciferase assays are shown in Figure 5-13, and 
demonstrate significant down-regulation of luciferase activity by miR-34a when 
co-transfected with the Notch1 and CSF1R plasmids, but not with IRF1 or MTF1.  
These data suggest that IRF1 and MTF1 are not genuine direct miR-34a targets, 
while CSF1R and Notch1 most likely are. 
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Figure 5-13 Luciferase validation of potential miR-34a targets 
Luciferase assays were performed to determine whether miR-34a binds its predicted targets; 
Notch1 (positive control), CSF1R, IRF1 or MTF1 (which contains two potential miR-34a binding 
sites – BS1 and BS2).  For each target, a section of the 3’UTR containing the biding site(s) for 
microRNA-34a was cloned into an expression vector downstream from a luciferase gene.  These 
constructs were then transfected into HEK 293 cells along with 25 nM control (Cm) or miR-34a 
(miR-34am) mimic.  Luciferase activity was then measured and normalised to the endogenous 
control (renilla).  Data represents mean plus standard error of the mean.  n = 3 technical replicates.  
Paired t test; * P < 0.05, *** P < 0.001. 
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 Discussion 5.4
The main aim of this part of the study was to gain an insight into the potential 
pathways regulated by miR-34a in monocytes, and see if we could infer from this 
the functional impact of the increased miR-34a expression we have observed in 
myeloid cells in the periphery and synovium of RA patients, or to other 
important role(s) for miR-34a in monocyte and macrophage function. 
We choose to use a miR-34a over-expression system, because we aimed to mimic 
high levels of miR-34a in the RA synovial fluid CD14+ cells, and in monocytes 
upon M-CSF stimulation.  Also, many studies, including one study looking at miR-
140 in cartilage development [411], have shown that over-expression of 
microRNA using microRNA mimics achieves a greater change in target gene 
expression than the use of microRNA inhibitors.  So we felt this was the optimal 
approach for novel pathway discovery, particularly given the small sample size. 
The key finding from this section of work was that upon miR-34a overexpression 
in monocytes, we can identify novel pathways that are regulated by the 
microRNA.  Of particular interest, upon miR-34a over-expression we observed 
possible regulation of IFN, PRR and metallothionein pathways.  These pathways 
could also be involved in the activation of monocyte-derived macrophages and 
dendritic cells – which will be further explored by other members of the 
laboratory in due course as time precluded my exploring all of these in the 
context of my thesis. 
 Possible implications of dysregulation of PRR and IFN 5.4.1
pathways 
The down-regulation of many PRRs and ISGs could render cells less capable of 
detecting and responding to viral infections.  Due to the significant regulation of 
these pathways, we were interested in studying the effect of miR-34a 
dysregulation on the response of cells to viral infection.  Some preliminary 
experiments were performed (collaboration with Dr Clive McKimmie using 
Semliki forest virus), however, we encountered some technical problems when 
trying to infect cells which had previously been transfected with microRNA 
mimics.  Consistent with our hypothesis, miR-34a has recently been linked to 
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viral infection.  Its expression is induced during Epstein-Barr virus (EBV) infection 
of primary human B cells, while its inhibition resulted in impaired growth of EBV-
transformed cells [412].  The potential role of miR-34a in the regulation of cell 
response to viruses will be further investigated in the laboratory in miR-34a-/- 
mice. 
STAT1, the key signalling molecule involved in up-regulating genes in response to 
IFNs, and IRF7, a key regulator of the type I IFN (IFNα/β) response, are both 
down-regulated in response to miR-34a overexpression.  This would suggest that 
the response of these cells to IFNs, and possibly IFNα and β production by miR-
34a over-expressing cells may be impaired.  Consistent with this, in the previous 
chapter we demonstrated decreased IFNα production in response to Cl097 
stimulation of miR-34a over-expressing macrophages, but saw no difference in 
IFNα when miR-34a was inhibited.  For this reason I would like to repeat these 
experiments using a range of inhibitor concentrations.  This would control for 
inefficient miR-34a inhibition that could mean we do not see the full effect of its 
knockdown.  
It is well documented that IFNs up-regulate MHC class II and co-stimulatory 
molecules on APCs, facilitating their activation of antigen-specific T cells [413, 
414].  Interestingly, alongside STAT1 and IRF7, my data also demonstrated down-
regulation of CD80.  However, the flow cytometry data on human macrophages 
transfected with miR-34a mimics and inhibitors in the previous chapter showed 
no effect of miR-34a manipulation on MHC class II or FcγR expression.  It would 
therefore be interesting to repeat these experiments and stimulate cells with 
IFNs and/or TLR ligands, and include markers to look at the expression of co-
stimulatory molecules, such as CD80 and CD86. 
Another key role of IFNs is to induce specific chemokine signatures.  In the array 
here, we demonstrate down-regulation of several chemokines upon miR-34a 
over-expression; including CCL8, CXCL10, CCL7, CXCL5, CXCL11 and CCL24, 
many of which are IFN-inducible [415-419].  Taken together these data suggest a 
key role for miR-34a in the induction of IFNs, and the subsequent immune 
responses, including chemokine-mediated inflammatory cell recruitment.  
Therefore, some of this work will be studied in a murine setting where these 
hypotheses can be further explored more easily. 
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Also interesting in this set of results is the up-regulation of TLR7 in miR-34a 
mimic transfected cells.  In chapter 4 we demonstrated that transfection of cells 
with a miR-34a mimic actually results in reduced cytokine production in response 
to simulation with the TLR7/8 agonist Cl097.  These data suggest that it is 
downstream effectors, such as signalling molecules that cause miR-34a’s 
negative effect on cytokine production, rather than an effect on TLR expression 
itself.  However, data from another member of our lab have shown that miR-34a 
over-expression increases TLR7 expression on monocyte-derived dendritic cells, 
which may in part be involved in the increased production of TNF-α upon TLR7 
stimulation of these cells.  These date indicate that miR-34a might have 
different target engagements depending on the on the particular cell type, even 
between monocyte-derived macrophages and dendritic cells. 
Interestingly, increased expression of STAT1 and IFN inducible genes is well 
documented in RA [420-422].  There is an increasing literature base looking at 
the relationship between the IFN signature and the response to therapy in 
patients, with contradictory findings.  There are studies suggesting that a high 
IFN signature in patients is predictive of a poor response to treatment with 
rituximab [423] and infliximab [424], while another study found that an elevated 
type I IFN signature predicted a good response to anti-TNF therapy.  This is 
interesting, as in chapter 3 we demonstrated increased miR-34a levels in our 
multiple drug resistant patients.  Thus, it would be interesting to look at the IFN 
signature in peripheral blood monocytes of these patients. 
 Possible implications of targeting metallothionein pathway 5.4.2
dysregulation 
As mentioned previously, metallothioneins are a family of heavy-metal binding 
proteins that are thought to be primarily involved in maintaining heavy metal 
homeostasis [399-401], and protection from free radicals [402-404].  However, a 
number of more recent studies suggest an important role for MT in immune 
responses.  MT expression is induced by a number of pro-inflammatory cytokines, 
including IL-1, IL-6 and IFN-γ [425-427], and MT-/- mice fair worse in a number of 
models of inflammatory disease.  One example of this is in an LPS-induced model 
of acute lung injury, where MT-/- mice had a greater degree of lung edema and 
neutrophil infiltration to the lung [428].  Relevant to the context of rheumatoid 
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arthritis, one group decided to test the effect of MT on the murine CIA model.  
They found that administration of two different isoforms of MT - MTI and MTII - 
dramatically reduced both the clinical and histological symptoms of disease, and 
that expression of the pro-inflammatory mediators TNF-α and Cox-2 were 
significantly lower in the injected joints of MT-injected mice compared to un-
injected controls [429].  A mutation in the metallothionein gene has been 
associated with diabetes and its cardiovascular complications [430], and most 
importantly recent meta-analysis reveal a strong association between a SNP in 
the 3’UTR of MTF-1 and RA [25].  The down-regulation of many metallothionein 
family members by miR-34a up-regulation in monocytes, therefore, could also 
suggest a pro-inflammatory effect on cells, although this does not agree with our 
monocyte derived-macrophage cytokine data.  The link between miR-34a and 
the metallothionein pathway will be investigated further in the lab in the 
context of monocyte-derived dendritic cells activation.  
 Targets 5.4.3
In an attempt to find direct miR-34a targets among genes down-regulated in 
monocytes overexpressing miR-34a, we compared down-regulated transcripts 
with predicted miR-34a targets found on TargetScan.  This method resulted in a 
list of 61 transcripts which are down-regulated upon miR-34a over expression 
and have predicted miR-34a binding sites in their 3’UTRs.  Supporting the use of 
this method, many of the molecules highlighted in these experiments are 
already verified miR-34a targets – including PDGFRA [431, 432], ACSL1 [433], 
CCND1 [434], MYCN [351] and DLL1 [435]. 
Of the 61 transcripts highlighted using this method, MTF1 (a master transcription 
factor regulating the expression of all members of the MT family), IRF1 (a 
transcription factor first recognised for its ability to regulate IFNβ expression), 
SIRT6 (a histone deacetylase linked to the regulation of NFκB-induced 
inflammation) and CSF1R (the receptor for M-CSF, which is involved in 
macrophage differentiation and function) were of particular interest in the 
context of myeloid cell biology and the pathways we found to be regulated by 
miR-34a over-expression in monocytes.  We therefore initially chose these four 
to validate by PCR and luciferase assays.  Of these 4, the only one which was 
down-regulated by PCR validation, and also gave a positive luciferase result was 
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CSF1-R.  Although this receptor is targeted by miR-34a, we provide data in 
chapter 4 showing that altering the miR-34a expression of 3 day M-CSF matured 
human PB CD14+ cells had no effect on CD16, CD64 or HLA-DR expression 24 
hours post transfection.  It is however possible that an effect on macrophage 
phenotype and maturation would manifest later than 24 hours after miR-34a 
manipulation, so given more time it would be interesting to examine the 
consequences of increased and decreased miR-34a expression at later time 
points.  
The negative luciferase result for MTF1 and IRF1 mean that while we observe 
significant regulation of interferon and metallothionein pathways following miR-
34a over-expression in monocytes, we are currently unsure what miR-34a targets 
are responsible for these changes.  One possibility is that the changes in MT and 
IFN pathways may result from a direct targeting of IFNβ by miR-34a [436].  Given 
more time I would investigate this by repeating the miR-34a over-expression 
experiments followed by PCR, but this time also using target protectors to 
prevent miR-34a targeting of IFNβ. 
One of the key limitations to this study was the use of miR-34a mimics to pull 
out potential targets of miR-34a in monocytes.  Although microRNA mimics are 
widely used in microRNA research, they do have a number of potential flaws. It 
is estimated that the majority of microRNA fluctuate in expression by around 20-
30%, but the levels of expression reached after transient transfection with 
mimics are much higher than this.  These supraphysiological levels of expression 
could lead to false-positive results, where the artificial levels of expression 
allow a microRNA to target low affinity targets that would not be regulated 
under normal conditions [365].  This said, it is unlikely that much of the 
transfected microRNA is actually incorporated into RISC complexes allowing it to 
become functionally active.  There are actually a number of current studies 
supporting the use of microRNA mimics followed by microarray analysis to find 
pathways and targets regulated by microRNA.  One of these studies transfected a 
miR-124 mimic into HeLa cells and found that 76% of down-regulated transcripts 
contained potential miR-124 seed matches in their 3’ UTR.  When the 
experiment was repeated using a miR-124 mimic with a mutated seed region, no 
such enrichment of potential binding sites was found [261].  We therefore chose 
  206 
 
 
to proceed with this method, while being aware of the potential flaws and 
knowing that additional methods would be required for proper validation.  
Another problem was the choice of monocytes as the cell type for transfection.  
While these are the best cells to study miR-34a over-expression, as they have 
low endogenous levels, we have seen on several occasions during this project 
that microRNA targets are very cell and time specific.  This means these results 
are useful for our first aim – to discover possible pathways regulated when miR-
34a expression is increased in monocytes, but the data may not give an insight 
into possible pathways responsible for the difference in cytokine production we 
observed in Chapter 4 when miR-34a expression was manipulated in 
macrophages. 
Given more time it would therefore be useful to perform similar profiling 
experiments, but this time use miR-34a inhibitors in monocyte-derived 
macrophages to see the direct effects of down-regulating endogenous miR-34a 
levels.  This may provide increased confidence in the transcript over-expression 
data, and provide clues to the cause(s) of the cytokine changes observed in 
macrophages.
 
  
 
 
Chapter 6 – Analysis of miR-34a knockout mice 
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 Introduction and Aims 6.1
Although major advances have been made towards understanding microRNA 
biology, many of their physiological and pathophysiological roles remain largely 
unknown.  In an attempt to better understand the roles of microRNA in vivo, 
many investigators have chosen to study loss of function in microRNA knockout 
mice.  To examine the role of microRNA as a whole, mice lacking some of the 
key microRNA-processing factors were generated, but lack of Dicer, Drosha or 
Ago2 individually in mice was embryonically lethal [269-271], so conditional 
knockouts had to be generated.  When dicer-1 was knocked down in embryonic 
stem cells alone, although viable, cells displayed severe defects in 
differentiation [272].  The deletion of either Drosha or Dicer in T cells only 
resulted in spontaneous inflammatory disease, while deletion specifically in the 
regulatory T cell lineage caused defective Foxp3 induction, and impaired the 
cells suppressive capabilities [437].  These studies highlight the importance of 
microRNA in general in cell differentiation and function, but do not help 
determine which microRNA are responsible. 
To look at the potential roles of specific microRNA a number of individual 
microRNA or microRNA family mice strain knockouts have been generated.  Some 
have no obvious phenotype (including miR-182, miR-208b and miR-499 [438, 
439]), while others result in partial embryonic lethality (miR-1-2 and miR-126 
[440-442]).  There are also cases where microRNA have been shown to exhibit 
redundancy between family members that share identical or highly similar seed 
regions.  This is the case for miR-133a-1 and miR-133a-2.  Deletion of either of 
these microRNA alone has no obvious phenotype, but deletion of both 
simultaneously results in embryonic lethality in approximately 50% of mice [443].  
There are also some examples of remarkable and very obvious phenotypes in 
single microRNA knockout mice, suggesting important immune-regulatory 
functions of particular microRNA.  For example, miR-146a null mice 
spontaneously develop autoimmunity, indicating the importance of this miRNA in 
the broad regulation of immune responses [280].  It may be reasonably 
considered that some microRNA function as master regulators, while others are 
simply fine tuners of the mRNA and processes they regulate. 
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In the case of microRNA-34a, two individual groups have successfully developed 
knockout mice.  In both reports mice were born at the expected Mendelian ratio, 
with no obvious developmental abnormalities [332, 444].  Because of the link 
between miR-34 microRNAs and p53 in human studies, one group focussed on the 
effect of miR-34 ablation on p53-dependant responses.  Concepcion et al show 
no obvious effects of miR-34 knockout on three well-characterised p53-
dependant processes – response to DNA damage, replicative senescence or 
response to oncogene activation.  A number of independent groups had reported 
a key role for miR-34 in the p53 pathway, but this report suggests, at least in 
mice, that miR-34a is not completely necessary for p53 function in vivo [444].  
The other group focused on another process that is also reported to implicate 
p53 – somatic cell reprogramming [332].  This is a process whereby 
differentiated somatic cells are induced to generate pluripotent stem cells 
(iPSCs) [182].  This process has previously been shown to be enhanced in p53 null 
mice [183, 184], and this study demonstrated that somatic reprogramming is also 
enhanced in cells from miR-34a knockout mice.  They went on the show direct 
targeting by miR-34a of 3 transcription factors involved in maintaining the self-
renewal and pluripotency of ESCs - Nanog, Sox2 and N-Myc.  
Neither of these groups focussed on immune cell phenotype or function, so given 
the effect of miR-34a on human macrophage activation described in Chapter 5, 
we decided to obtain miR-34a knockout mice and perform some studies looking 
from an immunological view point.  In this chapter we will look at monocytes 
and macrophages in the unchallenged mice, and also go on to challenge miR-34a 
null cells in vitro to see if complete absence of miR-34a in murine macrophages 
resembles the results we achieved upon artificial manipulation of miR-34a in 
human macrophages.  The knockout mouse will also allow us to subject the 
mouse to immunological stresses and observe any effect of absent miR-34a in 
the organism as a whole in vivo. 
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 Quantity and phenotype of monocytes in resting WT 6.2
and miR-34a knockout mice 
Before subjecting murine cells to any stimuli we wanted to check whether there 
were any underlying differences in the number or phenotype of the basic 
monocyte populations in the spleen, blood or bone marrow of the miR-34a 
knockout mice compared to wild type mice.  To do this we chose to analyse the 
cells by flow cytometry using a gating strategy similar to that frequently used by 
the Geissmann group [445].  Figure 6-1 shows a representative gating strategy 
used for one sample.  Firstly, a gate was drawn around the cells of interest 
(most importantly this gate excludes cellular debris and includes monocytes), 
then doublets and dead cells were excluded before a gate was drawn to 
enumerate the percentage of all monocytes that are positive for both CD115 
(CSF1R) and CD11b.  Finally, Figure 6-1E shows the gating strategy used to 
determine the proportion of the two main murine monocyte sub-populations: 
Ly6C- and Ly6Chi cells.  As demonstrated in Figure 6-2, the total number of 
CD11b+ CD115+ monocytes in the blood, spleen and bone marrow does not differ 
between WT and miR-34a knockout mice.  Next, we went on to look at the 
proportion of the two main monocyte sub-populations found in these locations.  
We took the CD11b+ CD115+ cells and divided them based on their Ly6C 
expression to Ly6C- and Ly6Chi.  The Ly6Chi monocytes or “inflammatory 
monocytes” are short-lived cells which are recruited to inflamed or infected 
tissues where they can differentiate into antigen-presenting cells and produce 
TNF, nitric oxide and reactive oxygen species.  The Ly6C− monocytes or 
“patrolling monocytes” migrate over the resting vasculature, and are thought to 
be the precursor of some resident myeloid cells [203].  Figure 6-3 shows the 
proportion of Ly6C- and Ly6Chi cells as a percentage of total CD11b+ CD115+ 
monocytes in the blood, spleen and bone marrow of WT and miR-34a knockout 
mice.  Here we have shown that despite targeting of CD115 by miR-34a (chapter 
5 and [357]), no differences are found in the total percentage of monocytes, or 
in the percentage of Ly6C- or Ly6Chi cells in the blood, spleen or bone marrow of 
WT and miR-34a knockout mice.  
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Figure 6-1 Gating strategy used to quantify the percentage of monocytes in murine blood, 
spleen and bone marrow 
Cells were isolated from the blood, spleen and bone marrow of mice and this gating strategy was 
used to quantify the total number of monocytes, and also the percentage of Ly6C
hi
 and Ly6C
-
 cells.  
Firstly, a gate was drawn around the cells of interest (A), then doublets and dead cells were 
excluded (C and D, respectively) before a gate was drawn to quantify the percentage of CD115
+ 
CD11b
+
 monocytes (D).  The CD115
+
 CD11b
+
 monocytes were then subdivided based on their 
expression of Ly6C (E). 
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Figure 6-2 Percentage of CD115
+
 CD11b
+
 monocytes in the blood, spleen and bone marrow 
of wild type and miR-34a knockout mice 
Cells were isolated from the blood, spleen and bone marrow of wild type (WT) and miR-34a 
knockout (miR-34a
-/-
) mice and analysed by flow cytometry to quantify the percentage of single, live 
cells that were CD115
+
 CD11b
+
 monocytes in these locations.  These graphs show the total 
percentage of monocytes in the blood (A), spleen (B) and bone marrow (C) of the mice.  n = 7 mice 
per group over 2 independent experiments.  Data are shown as mean plus standard error of the 
mean.  No significant differences were observed using an unpaired t test. 
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Figure 6-3 Percentage of Ly6C
hi
 and Ly6C
-
 monocytes the blood, spleen and bone marrow of 
wild type and miR-34a knockout mice 
Cells were isolated from the blood, spleen and bone marrow of wild type (WT) and miR-34a 
knockout (miR-34a
-/-
) mice and analysed by flow cytometry to quantify the percentage of CD115
+
 
CD11b
+
 monocytes that were Ly6C
hi
 or Ly6C
-
.  The graphs show percentage of these monocyte 
subpopulations in the blood (A), spleen (B) and bone marrow (C) of the mice.  n = 7 mice per group 
over 2 independent experiments.  Data shown as mean plus standard error of the mean.  No 
significant differences were observed using an unpaired t test. 
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 TNF production by WT and miR-34a
-/-
 macrophages 6.3
upon stimulation 
In chapter 4 I showed that miR-34a regulates cytokine production by human M-
CSF-matured monocyte-derived macrophages.  So we next wished to determine 
whether this was also true in murine cells.  Bone marrow was isolated from WT 
and miR-34a knockout mice and cells matured with M-CSF toward macrophages 
for 7 days.  These macrophages were then left un-stimulated, or stimulated with 
1 ng/ml LPS or 1 μg/ml Cl097 for a further 24 hours.  The concentration of TNF-α 
in the supernatants was measured by ELISA, and as shown in Figure 6-4, no 
differences in TNF-α concentration were seen between macrophages derived 
from WT or miR-34a knockout mice.  The TNF-α concentration in the 
supernatants of un-stimulated cells was also measured – but these values were 
undetectable.  Here, we demonstrate that unlike with human M-CSF-matured 
macrophages, knock down of miR-34a seems to have no effect on TNF-α 
production by murine M-CSF-matured macrophages in vitro following LPS or 
Cl097 stimulation. 
 
Figure 6-4 TNF production by bone marrow macrophages from WT and miR-34a
 
knockout 
mice after TLR stimulation 
Bone marrow cells were isolated from WT and miR-34a
-/-
 mice and M-CSF matured for 7 days to 
generate bone marrow macrophages.  These cells were then stimulated for 24 hours with 1 ng/ml 
LPS or 1 μg/ml Cl097.  A TNF ELISA was performed on the supernatants and results are shown in 
the graphs above.  Data shown as mean plus standard error of the mean.  Bone marrow from 4 
mice was grouped for each experiment, n = 3 individual experiments.  Data shown as mean plus 
standard error of the mean.  No significant differences were observed using an unpaired t test. 
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 In vivo stimulation of WT and miR-34a knockout mice 6.4
Next, we wanted to subject the mice to stress to see if there was any difference 
in the ability of miR-34a knockout mice to respond to immune challenge in vivo.  
Sterile peritonitis models are often used to study the acute inflammatory 
response, which is characterised by the coordinated recruitment of immune cells 
in response to inflammatory cytokines and chemokines – the production of many 
of which is initiated by resident peritoneal macrophages.  We chose to use an 
LPS peritonitis model, and collect peritoneal lavage 4 hours after the LPS intra-
peritoneal (IP) injection.  This would allow the collection of the peritoneal 
exudate that can be used to simultaneously analyse the presence of 
inflammatory cytokines and chemokines, and also the cellular infiltrate.  These 
models are often used to phenotype transgenic mice as they are a good way to 
detect any defect or enhancement in the inflammatory response involving 
multiple cell types.  
Accordingly, mice were injected IP with 100 μg LPS per mouse, and a peritoneal 
lavage performed with 2 mls PBS 4 hours later.  1.5 mls of fluid was retrieved, 
which was then centrifuged to separate the cells from the fluid.  The lavage 
fluid was then frozen so a luminex could be performed at a later date, and the 
cells were immediately counted and stained for analysis by flow cytometry.   
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 Flow cytometry analysis of peritoneal exudate cells 4 hours 6.4.1
after LPS injection 
Figure 6-5 shows the initial gating strategy used to phenotype cells in the 
peritoneal exudate.  First of all a gate was drawn around total leukocytes, then 
single and live cells were gated for their expression of Ly6C and Ly6G.   Figure 
6-5D shows the gate used to quantify the percentage of single, live Ly6C/Ly6G 
double positive cells, which are primarily neutrophils.  Panel E and F show the 
percentage of Ly6C+, Ly6G+ cells in PBS-injected control mice and the LPS-
injected mice respectively.  As expected, the LPS-injected mice have a much 
higher percentage of neutrophils than the control mice, but no differences are 
seen between the wild type and miR-34a knockout mice.  
We next analysed the percentage of Ly6G- cells, which were F4/80hi macrophages 
in the peritoneal exudate (gating shown in Figure 6-6).  As expected, control 
mice have a higher percentage of macrophages compared to LPS-injected mice, 
and again we found no differences between the wild type and miR-34a knockout 
mice. 
We also tried to look at monocyte recruitment into the peritoneal cavity using 
CD11b and CD115 expression but found few cells.  Whereas 4 hours post IP 
stimulation is when neutrophil numbers in the peritoneal cavity peak, this time 
point is rather early for monocyte recruitment, so a later time point, such as 24 
hours after injection would have been required for this purpose [446].  Available 
mouse numbers precluded such an approach. 
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Figure 6-5 The percentage of Ly6C+, Ly6G+ neutrophils in the peritoneal cavity of WT and 
miR-34a-/- mice after LPS-induced peritonitis 
10 week old WT and miR-34a
-/-
 mice were injected intraperitoneally with LPS (100 μg/mouse).  4 
hours later the peritoneal cavity was washed with 2 mls PBS.  The cells in this exudate were then 
stained and analysed via flow cytometry.  First a gate was drawn around cells of interest (A), then 
doublets (B) and dead cells (C) excluded before cells were analysed for their expression of Ly6C 
and Ly6G (D).  The pink gate shown in panel D was used to quantify the percentage of Ly6C
+
, 
Ly6G
+
 cells.  The graphs shown in panel E and F show the percentage of these cells in PBS 
injected controls and LPS-injected mice respectively.  n = 12 (LPS) and 8 (PBS) mice over 3 
independent experiments.  Line on graphs represents the mean plus standard error of the mean.  
No significant differences were observed using an unpaired t test. 
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Figure 6-6 The percentage of F4/80
+
 macrophages in the peritoneal cavity of WT and miR-
34a
-/-
 mice after LPS-induced peritonitis 
10 week old WT and miR-34a
-/-
 mice were injected intraperitoneally with LPS (100 μg/mouse).  4 
hours later the peritoneal cavity was washed with 2 mls PBS.  The cells in this exudate were then 
stained and analysed via flow cytometry.  Live, single cells were gated on Ly6G- (A), then analysed 
for their expression of F4/80 (B).  The graphs in panel C and D show the percentage of cells 
positive for F4/80 in the PBS control group and LPS injected mice respectively.  n = 12 (LPS) and 8 
(PBS) mice over 3 independent experiments.  Line on graphs represents the mean plus standard 
error of the mean.  No significant differences were observed using an unpaired t test. 
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 Luminex analysis of peritoneal exudate and serum of 6.5
mice following LPS-induced peritonitis 
While performing the LPS-induced peritonitis experiments in WT and miR-34a 
knockout mice the peritoneal exudate was stored for luminex analysis.  During 
these experiments we also collected blood from all mice, and separated and 
stored the serum to measure systemic cytokine concentrations in response to IP 
LPS.  This would allow us to investigate the acute local cytokine production, 
primarily by resident peritoneal macrophages, and also the peripheral cytokine 
responses by multiple cell types.  The luminex assays were performed using the 
Invitrogen cytokine mouse 20-plex kits.  
The concentrations for all analytes which were measurable in the majority of 
samples are shown in Figure 6-7.  The results show no significant differences in 
the measured cytokines, and suggest that the absence of miR-34a has no effect 
on the local acute inflammatory cytokine production in response to LPS 
injection.  Also measured was the cytokine expression in mice injected with PBS 
as a control, which was undetectable for all analytes in most samples. 
The cytokine measurements in the serum of mice are shown in Figure 6-8 and 
Figure 6-9.  Figure 6-8 shows the results for all analytes which were measurable 
in the majority of samples where no significant differences were found between 
WT and miR-34a knockout mice.  For the serum, however, significant differences 
were found between the concentrations of IL-12, GM-CSF, the IFN driven 
chemokines: IP-10 and KC and also the T cell survival factor IL-2.  In all cases the 
miR-34a knockout mice appear to have lower expression of these cytokines than 
the wild type mice (shown in Figure 6-9).  Although these results achieve 
statistical significance, the concentrations in most mice are fairly similar, with a 
few miR-34a null mice having lower cytokine concentrations across the board.  
Further repetition would therefore be required to see if this really is a true 
phenomenon, or simply experimental variation.  It would also be useful to study 
longer time points to allow for the full systemic response to develop. 
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Figure 6-7 Cytokine luminex on the peritoneal wash of mice after LPS-induced peritonitis 
10 week old WT and miR-34a
-/-
 mice were injected intraperitoneally with LPS (100 μg/mouse).  4 
hours later a peritoneal lavage was performed with 2 mls PBS.  The cytokine concentrations in this 
peritoneal lavage fluid were then measured by luminex, and all analytes which were measurable in 
the majority of samples are shown above.  Where a few samples were below the standard curve 
the value of half the bottom standard is given and data points are highlighted in red.  Each data 
point represents peritoneal exudate from a single mouse with the line showing the average 
concentrations.  n=12 mice from 3 independent experiments.  No significant differences were 
observed using an unpaired t test or Mann-Whitney U test (test used determined by outcome of 
D'Agostino and Pearson omnibus normality test). 
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Figure 6-8 Cytokine luminex on the serum of mice after LPS-induced peritonitis 
10 week old WT and miR-34a
-/-
 mice were injected intraperitoneally with LPS (100 μg/mouse).  4 
hours later blood was collected by cardiac puncture.  The cytokine concentrations in the serum 
were then measured by luminex, and all analytes which were measurable in the majority of 
samples are shown above.  Where a few samples were below the standard curve the value of half 
the bottom standard is given and data points are highlighted in red.  Each data point represents the 
serum sample from a single mouse with the line showing the average concentrations.  n=12 mice 
from 3 independent experiments.  No significant differences were observed using an unpaired t test 
or Mann-Whitney U test (test used determined by outcome of D'Agostino and Pearson omnibus 
normality test). 
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Figure 6-9 Cytokine luminex on the serum of mice after LPS-induced peritonitis 
10 week old WT and miR-34a
-/-
 mice were injected intraperitoneally with LPS (100 μg/mouse).  4 
hours later blood was collected by cardiac puncture.  The cytokine concentrations in the serum 
were then measured by luminex, and all analytes which were measurable in the majority of 
samples with significant differences are shown above.  Each data point represents the serum 
sample from a single mouse with the line showing the average concentrations.  n=12 mice from 3 
independent experiments.  Unpaired t test or Mann-Whitney U test; * p < 0.05 (test used 
determined by outcome of D'Agostino and Pearson omnibus normality test). 
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 Discussion 6.6
Having already shown that manipulation of miR-34a in human monocyte-derived 
macrophages results in significant changes in cytokine production, this part of 
the study set out to determine the effects of total loss of miR-34a on innate 
immune system function using miR-34a knockout mice. 
The first key finding of this work was that there is no difference in the total 
number of monocytes, or in the percentage of the Ly6Chi or Ly6C- monocyte 
subsets in miR-34a knockout mice compared to wild type mice.  This is 
interesting, as our work on human cells demonstrated that miR-34a targets the 
MCSF receptor CD115, and a recent study by Riepsaame et al [357] showed that 
miR-34a also targets CD115 in the mouse.  This group went on to show that miR-
34a inhibition during DC maturation resulted in an increased expression of 
CD115, and a decrease in the percentage of bone marrow-derived MHCIIhi CD86hi 
differentiated DCs.  These data suggest that miR-34a may not be involved in 
monocyte development, or in the regulation of CD115 expression in monocytes, 
but perhaps plays a role in the final stages of cell maturation.  For this reason, if 
given more time I would like to investigate the expression of mature macrophage 
and DC markers between wild type and miR-34a knockout mice in various 
tissues.  
The next part of the murine study set out to investigate whether loss of miR-34a 
in the mouse resembled the clear phenotype we saw in the previous chapter 
when miR-34a was inhibited in human macrophages.  While in human MCSF-
matured macrophages we saw significant up-regulation of TLR-induced TNF-α 
production when miR-34a was actively inhibited, here we saw no difference in 
the TNF-α production between wild type and miR-34a knockout M-CSF-matured 
bone marrow-derived macrophages.  This could be explained in a number of 
ways.  Perhaps whole organism loss of miR-34a results in compensatory 
mechanisms regulating cytokine production so that miR-34a is no longer required 
for this role, or perhaps the miR-34a targets responsible for the changes in 
cytokine production in human cells are not regulated in the murine system.  
Indeed, the binding sites in some of our predicted targets that could be involved 
in cytokine production, such as IRAK2 and IRAK4, are not conserved between 
humans and mice.  
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Next, we set out to determine the potential role of miR-34a in inflammatory 
processes, so chose to initially study an acute model of inflammation.  The LPS-
induced peritonitis model would allow us to study the inflammatory cell 
infiltrate, and also look at the production of cytokines and chemokines locally by 
the peritoneal cells, and peripherally in the serum.  When studying the cells 
found in the peritoneal exudate, no significant differences were found in 
neutrophil infiltration, or in the percentage of macrophages between the wild 
type and miR-34a knockout mice.  This was initially intended to be a pilot study, 
however, and to be certain there were no differences in the cellular infiltrate 
the experiment would need to be repeated using a more extensive list of 
antibodies; including CD3 (T cells), B220 (B cells) and Siglec F (eosinophils).  This 
would allow more certainty over the exact cell types being measured, and the 
addition of other markers would also let us observe potential differences in cell 
subsets.  We also wanted to look at monocyte recruitment to the sites of 
inflammation, but at the 4 hour time point this is limited.  Although later time 
points could not be carried out during this body of work, these experiments are 
currently ongoing in the lab. 
The luminex data give an insight into the local and peripheral cytokine 
production in response to IP LPS in the wild type and miR-34a knockout mice.  
While there were no significant differences found in the local cytokine 
production, the possible differences seen in the serum warrant further study to 
determine whether there are true differences in some of the miR-34a knockout 
mice.  If this turned out to be the case, it may suggest that although there is no 
difference in the response of resident peritoneal cells (mainly macrophages) to 
infections, resident immune cells in other parts of the body (spleen, lymph 
nodes) are affected by the lack of miR-34a.  Interestingly, this could agree with 
work being carried out by other members of the lab, where it has been shown 
that the cytokine production by bone marrow-derived DCs in response to TLR 
stimulation is different between wild type and miR-34a knockout mice.  It would 
therefore be interesting to isolate differentiated macrophages and DCs, as well 
as other cell subsets from various tissues to test their response to stimulation, 
rather than studying precursor-derived in vitro matured cells or the whole 
organism response.  This may help identify in which cells cytokine production 
could be affected by lack of miR-34a. 
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Access to the miR-34a knockout mice came quite late into my PhD, so by the 
time our colonies had been backcrossed and bred in house we were not left 
enough time to do all of the planned experiments.  Given increased expression 
of miR-34a in RA tissues was where this project started, we wanted to perform 
an arthritis model.  Initially we performed preliminary experiments using the CIA 
model, but the miR-34a knockout mice are on a C57BL/6 background, and these 
animals are relatively resistant to this particular model [447].  Studies looking at 
this model, and others are therefore currently ongoing in the laboratory. 
In conclusion, this short study into miR-34a knockout mice has shown that the 
number of monocytes and monocyte sub-populations is not altered in the blood, 
spleen or bone marrow of mice lacking miR-34a.  We have also shown that unlike 
in human cells, lack of miR-34a seems to have no effect on the TNF-α production 
of MCSF-matured macrophages.  We then used an acute LPS-induced peritonitis 
model to demonstrate that lack of miR-34a doesn’t affect local cytokine 
production, or the early recruitment of neutrophils to the peritoneal cavity, 
while systemic cytokine production requires further study. 
 
  
 
 
Chapter 7 – Discussion 
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At the beginning of this study, preliminary data from our laboratory suggested 
that miR-34a expression was up-regulated in SF CD14+ cells compared to 
matched PB samples.  The first aim of this body of work, therefore, was to 
confirm this finding, and to proceed thereafter to look at the expression of miR-
34a in RA compared to control samples.  I was able to confirm that miR-34a 
expression was significantly up-regulated in SF CD14+ cells, while the other 
members of the miR-34 family – miRs 34b and 34c – were not.  My work must be 
considered in the general context of an evolving field of miR mediated 
regulation of gene expression, and also that of my laboratory in which a number 
of miRs are being examined for their potential functional impact on RA disease 
pathogenesis.  Specifically, we have been trying to generate an overall picture 
of how microRNA expression changes when monocytes arrive in the 
inflammatory, maturation-inducing environment of the synovium, with the aim 
to dissect the role of these changes to monocyte and macrophage activation and 
function.   
We are currently studying a number of microRNA that are summarised in Figure 
7-1, including miR-155 which is up-regulated in synovial monocytes, and miR-223 
which is down-regulated.  Extensive published functional data implicate both of 
these microRNA in the regulation of synovial macrophages – however many 
elements of the gene expression matrix in these cells cannot be accounted for 
by these miRs alone, and hence other pathways are of current interest.  The role 
of my PhD was to focus on dissecting the possible causes and functional 
implications of miR-34a dysregulation in monocytes and macrophages.   
As well as being increased in SF CD14+ cells compared to PB cells, we were able 
to demonstrate that miR-34a expression is increased in synovial tissues from RA 
patients compared to OA samples, and that some of the miR-34a positive cells 
were CD68+ macrophages.  Of particular interest, miR-34a was also up-regulated 
in PB CD14+ cells of biologic-resistant RA patients compared to healthy controls.  
Among the potential stimuli present in the synovial microenvironment (as 
depicted in Figure 7.1) we discovered that M-CSF and GM-CSF, but not TLR 
ligands, triggered the expression of miR-34a in monocytes.  Dissecting a 
functional role for this microRNA was crucial for determining the possible 
consequence(s) of its dysregulation in RA. 
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Figure 7-1 Schematic of microRNA changes in PB vs SF CD14
+
 cells 
Studies in our laboratory have shown that the microRNA expression profile of PB CD14
+
 cells 
significantly differs from SF CD14
+
 cells.  We propose that upon entering the synovial 
microenvironment, contact with various mediators (including M-CSF, GM-CSF and TLR ligands) 
causes changes in microRNA expression.  We have demonstrated differential expression of many 
microRNA – including miR-155, miR-34a, miR-223 and miR-146a. 
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Using over and under-expression systems to look at miR-34a function in MCSF-
matured macrophages, we found that over-expressing miR-34a reduced TLR-
induced cytokine production, while inhibiting miR-34a increased cytokine 
production.  This should mean that increased miR-34a expression in RA has a 
predominantly anti-inflammatory effect, and thereby could assist in promoting 
the resolution of inflammation.  However, we know that monocytes in RA display 
an activated, pro-inflammatory phenotype – or at least that a predominant 
subset are considered to play a pro-inflammatory role.  I interpret my 
observations as reflecting a failure of miR-34a to mediate a normally 
homeostatic regulatory arm in terms of cellular activation.  This failure of miR-
34a to dampen inflammation could be down to several factors.  One of these 
could be the altered levels of several other microRNA in the synovial myeloid 
cells.  There are several microRNA known to be differentially expressed in RA SF 
CD14+ cells, some of which exert pro-inflammatory effects on the cells, and 
some of which have an anti-inflammatory effect.  There is therefore likely a 
balancing act between these counteracting mechanisms.  We know that miR-155 
is over-expressed in monocytes and macrophages in RA, and this microRNA 
targets SHIP-1, an inhibitor of TLR and PI3/Akt kinase pathways, as well as 
SOCS1.  Increased expression of this microRNA therefore in general has an 
inflammation promoting effect on the cells [300].  We also know that miR-223 is 
down-regulated in RA monocytes.  This microRNA targets NLRP3, thereby 
limiting the production of IL-1 family members, so its down-regulation in RA also 
has an inflammation promoting effect on cells [342].  Perhaps in monocytes in 
RA, the effects of altered microRNA that promote inflammation (like miR-155 
and miR-223) dominate, thereby limiting the true ‘potential’ effects of miR-34a 
over-expression.  Alternatively, it is possible that miR-155 triggers the acute pro-
inflammatory activation of macrophages, which is negatively fine-tuned by 
constitutively high levels of miR-34a, likely in collaboration with other anti-
inflammatory miRs such as miR-146.   
Studies have been conducted that demonstrate microRNA hierarchy where two 
microRNA with opposing actions are over-expressed simultaneously.  One 
particular study in Treg cells provided data to show that over-expression of miR-
155 in Tregs results in their increased production of TNF, IFNγ and IL-17, while 
over-expression of miR-146a resulted in reduced production of all three 
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cytokines.  Over-expression of both microRNA together, however, resulted in a 
cytokine profile mimicking that observed when miR-146a alone was over-
expressed.  This study suggested that the effects of miR-146a were dominant 
over miR-155 in the Treg cells [448].  In our case we propose that the pro-
inflammatory effects of increased miR-155 and reduced miR-223 dominate over 
the anti-inflammatory effects of increased miR-34a and 146a in monocytes in the 
synovium (Figure 7-2), and therefore promote the pro-inflammatory phenotype 
witnessed in these cells.  In fact, mechanistic experiments looking at the effects 
of simultaneous over-expression of miR-155 and miR-34a in monocytes are 
currently being undertaken in the laboratory – results are awaited with 
considerable interest.  Long-term experimental plans include simultaneous 
overexpression of these miRs in DICER specific human monocyte/macrophage 
deficient cells (depleted from all other miRs) to dissect the details of miR-155 
and miR-34a interactions in these cells.  It would also be interesting to 
determine whether more profound anti-inflammatory effects are observed when 
miR-34a is overexpressed and miR-155 inhibited simultaneously. In addition, 
similar experiments will be conducted in monocyte and monocyte derived 
macrophages from RA patients, which show high levels of both miRNAs.   
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Figure 7-2 microRNA balancing act in synovial fluid CD14
+
 cells 
Several microRNA are known to be differentially expressed in monocytes in RA.  These include 
alterations which should have an anti-inflammatory effect on cells (increased miR-146a and miR-
34a), as well ones which will have a pro-inflammatory effect (increased miR-155 and decreased 
miR-223).  We therefore propose that in RA, although some microRNA are altered in an attempt to 
restore balance and dampen the on-going inflammation, the effects of decreased miR-223 and / or 
increased miR-155 dominate, and add to the pro-inflammatory phenotype observed in these cells. 
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The anti-inflammatory effect of miR-34a in macrophages was initially surprising 
to us, as data from another member of the lab had already shown that miR-34a 
overexpression in monocyte-derived DCs actually resulted in increased LPS-
induced TNF-α production.  Since these experiments were carried out, however, 
another group have reported similar data on the effect of miR-34a manipulation 
on macrophage cytokine production [354].   
Supporting the differences observed between monocyte-derived macrophages 
and dendritic cells, one target we have demonstrated that plays a key role in 
miR-34a function in DCs is Axl.  Axl is a member of the TAM (TYRO3, Axl and 
Mer) family of receptor tyrosine kinases.  These receptors are involved in 
dampening immune responses, and are capable of inhibiting TLR signalling 
through the induction of SOCS1 and SOCS3.  Data from our lab suggests that miR-
34a, by inhibiting Axl, facilitates pro-inflammatory cytokine production by DCs, 
and also promotes Th17 cell differentiation upon TLR stimulation.  Interestingly, 
although Axl is highly expressed by DCs, a recent study actually demonstrated 
that macrophages express very low levels of Axl compared to DCs [449].  This 
differential expression of Axl, and perhaps other mRNA targets of miR-34a, could 
explain the different role for miR-34a in these cells.  miR-34a has a number of 
verified and / or predicted targets that could have a pro-inflammatory effect on 
cells (Axl and SOCS3), but also several that would have an anti-inflammatory 
effect (Notch1, IRAK2, IRAK4 and MAP3k14).  We therefore hypothesise that the 
differential expression of potential target transcripts between macrophages and 
DCs could account for the differential effect of miR-34a in these cells.  Our 
hypothesis for the distinct role of miR-34a in macrophages and DCs is 
summarised in Figure 7-3. 
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Figure 7-3 Current hypothesis of the role of miR-34a in macrophages and dendritic cells 
Experimental manipulation of miR-34a in macrophages and dendritic cells has shown differential 
regulation of TLR-induced cytokine production. When miR-34a expression is increased in 
macrophages it could target several transcripts – possibly including Notch1, IRAK2, IRAK4 and 
MAP3k14. This could explain the reduced cytokine response observed in response to TLR 
stimulation of miR-34a over-expressing cells. In dendritic cells, however, when miR-34a is 
upregulated it targets Axl and possibly other transcripts like SOCS3, which could explain the 
increased cytokine production observed upon TLR stimulation of miR-34a over-expressing DCs.* = 
predicted according to TargetScan, but not yet experimentally validated. 
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The key differences between the effect of miR-34a manipulation on 
macrophages and dendritic cells clearly highlights the importance of taking the 
utmost care when interpreting or comparing data between cell types.  The role 
of microRNA is very dependent on the expression of target transcripts in the cell 
at that particular time.  This could be particularly important when studying cell 
lines (which could confound observations) with the aim to detect and predict the 
role of a given microRNA in primary cells.  In light of this work, we plan to 
repeat some of these experiments using patient-derived synovial fluid CD14+ 
cells.  Although here we have dissected a functional role for miR-34a in 
macrophages, it will be interesting and important to determine what effect(s) 
manipulating miR-34a has on freshly isolated patient cells.  
In the context of miR-34a’s role in broad macrophage biology, it would be 
interesting to test the effect of miR-34a not only in the acute inflammatory 
response presented in this thesis, but also in LPS tolerance and innate immune 
memory.  It has been shown that another inhibitory / anti-inflammatory 
microRNA, miR-146, is critical for the development of endotoxin induced 
tolerance [450].  Finally, given more time I would also test the role of miR-34a 
in the development and activation of GM-CSF primed, inflammatory 
macrophages.  These cells are considered more prone to the production of pro-
inflammatory stimuli than M-CSF differentiated macrophages [451], so it would 
be interesting to determine whether miR-34a had an inflammation promoting or 
dampening role in these cells. 
In this study we also used a microarray to investigate, at a transcriptional level, 
pathways that could be regulated by miR-34a.  We found several pathways, 
including particularly the interferon, metallothionein and chemokine pathways, 
where many members were down-regulated upon over-expression of miR-34a in 
monocytes.  However, none of the targets we hypothesise are involved in the 
reduced cytokine production following miR-34a over-expression in macrophages 
were highlighted.  Since monocytes strongly up-regulate miR-34a during 
differentiation towards dendritic cells, we are planning to investigate whether 
identified novel pathways underlie the function of miR-34a in these cells.  For 
example, we speculate that inhibition of the IFN pathway by miR-34a may be 
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relevant to the pro-inflammatory action of this miR in DCs, as the miR-34a target 
Axl requires IFN signalling for the induction of SOCS in DCs [449].  
In light of our recent observation that microRNA targeting is extremely cell 
specific, we aim to perform miR over and under-expression experiments in 
macrophages and dendritic cells.  This would allow us to determine whether any 
of these pathways highlighted in monocytes are also relevant in macrophages 
and / or DCs, and also look more specifically at the potential targets responsible 
for the altered TLR-induced cytokine production following miR-34a 
manipulation. 
Taken together, this study and several others demonstrate a complex role for 
miR-34a in the regulation of myeloid cell biology.  In this study I have shown that 
miR-34a is increased in monocytes following culture with M-CSF or GM-CSF, while 
Krzeszinski et al demonstrated that miR-34a is down-regulated during the 
differentiation of osteoclasts with M-CSF and RANKL [339].  A key role for miR-
34a in human monocyte to DC differentiation and subsequent DC function (as 
manifested by developing high levels of MHC II expression and phagocytic 
properties) has already been supported by other studies [357, 452], and we have 
shown that miR-34a inhibits TLR-induced cytokine production by monocyte-
derived macrophages, but promotes TLR-induced cytokine production by 
monocyte-derived DCs.  Both human and murine studies have also shown that 
miR-34a targets transforming growth factor-b-induced factor 2 (Tgif2), thereby 
inhibiting osteoclastogenesis and bone resorption [339].  These data highlight 
the importance of miR-34a in myeloid cell differentiation and function, but 
could mean that harnessing its potential as a therapeutic in inflammatory 
disease may be difficult.  While miR-34a over-expression could dampen the 
inflammatory response by macrophages and perhaps reduce bone erosions by 
inhibiting osteoclastogenesis, it could act on DCs to promote cytokine production 
and inflammation. 
In summary, this study is the first to demonstrate increased miR-34a expression 
in monocytes and macrophages in RA.  It also agrees with other studies [354] in 
demonstrating that miR-34a reduces TLR-induced cytokine production in 
macrophages – and therefore has an anti-inflammatory effect on these cells.  We 
propose that miR-34a over-expression in monocytes and macrophages in RA is an 
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attempt to attenuate inflammation, which fails due to the strong pro-
inflammatory milieu, including the dysregulation of other inflammation 
promoting microRNA.  Future work in the lab will therefore focus on looking at 
the effects of manipulating multiple microRNA simultaneously, to explore the 
hierarchy and dominance of microRNA in synovial fluid cells. 
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